	OMIM no.	Disease Name	Disease Name comments	Gene Affected	Enzyme/protein Defected	EC number/ Protein Entry	Drug formulation/Dosage	Drug name comments	Drug name	Drug ID	Study Type (Evidence code)	Mutations improved by treatment	Mutations improved by treatment comments	Mutation that didn't get benefits out the treatment	Mutation that didn't get benefits out the treatment comments	Treatment mechanism of action	Abbreviation for treatment mechanism	new ontology category	Population information	phenotypes  improved	phenotypes  improved comments	Phenotypes  IDS	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
1	#202110	17-alpha-hydroxylase deficiency 		CYP17A1	Steroid 17-alpha-hydroxylase	1.14.14.19			Hydrocortisone	DB00741	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormal plasma aldosterone		HP:0040085	https://www.ncbi.nlm.nih.gov/pubmed/26161337		https://www.ncbi.nlm.nih.gov/pubmed/18458702								
																				Abnormality of potassium homeostasis		HP:0011042											
																				Abnormal circulating renin		HP:0040084											
																				Hypertension		HP:0000822											
									Dexamethasone	DB01234	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormal plasma aldosterone		HP:0040085	https://www.ncbi.nlm.nih.gov/pubmed/18458702#										
																				Hypokalemia		HP:0002900	https://www.ncbi.nlm.nih.gov/pubmed/27853336	https://www.ncbi.nlm.nih.gov/pubmed/18458702#									
																				Abnormal circulating renin		HP:0040084											
																				Hypertension		HP:0000822	https://www.ncbi.nlm.nih.gov/pubmed/27853336	https://www.ncbi.nlm.nih.gov/pubmed/18458702#									
																				Bone mass loss		NA											
									Testosterone	DB00624	ECO:0000352					Functional interaction	B	metabolite replacement		Puberty and gonadal disorders		HP:0008373	https://www.ncbi.nlm.nih.gov/pubmed/26161337#										
									Estrogen replacement (Estradiol)	DB00783	ECO:0000352					Functional interaction	B	metabolite replacement		Puberty and gonadal disorders		HP:0008373	https://www.ncbi.nlm.nih.gov/pubmed/27853336	https://www.ncbi.nlm.nih.gov/pubmed/26161337#	https://www.ncbi.nlm.nih.gov/pubmed/18458702#								
																																	
																				Amenorrhea		HP:0000141											
									Pioglitazone	DB01132	ECO:0007121 /ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Insulin resistance		HP:0000855		https://www.ncbi.nlm.nih.gov/pubmed/19755409	https://clinicaltrials.gov/ct2/show/NCT00151710								
																				Hypertension		HP:0000822											
2	# 236792	L-2-HYDROXYGLUTARIC ACIDEMIA		L2HGDH	L-2-hydroxyglutarate dehydrogenase.	1.1.99.2			Riboflavin	DB00140 	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Cognitive impairment		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/22391998										
																				L-2-hydroxyglutaric aciduria		HP:0040144	https://www.ncbi.nlm.nih.gov/pubmed/24321868										
																				Poor motor coordination		HP:0002275	https://www.ncbi.nlm.nih.gov/pubmed/24321868										
									Flavin adenine dinucleotide + levocarnitine chloride.	DB03147 +DB00583	ECO:0000352					Direct interaction+Functional interaction	A+B	combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		defected  L-2-HGDH enzyme activity (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/18362286	https://www.ncbi.nlm.nih.gov/pubmed/22391998									
																				L-2-hydroxyglutaric aciduria		HP:0040144	https://www.ncbi.nlm.nih.gov/pubmed/18362286	https://www.ncbi.nlm.nih.gov/pubmed/22391998									
																				Leukodystrophy		HP:0002415											
																				dystonia		HP:0001332											
																				Neurological impairment		HP:0000707	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+SUCCESSFULLY+TREATED+ADULT+PATIENT+WITH+l-2-HYDROXYGLUTARIC+ACIDURIA&btnG=										
									FAD+Riboflavin	DB03147+DB00140	ECO:0000352					Direct interaction+Functional interaction	A+B	combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		Neurological impairment		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/26208971	https://www.ncbi.nlm.nih.gov/pubmed/18343698	https://www.ncbi.nlm.nih.gov/pubmed/22840416/	https://www.ncbi.nlm.nih.gov/pubmed/22840416							
																																	
	# 203700	ALPERS SYNDROME		POLG	DNA polymerase subunit gamma-1	2.7.7.7			Magnesium	DB14513	ECO:0000352					Symptomatic		symptomatic therapeutic procedure		Status epilepticus		HP:0002133	https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract										
								EPI-743 potently protected fibroblasts derived from Leigh syndrome (see Fig 5C for representative dose-response rescue curve for Subject 4), Alpers syndrome, and Rett syndrome patients from ferroptosis induced by GSH depletion and excess iron. EPI-743 treatment also protected additional patient-derived fibroblasts from RSL3-induced lipid oxidation and ferroptosis.	EPI-743, α-tocotrienol quinone	DB11917	ECO:0001565/ECO:0007764					Functional interaction	B	functional complementation of a genetically defective protein		Sizures	The study was preformed on a cell line and the expected phenotypes to be corrected is frequent seizures.	HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/30921410	https://clinicaltrials.gov/ct2/show/NCT01370447									
																																	
																																	
																																	
	#615182	Combined D,L-2-hydroxyglutaric aciduria		SLC25A1	Tricarboxylate transport protein, mitochondrial	P53007			Citrate treatment	DB09125	ECO:0000352					Functional interaction	B	metabolite replacement		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/24687295										
																				D-2-hydroxyglutaric aciduria		HP:0012321											
																				L-2-hydroxyglutaric aciduria		HP:0040144											
																				Elevated circulating succinate		HP:0020149											
																				Hypocitraturia		HP:0012405											
3	# 300438	2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558	HSD17B10	3-hydroxyacyl-CoA dehydrogenase type II	1.1.1.35/1.1.1.51/1.1.1.178			Benzhexol	DB00376	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tremor		HP:0001337	https://www.ncbi.nlm.nih.gov/pubmed/12555940										
																				Dystonia		HP:0001332	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+case+of+adult-onset+type+II+citrullinemia+in+which+oral+administration+of+L-Arginine+Granules+improved+the+patient%27s+encephalopathy+and+the+increased+level+of+serum+ammonia&btnG=										
									Vigabatrin	DB01080 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985	https://www.ncbi.nlm.nih.gov/pubmed/11102558									
									Levodopa 	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/30013934										
									Carbidopa	DB00190	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tremor		HP:0001337	https://www.ncbi.nlm.nih.gov/pubmed/30013934										
									Cefoperazone sodium	DB01329	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal inflammatory response		HP:0012647	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Clinical+Diagnosis+and+Treatment+of+2-Methyl-3-Hydroxybutyryl-CoA+Dehydrogenase+Deficiency+in+One+Infant%3A+A+Case+Report&btnG=										
									Tazobactam sodium	DB01606	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal inflammatory response		HP:0012647	https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37										
									B vitamins	A11E	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormality of the nervous system		HP:0000707	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Clinical+Diagnosis+and+Treatment+of+2-Methyl-3-Hydroxybutyryl-CoA+Dehydrogenase+Deficiency+in+One+Infant%3A+A+Case+Report&btnG=										
									Creatine phosphate sodium	DB13191	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormality of cardiovascular system physiology		HP:0011025											
									Carbamazepine	DB00564	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/22132097										
								The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)	Carnitine 	DB00583	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal muscle physiology		HP:0011804	https://www.ncbi.nlm.nih.gov/pubmed/22132097										
																																	
																																	
4	# 610006	2-methylbutyryl-CoA dehydrogenase deficiency		ACADSB	3-hydroxy-2-methylbutyryl-CoA dehydrogenase	1.1.1.178			L-Carnitine+ low-protein diet	DB00583+NA	ECO:0000352					Symptomatic+Functional interaction	C+B	combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion		Abnormality of muscle physiology		HP:0011804	https://www.ncbi.nlm.nih.gov/pubmed/12837870										
																				Elevated serum toxic intermediates in isoleucine pathway		HP:0001939											
5	210200	3-methylcrotonyl-CoA carboxylase deficiency 		MCCC1/MCCC2	3 Methylcrotonyl-CoA carboxylase	6.4.1.4		"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630"	Biotin	DB00121	ECO:0000352	MCCA-R385S(heterozygote mutation)	https://www.ncbi.nlm.nih.gov/pubmed/15359379	MCCB-(IVS16þ1G>A)/ MCCB-missense mutation E99Q Homozygous mutation		Direct interaction	A	activity modification of a genetically defective protein		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/	https://www.ncbi.nlm.nih.gov/pubmed/18155630	https://www.ncbi.nlm.nih.gov/pubmed/15877210		https://www.ncbi.nlm.nih.gov/pubmed/25732994	https://www.ncbi.nlm.nih.gov/pubmed/16773504	https://www.orpha.net/data/patho/GB/uk-MCC.pdf				
												heterozygote missense mutation, MCCA-R385S	https://www.ncbi.nlm.nih.gov/pubmed/16773504							Organic aciduria		HP:0001992											
																				EEG abnormality		HP:0002353											
																				Hypsarrhythmia		HP:0002521	https://www.ncbi.nlm.nih.gov/pubmed/16773504										
									vigabatrin	DB01080 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
																				Increased 3-hydroxyisovaleric acid excretion		NA											
																				Increased 3-methylcrotonylglycine excretion		NA											
																				Abnormal Biotinidase activity in plasma		HP:0012379											
																				EEG abnormality		HP:0002353											
									L-Carnitine	DB00583	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormality of muscle physiology		HP:0011804	https://www.ncbi.nlm.nih.gov/pubmed/10485305	https://www.ncbi.nlm.nih.gov/pubmed/18155631	https://www.ncbi.nlm.nih.gov/pubmed/17968484	https://www.ncbi.nlm.nih.gov/pubmed/16835865	https://www.ncbi.nlm.nih.gov/pubmed/16773504						
																				Secondary carnitine deficiency		HP:0003234*	https://www.ncbi.nlm.nih.gov/pubmed/8831079										
																				Elevated serum toxic intermediates		HP:0001939											
								"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896"	Glycine	DB00145 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	Drug name: controversial results	3-methylcrotonyl-CoA accumulation		NA	https://www.ncbi.nlm.nih.gov/pubmed/7474896	https://www.ncbi.nlm.nih.gov/pubmed/18155630	https://www.ncbi.nlm.nih.gov/pubmed/8831079								
																				Accumulation of 3-methylcrotonyl-CoA metabolite level (Metabolism abnormality)*		HP:0001939 *											
									Glycine +L-Carnitine	DB00145 +DB00583	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Acute metabolic crisis (Metabolism abnormality)*		HP:0001939 *	https://www.ncbi.nlm.nih.gov/pubmed/7474896	https://www.ncbi.nlm.nih.gov/pubmed/3956533									
																				Accumulation of 3-methylcrotonyl-CoA metabolite level (Metabolism abnormality)*		HP:0001939 *	https://www.ncbi.nlm.nih.gov/pubmed/7474896		https://www.ncbi.nlm.nih.gov/pubmed/11181649								
6	# 231530	3-alpha hydroxyacyl-CoA dehydrogenase deficiency 		HADH	3-hydroxylacyl-CoA dehydrogenase	1.1.1.35		 low-dose carnitine (25 mg/kg/day)	Low long-chain fats diet+Medium-chain triglycerides (MCT)+Essential fatty acids+L-carnitine	NA+DB13959+NA+DB00583	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+dietary regime modification+dietary supplementation+dietary supplementation+functional complementation of a genetically defective protein	 Drug name: Use is controverial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/?otool=igbcambulib	Secondary carnitine deficiency(Carnitine deficiency)*		HP:0003119	https://www.ncbi.nlm.nih.gov/pubmed/27117294										
																				Elevated serum creatine kinase		HP:0003236											
																				Myocardial lipid accumulation 		NA											
									Creatine	DB00148	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Exercise intolerance		HP:0003546											
																				Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/12872842										
									Vitamin E supplements	DB00163 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormality of peripheral nerves		HP:0045010	https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc										
																				Neuropathy		HP:0009830											
									Triheptanoin	DB11677	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Myalgia		HP:0003326	https://clinicaltrials.gov/ct2/show/study/NCT01379625	https://www.ncbi.nlm.nih.gov/pubmed/27117294									
																				Abnormal cardiac function		HP:0011025											
																				Fatigue		HP:0011025											
									Prednisone	DB00635	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Fatigue		HP:0011025	https://www.ncbi.nlm.nih.gov/pubmed/7748366	https://www.ncbi.nlm.nih.gov/pubmed/7748366									
																				Impaired nerve conduction		HP:0040129											
																				Defected sarcolemma		NA											
																				Defected neuronal plasma membrane		NA											
7	% 236795	3-Hydroxyisobutyric aciduria 		ALDH6A1	3-hydroxyisobutyrate dehydrogenase	1.1.1.31			Carnitine	DB00583 	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Acidemia		HP:0001941	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Disorders+of+Valine-Isoleucine+Metabolism+Bruce+Barshop&btnG=										
8	250950	3-methylglutaconyl-CoA hydratase deficiency (AUH defect) 		AUH	Methylglutaconyl-CoA hydratase	4.2.1.18			L-carnitine	DB00583 	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/28348715	https://www.ncbi.nlm.nih.gov/pubmed/20882351									
																				Abnormality of movement		HP:0100022											
																				Metabolic Decompensation		HP:0001939	https://www.ncbi.nlm.nih.gov/pubmed/11400757/										
																				Delayed Growth		HP:0001510											
9	261640	6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency		PTPS	6-pyruvoyl-tetrahydropterin synthase	4.2.3.12			Sapropterin	DB00360	ECO:0007121/ECO:0000352					Functional interaction	B	metabolite replacement		Behavioral abnormality		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/19323589	https://www.ncbi.nlm.nih.gov/pubmed/22832064	https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12003346							
																functional complementation of a genetically defective protein by stimulation				Personality disorder		HP:0012075											
																				Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/22832064										
									Antisense morpholino oligonucleotides (AMOs)	NA	ECO:0001565	c.84−322A>T, c.163 + 695_163 + 751del57, or c.164−712A>T				Direct interaction	A	direct complementation of a genetically defective protein		Pseudoexon activation 		NA	https://www.ncbi.nlm.nih.gov/pubmed/21542064										
									BH4+L-Dopa+5HTP	DB00360+DB01235+DB02959	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/25304915	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/									
																				Abnormality of neurotransmitter metabolism		HP:0012535	https://www.ncbi.nlm.nih.gov/pubmed/25304915										
																				Neurological abnormality		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/25304915										
																				Neurodevelopmental abnormality		HP:0012759	https://www.ncbi.nlm.nih.gov/pubmed/25304915										
																				Intellectual disability		HP:0001249	https://www.ncbi.nlm.nih.gov/pubmed/25304915										
																				Delayed CNS mylinaton	The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879	HP:0002188	https://www.ncbi.nlm.nih.gov/pubmed/16601879										
								The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879	Oxitriptan	DB02959	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormality of neurotransmitter metabolism		HP:0012535	https://www.ncbi.nlm.nih.gov/pubmed/25304915	https://www.ncbi.nlm.nih.gov/pubmed/16601879									
																				Abnormality in serotonin turnover (Abnormality of circulating hormone level)		HP:0003117											
								"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/"	Levodopa (L-dopa)	DB01235	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormality of neurotransmitter metabolism		HP:0012535	https://www.ncbi.nlm.nih.gov/pubmed/25304915	https://www.ncbi.nlm.nih.gov/pubmed/16601879									
																				Paroxysmal movements		HP:0007166											
																				Movement disorder		HP:0100022											
								"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/"	Carbidopa	DB00190	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Abnormality of neurotransmitter metabolism		HP:0012535	https://www.ncbi.nlm.nih.gov/pubmed/25304915	https://www.ncbi.nlm.nih.gov/pubmed/16601879									
								The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083	Pramipexole + L-dopa	DB00413+DB01235	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+metabolite replacement	 Drug name: The addition of  pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy. Similar benefits may be expected in other forms of inherited tetrahydrobiopterin deficiency. https://www.ncbi.nlm.nih.gov/pubmed/19704083	Movement Disability 		HP:0100022	https://www.ncbi.nlm.nih.gov/pubmed/19704083										
																				High prolactin level		HP:0000870											
																				Behavioural Disability		HP:0000708											
																				Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*		NA											
								It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf	Selective monoamine oxidase (MAO) B inhibitor	DB01247 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Low dopamine level		HP:0012656	https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Deprenyl+in+6-Pyruvoyl+Tetrahydropterin+Synthase+Deficiency&btnG=	https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/								
									Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase	NA	ECO:0001565					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Low tetrahydrobiopterin level		HP:0040210	https://www.ncbi.nlm.nih.gov/pubmed/8864759										
																																	
									Folinic acid	DB03256	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormal serum folate		HP:0040087											
	# 261630	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C		QDPR	Dihydropteridine reductase	1.5.1.34			BH4	DB00360						Functional interaction	B	metabolite replacement		Elevated Phe level in blood		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/7110811/	https://www.ncbi.nlm.nih.gov/pubmed/8433887/									
																				Neurological abnormality		HP:0000707											
									BH4+L-dopa+5-hydroxytryptophan	DB00360+DB01235+DB02959	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement		Elevated blood phenylalanine concentration		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/12003346	https://www.ncbi.nlm.nih.gov/pubmed/7110811/	https://www.ncbi.nlm.nih.gov/pubmed/23138986								
																				Abnormality of neurotransmitter metabolism		HP:0012535											
																				Neurological abnormality		HP:0000707											
									BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid	DB00360+DB01235+DB02959+DB03256	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein		Developmental delay		HP:0001263	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/										
																				Delayed receptive language		HP:0010863											
																				Neurological impairment		HP:0000707											
																				Hyperphenylalaninemia		HP:0004923											
									Folinic acid	DB03256	ECO:0000352					Functional interaction	B	compensatory complementation of a genetically defective protein		Progressive basal ganglia calcification		HP:0002135	https://www.ncbi.nlm.nih.gov/pubmed/2785251	https://www.ncbi.nlm.nih.gov/pubmed/12003346									
																				Subcortical calcification		HP:0007346											
																				Seizure		HP:0001250											
																																	
10	# 200100	Abetalipoproteinemia	The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038	MTTP	microsomal triglyceride transfer protein	P55157			Vitamin E therapy	DB00163 	ECO:0000352					Functional interaction	B	metabolite replacement		Nervous system abnormalities		HP:0002011	https://www.ncbi.nlm.nih.gov/pubmed/30358967	https://www.ncbi.nlm.nih.gov/pubmed/26086616	https://www.ncbi.nlm.nih.gov/pubmed/25488886		https://www.ncbi.nlm.nih.gov/pubmed/24288038						
																				Neurologic dysfunction 		HP:0000707											
																				Retinopathy		HP:0000488	https://www.ncbi.nlm.nih.gov/pubmed/3954973/										
									Medium-chain fatty acid supplements	DB13959	ECO:0000352					Functional interaction	B	metabolite replacement		Growth impairment		HP:0008897											
									Vitamin K	CHEBI:28384	ECO:0000352					Functional interaction	B	metabolite replacement		Malabsorption of lipid-soluble vitamins (Fat malabsorption)*		HP:0002630	https://www.ncbi.nlm.nih.gov/pubmed/26396722										
									Vitamin D	DB11094	ECO:0000352					Functional interaction	B	metabolite replacement		Malabsorption of lipid-soluble vitamins (Fat malabsorption)*		HP:0002630											
								Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031	Vitamin A+ Vitamin E	DB00162+DB00163 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement		Retinal degeneration		HP:0000546	https://www.ncbi.nlm.nih.gov/pubmed/11767031	https://www.ncbi.nlm.nih.gov/pubmed/30731125									
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/14749227										
									Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K	DB13959+DB00162+DB11094+DB00163+CHEBI:28384	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement		Neurological abnormalities		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/24288038										
																				Disease progression (Progressive)		HP:0003676											
								Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/	Progesteron	DB00396	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Female infertility		HP:0008222											
									Vitamin B12+iron	DB00115+DB01592	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Anemia		HP:0001903											
									Levothyroxine	DB00451	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Subclinical hypothyroidism		HP:0000821	https://www.ncbi.nlm.nih.gov/pubmed/26396722	https://www.ncbi.nlm.nih.gov/pubmed/17132287/									
									Vitamin E+Vitamin A+Vitamin D+Vitamin K+Omega-3-acid ethyl esters+Low fat diet+high medium-chain TG	DB00163 +DB00162+DB11094+CHEBI:28384+DB09539+NA+DB13959	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B+B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+dietary regime modification+metabolite replacement		Diarrhea		HP:0002014	https://www.ncbi.nlm.nih.gov/pubmed/30875496										
																				Impaired growth 		 HP:0001510											
11	# 604290	Aceruloplasminemia		CP	Ferroxidase	1.16.3.1			Deferasirox	DB01609	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		High serum ferritin concentration		HP:0003281	https://www.ncbi.nlm.nih.gov/pubmed/23049345	https://www.ncbi.nlm.nih.gov/pubmed/20301666	https://www.ncbi.nlm.nih.gov/pubmed/12044538	https://www.ncbi.nlm.nih.gov/pubmed/23049345	https://www.ncbi.nlm.nih.gov/pubmed/17911185						
																				Elevated hepatic iron concentration		HP:0012465	https://www.ncbi.nlm.nih.gov/pubmed/20801540										
																				Frequent falls 		HP:0002359	https://www.ncbi.nlm.nih.gov/pubmed/17911185										
																				"Gait imbalance
"		HP:0002141	https://www.ncbi.nlm.nih.gov/pubmed/17911185										
																				Cognitive impairment		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/17911185										
																				Gait disturbance 		HP:0001288	https://www.ncbi.nlm.nih.gov/pubmed/17911185										
									Vitamin E+ Zinc 	DB00163 +DB01593	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Tissue damage		NA	https://www.ncbi.nlm.nih.gov/pubmed/20301666		https://www.ncbi.nlm.nih.gov/pubmed/17307325								
																				Liver dysfunction		HP:0001410											
																				Pancreatic dysfunction		HP:0001738											
									Desferrioxamine	DB00746	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Increased serum ferritin		HP:0003281	https://www.ncbi.nlm.nih.gov/pubmed/9066364										
																				Diabetes mellitus		HP:0000819	https://www.ncbi.nlm.nih.gov/pubmed/9066364										
																				Elevated hepatic iron concentration		HP:0012465	https://www.ncbi.nlm.nih.gov/pubmed/15082597	https://www.ncbi.nlm.nih.gov/pubmed/9066364									
																				Iron accumulation in brain		HP:0012675	https://www.ncbi.nlm.nih.gov/pubmed/21594898										
								Deferiprone therapy had no beneficial effects in an individual in a previous report.https://www.ncbi.nlm.nih.gov/pubmed/15082597	Deferiprone	DB08826	ECO:0000179/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Iron accumulation in retina		HP:0011031	https://www.ncbi.nlm.nih.gov/pubmed/21051716										
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/21051716										
12	606175	Acetyl-carnitine deficiency (Carnitine acetyltransferase deficiency)		CRAT	Carnitine acetyltransferase	2.3.1.7			Acetylcarnitine	DB08842	ECO:0000352					Functional interaction	B	metabolite replacement		Fasting ketogenesis		HP:0001946/HP:0025212	https://www.ncbi.nlm.nih.gov/pubmed/30061399										
																				Cardiac dysfunction		HP:0011025											
																				Delayed growth		HP:0001510											
																				Cognitive impairment		HP:0100543											
								THe hyperlipidemic drug fenofibrate being a more potent one, as a consequence of its pharmacological interaction	L-carnitine + fenofibrate	DB00583+DB01039	ECO:0001565					Direct interaction+Direct interaction	A+A	combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+activity modification of a genetically defective protein by transcriptional or translational modification		Abnormal CrAt activity (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/24962334										
13	# 201100	Acrodermatitis enteropathica 		SLC39A4	zinc/iron-regulated transporter-like protein 	Q6P5W5			Zinc 	DB01593	ECO:0000352					Functional interaction	B	metabolite replacement		Skin inflammation		HP:0011123	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/	https://www.ncbi.nlm.nih.gov/pubmed/24718477									
																				Alopecia		HP:0001596											
																				Agitation		HP:0000713											
																				Irritability		HP:0000737											
																				Diarrhea		HP:0002014											
																				Emotional disturbances		HP:0000712											
									Zinc+ linoleic acid	DB01593+DB14104	ECO:0000352					Functional interaction+Symptomatic	B+C	combination therapeutic procedure+metabolite replacement+symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/16224175										
								"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070"	Diiodoquinoline	DB09115	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Acrodermatitis (Dermatitis)*		HP:0011123	https://www.ncbi.nlm.nih.gov/pubmed/14354277	https://www.ncbi.nlm.nih.gov/pubmed/13044560	https://www.ncbi.nlm.nih.gov/pubmed/4929571	https://www.ncbi.nlm.nih.gov/pubmed/1275520							
																				Diarrhea		HP:0002014											
																				Alopecia		HP:0001596											
																				Perioral dermatitis		HP:0040181											
									Clioquinol	DB04815	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Dermatitis		HP:0011123	https://www.ncbi.nlm.nih.gov/pubmed/375935										
																																	
																																	
								A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644	Zn-DTSM (zinc ionophore)	PubChem SID:329770515	ECO:0001565/ ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Generalized abnormality of skin		"HP:0011354
"	https://www.ncbi.nlm.nih.gov/pubmed/30669644										
																				Failure to thrive		"HP:0001508
"											
																																	
																																	
14	# 176000	Acute intermittent porphyria 		HMBS	Hydroxymethylbilane synthase.	2.5.1.61		"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787"	Glucose	DB09341	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Excretion of heme precursors (Abnormality of the heme biosynthetic pathway)*		HP:0010472	https://clinicaltrials.gov/ct2/show/NCT02180412		https://www.ncbi.nlm.nih.gov/pubmed/26366103								
																				Abdominal pain		HP:0002027											
																				Nausea and Vomiting		HP:0002017											
																				Mild attack:mild pain (Mild)*		HP:0012825	https://www.ncbi.nlm.nih.gov/pubmed/23605132/										
									Panhematin	DB03404	ECO:0000352/ECO:0007121					Functional interaction	B	metabolite replacement		Pain		HP:0012531	https://clinicaltrials.gov/ct2/show/NCT02922413	https://clinicaltrials.gov/ct2/show/NCT02180412	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/	https://www.ncbi.nlm.nih.gov/pubmed/15767622/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201					
																				Hypertension		HP:0000822											
																				Tachycardia		HP:0001649											
																				Abnormal mental status		HP:0100543											
																				Acute attack (Acute)*		HP:0011009											
								The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/	rh-HMBS	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Accumulated  plasma porphobilinogen		NA	https://www.ncbi.nlm.nih.gov/pubmed/17375984/										
																				Accumulated  urine porphobilinogen		HP:0012217											
									rhPBGD	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Eevated porphyrin precursors porphobilinogen		HP:0012217	https://www.ncbi.nlm.nih.gov/pubmed/15208740/										
									rAAV8-mediated gene therapy expressing murine HMB-synthase 	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hepatic metabolic abnormalities (Metabolism abnormality)*		HP:0001939*	https://www.ncbi.nlm.nih.gov/pubmed/19861948										
																				Abnormal neuromotor function		HP:0002333											
								 There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317	AAV2/5-PBGD	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Low PBGD expression in liver (Abnormality of circulating enzyme level)*		HP:0011021	https://www.ncbi.nlm.nih.gov/pubmed/24933563	https://www.ncbi.nlm.nih.gov/pubmed/24933563									
									Givosiran	DB15066	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Abnormal circulating porphyrin concentration		HP:0010472	https://www.ncbi.nlm.nih.gov/pubmed/30766957	https://www.ncbi.nlm.nih.gov/pubmed/30726693	https://www.ncbi.nlm.nih.gov/pubmed/24821812	https://clinicaltrials.gov/ct2/show/NCT02452372							
15	# 614723	Adenine phosphoribosyltransferase deficiency 		APRT	Adenine phosphoribosyltransferase	2.4.2.7			Allopurinol	DB00437 	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Urolithiasis		HP:0000787	https://clinicaltrials.gov/ct2/show/NCT02752633	https://www.ncbi.nlm.nih.gov/books/NBK100238/	https://academic.oup.com/ckj/article/9/6/800/2709623	https://www.ncbi.nlm.nih.gov/pubmed/29241594							
																				Crystalline nephropathy		HP:0000112											
																				Hematuria		HP:0000790											
																				Dysuria		HP:0100518											
																				Recurrent urinary tract infections		HP:0000010											
																				Chronic kidney disease		HP:0012622											
																				Elevated Urinary DHA excretion		NA	https://www.ncbi.nlm.nih.gov/pubmed/29241594										
																				Kidney stones 		HP:0000787											
								"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/"	Febuxostat	DB04854	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Urolithiasis		HP:0000787	https://clinicaltrials.gov/ct2/show/NCT02752633	https://www.ncbi.nlm.nih.gov/books/NBK100238/	https://www.ncbi.nlm.nih.gov/pubmed/29241594								
																				Crystalline nephropathy		HP:0000112											
																				Hematuria		HP:0000790											
																				Dysuria		HP:0100518											
																				Recurrent urinary tract infections		HP:0000010											
																				Chronic kidney disease		HP:0012622											
																				Elevated Urinary 2,8-dihydroxyadenine (DHA) excretion		NA	https://www.ncbi.nlm.nih.gov/pubmed/29241594										
16	# 102700	ADENOSINE DEAMINASE DEFICIENCY, PARTIAL,		ADA	Adenosine deaminase	3.5.4.4			Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase)	DB14712	ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein		Lymphopenia		HP:0001888	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/	https://clinicaltrials.gov/ct2/show/NCT03878069								
																				Hepatosplenomegaly		HP:0001433											
																				Elevated liver enzyme levels		HP:0002910											
																				Low weight		HP:0004325											
																				Abnormal eosinophil counts		HP:0001879											
																				Hemolysis		HP:0001878			https://www.ncbi.nlm.nih.gov/pubmed/20301530								
																				Thyroid antibodies (autoimmunity)*		HP:0002960											
																				Abnormal immune function		HP:0010978	https://clinicaltrials.gov/ct2/show/NCT01420627		https://www.ncbi.nlm.nih.gov/pubmed/16002636								
																				Dermatitis		HP:0011123											
								Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/	Pegademase bovine ((PEG-ADA))	DB00061  	ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein		Abnormal immune function		HP:0010978	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/										
																				Recurrent infection 		HP:0002719											
																				Frequent, severe infections 		HP:0002719											
																				Abnormal lymphocyte counts		HP:0040088											
																				Abnormal number of b cells		HP:0010975											
																																	
								IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/	Immune Globulin Human	DB00028	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Recurrent infection		HP:0002719	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/										
17	# 615511	Adenosine monophosphate deaminase 1 deficiency 		 AMPD1	AMP deaminase	3.5.4.6			D- Ribose	DB02053 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Exercise-induced muscle fatigue		HP:0009020	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Genetic+Predictors+of+Adenosine+Monophosphate+Deaminase+Deficiency&btnG=										
																				Exercise-induced myalgia		HP:0003738											
																				Limb muscle weakness		HP:0003690											
																				Muscle cramps		HP:0003394											
18	# 300100	Adrenomyeloneuropathy 		ABCD1	adrenoleukodystrophy protein			It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732 3:https://www.ncbi.nlm.nih.gov/pubmed/10449548?dopt=Abstract	Lorenzo's oil (Terminated)	DB12528	ECO:0007121					Supportive	C	symptomatic therapeutic procedure		Disease progression		HP:0003678	https://clinicaltrials.gov/ct2/show/NCT00545597	https://www.ncbi.nlm.nih.gov/pubmed/16009761	https://www.ncbi.nlm.nih.gov/pubmed/7666063	https://www.ncbi.nlm.nih.gov/pubmed/15670720/							
																				Abnormal elevated level of VLCFA in plasma		HP:0003455											
									Lenti-D gene therapy (advanced self-inactivating lentiviral vector TYF-ABCD1)	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Functional disability (Constitutional symptom)*		HP:0025142	https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4	https://clinicaltrials.gov/ct2/show/NCT01896102	https://www.ncbi.nlm.nih.gov/pubmed/28976817								
								The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/	Sobetirome (NV1205)	DB07425	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementatoin of a genetically defective protein by stimulation		Elevated long chain fatty acids		HP:0003455	https://www.ncbi.nlm.nih.gov/pubmed/28200172	https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3									
									Bezafibrate 	DB01393	ECO:0001565					Functional interaction	B	functional complementatoin of a genetically defective protein by inhibition		High very long‐chain fatty acids		HP:0008167	https://www.ncbi.nlm.nih.gov/pubmed/22447153										
								Contraversial results for this treatment option.	Lovastatin	DB00227	ECO:0000352/ECO:0001565/ECO:0007121					Symptomatic	C	functional complementatoin of a genetically defective protein		High plasma level of very-long-chain fatty acids  		HP:0003455	https://www.ncbi.nlm.nih.gov/pubmed/16949688	https://www.ncbi.nlm.nih.gov/pubmed/10870849	https://www.ncbi.nlm.nih.gov/pubmed/20089986								
																				High plasma levels of hexacosanoic acid 		NA	https://www.ncbi.nlm.nih.gov/pubmed/10870849										
								All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub 	Interferon beta + Thalidomide	DB00060+DB01041	ECO:0007121					Supportive+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure					https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20		https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects								
									Temsirolimus	DB06287	ECO:0000179/ECO:0001565					Functional interaction	B	functional complementatoin of a genetically defective protein by inhibition		Imparied autophagy		MP:0030940	https://www.ncbi.nlm.nih.gov/pubmed/25549970										
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/26073123	https://www.ncbi.nlm.nih.gov/pubmed/26684655									
																				Axonal degeneration		MP:0005405	https://www.ncbi.nlm.nih.gov/pubmed/26073123										
									Pioglitazone 	DB01132	ECO:0000179					Functional interaction	B	functional complementatoin of a genetically defective protein by stimulation		Axonal degeneration		MP:0005405	https://www.ncbi.nlm.nih.gov/pubmed/26684655										
																				Locomotor disability		MP:0001392											
																				Oxidative stress		HP:0025464											
																				Low ATP level		MP:0010106											
									α-tocopherol+ N-acetyl-cysteine + α-lipoic acid	DB00163+DB06151+DB00166	ECO:0000179					symptomatic+symptomatic+symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative damage 		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/22353463	https://www.ncbi.nlm.nih.gov/pubmed/21786300									
																				Energetic failure(Fatigable weakness)*		HP:0003473	https://www.ncbi.nlm.nih.gov/pubmed/22353463										
																				Axonal degeneration		MP:0005405	https://www.ncbi.nlm.nih.gov/pubmed/22353463	https://www.ncbi.nlm.nih.gov/pubmed/21786300									
																				Locomotor impairment		MP:0001392	https://www.ncbi.nlm.nih.gov/pubmed/22353463	https://www.ncbi.nlm.nih.gov/pubmed/21786300									
									α-lipoic acid + N-acetyl-cysteine	DB00166+DB06151	ECO:0000179					Symptomatic+symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative damage 		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/21453200										
									Lentiviral-mediated gene therapy of hematopoietic stem cells	NA	ECO:0000179/ECO:0001565					Direct interacion	A	direct complementation of a genetically defective protein by gene therapy		Hyperintensity of cerebral white matter on MRI 		HP:0030890	https://www.ncbi.nlm.nih.gov/pubmed/19892975?dopt=Abstract										
																				CNS demyelination 		HP:0007305	https://www.ncbi.nlm.nih.gov/pubmed/19892975										
									Hydrocortisone	DB00741	ECO:0000352					Functional interaction	B	metabolite replacement		Spastic paraparesis		HP:0002313	https://www.ncbi.nlm.nih.gov/pubmed/19892975										
																				Polyneuropathy		HP:0001271	https://www.ncbi.nlm.nih.gov/pubmed/19892975										
																				Adrenal insufficiency		HP:0008207	https://www.researchgate.net/publication/301352258_Adrenoleukodystrophy_two_case_reports										
								Repeated cyclophosphamide pulse therapy has failed to halt the clinical progression or alter the gadolinium accumulation in two cases of childhood cerebral ALD.	Cyclophosphamide	DB00531	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/22430161										
19	# 263570	Adult polyglucosan body disease 		GBE1	Limit dextrin alpha-1,6-maltotetraose-hydrolase	3.2.1.196			Triheptanoin	DB11677	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Muscle pain		HP:0003326	https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1										
																				Defective heart function		HP:0011025											
																				Lack of energy		HP:0012378											
20	# 603471	adult-onset type II citrullinemia	Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/	 SLC25A13	citrin ( protein)	Q9UJS0		Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749	Medium-chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High blood ammonia level		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/29651749		https://www.ncbi.nlm.nih.gov/pubmed/26427088								
																				Relapse of hyperammonemic encephalopathy		HP:0001298*											
																				High plasma citrulline levels		HP:0011966											
																				Low plasma glutamine levels		HP:0010903											
									L-Arginine	DB00125 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/18958581	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/	https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315								
																				Disease progression (Rapidly progressive)*		HP:0003678*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/										
																				Encephalopathy		HP:0001298	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+case+of+adult-onset+type+II+citrullinemia+in+which+oral+administration+of+L-Arginine+Granules+improved+the+patient%27s+encephalopathy+and+the+increased+level+of+serum+ammonia&btnG=										
									Pyruvic acid	DB00119	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/	https://www.ncbi.nlm.nih.gov/books/NBK1181/									
								It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/	L-Arginine+Pyruvic acid	DB00125+DB00119	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Anorexia		HP:0002039	https://www.ncbi.nlm.nih.gov/pubmed/18958581										
																				Lethargy		HP:0001254											
																				Fatigue		HP:0012378											
																				Poor growth		HP:0001510											
																				Hyperammonemia		HP:0001987											
																				Elevated plasma citrulline level		HP:0011966											
																				Elevated threonine-to-serine ratio (Abnormality of amino acid metabolism)*		HP:0004337*											
																				Elevated serum pancreatic secretory trypsin inhibitor		NA											
								"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956"	D-mannitol	DB00742	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Brain oedema		HP:0002181	https://www.ncbi.nlm.nih.gov/pubmed/16449956										
21	# 612953	Adult-onset dystonia-parkinsonism 		PLA2G6	Phospholipase A(2)	3.1.1.4		It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	Pergolide	DB01186	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name: It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	Parkinsonism		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/24613933										
								Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/	L- dopa	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Parkinsonism		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/25660576/	https://www.ncbi.nlm.nih.gov/pubmed/20938027	https://www.ncbi.nlm.nih.gov/pubmed/19087156/	https://www.ncbi.nlm.nih.gov/pubmed/18570303/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/	https://www.ncbi.nlm.nih.gov/pubmed/20619503					
22	# 615395	Combined oxidative phosphorylation deficiency 16		MRPL44	MITOCHONDRIAL RIBOSOMAL PROTEIN L44	Q9H9J2			Creatine	DB00148	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Low physical capacity (Constitutional symptom)*		HP:0025142	https://www.ncbi.nlm.nih.gov/pubmed/25797485										
23	# 607765	Congenital bile acid synthesis defect, type 1		HSD3B7	3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE	1.1.1.181/Q9H2F3			Cholic acid	DB02659 	ECO:0007121					Functional interaction	B	metabolite replacement		Hepatic Biochemical abnormalities (Laboratory abnormality)*		HP:0001939*	https://www.ncbi.nlm.nih.gov/pubmed/11067870										
																				Histologic abnormalities in liver (Abnormal test result)*		HP:0500014											
																				Progression of the disease (Rapidly progressive)*		HP:0003678*											
																				Bile flow defect		HP:0001396											
																				Synthesis of atypical bile acids		NA											
																				Production of toxic intermediates (Abnormality of metabolism)*		HP:0001939*											
																				Fat soluble vitamin malabsorption (Fat malabsorption)*		HP:0002630*											
									Chenodeoxycholic acid	DB06777	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal liver function tests		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/2072042	https://www.ncbi.nlm.nih.gov/pubmed/11067870									
																				Pruritus		HP:0000989	https://www.ncbi.nlm.nih.gov/pubmed/11067870										
																				Abnormal urinary steroids levels (Abnormality of urine hormone level)*		HP:0012029											
									Ursodeoxycholic acid	DB01586	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal liver function tests		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/7915305										
									Glycocholic Acid	DB02691	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/										
																				Fat soluble vitamin malabsorption (Fat malabsorption)*		HP:0002630*											
									Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid	DB00162+DB11094+DB01022+DB00163+DB01586+DB06777	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B+B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Fat soluble vitamin malabsorption (Fat malabsorption)*		HP:0002630*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/										
																				Abnormal gait		HP:0001288											
																				Muscle weakness		HP:0001324											
24	# 235555	Congenital bile acid synthesis defect, type 2 		AKR1D1	DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE	EC 1.3.1.3		Treatment with cholic acid (10–20 mg/kg daily) should be titrated to ensure that urinary excretion of Δ4-3-oxo bile acids ceases. https://www.ncbi.nlm.nih.gov/pubmed/18577977	Cholic acid	DB02659 	ECO:0000352					Functional interaction	B	metabolite replacement		Biochemical abnormalities		HP:0001939*	https://www.ncbi.nlm.nih.gov/pubmed/8225213	https://www.ncbi.nlm.nih.gov/pubmed/19622360									
																				Histologic abnormalities in liver (Abnormal test result)*		HP:0500014											
																				Disease progression (Rapidly progressive)*		HP:0003678*											
																				Bile flow defect		HP:0001396											
																				Synthesis of atypical bile acids		NA											
																				Production of bile acid toxic intermediates		HP:0001939*											
																				Fat soluble vitamin malabsorption (Fat malabsorption)*		HP:0002630*											
								While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100	Chenodeoxycholic acid + cholic acid	DB06777+DB02659 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement		Abnormal liver function tests		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/8707100										
																				Abnormal bilirubin level		HP:0002904											
								There are some studies that have concerns over potential hepatotoxicity in animal models of the disease when treated by bile acid replacement therapy that result in curbing the use of chenodeoxycholic acid.https://www.ncbi.nlm.nih.gov/pubmed/15383928/ https://www.ncbi.nlm.nih.gov/pubmed/7075428/ https://www.ncbi.nlm.nih.gov/pubmed/7409382/	Chenodeoxycholic acid	DB06777	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal liver function 		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/28697823	https://www.ncbi.nlm.nih.gov/pubmed/2248502/									
																				Hepatomegaly 		HP:0002240											
																				Abnormal bilirubin level		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/2248502/										
																				Poor appetite		HP:0004396	https://www.ncbi.nlm.nih.gov/pubmed/2248502/										
																				Pruritus		HP:0000989	https://www.ncbi.nlm.nih.gov/pubmed/2248502/										
																				Lethargy		HP:0001254	https://www.ncbi.nlm.nih.gov/pubmed/2248502/										
25	# 203500	Alkaptonuria 		HGD	Homogentisate 1,2-dioxygenase.	1.13.11.5		Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864 https://www.ncbi.nlm.nih.gov/pubmed/31037385. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html	Nitisinone	DB00348  	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Disease progression (Rapidly progressive)*		HP:0003678*	https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4	https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/28813744	https://www.ncbi.nlm.nih.gov/pubmed/30477028	https://www.ncbi.nlm.nih.gov/pubmed/30049652	https://www.ncbi.nlm.nih.gov/pubmed/28643719	https://clinicaltrials.gov/ct2/show/NCT01390077?cond=alkaptonuria&draw=2&rank=4				
																				Ochronosis progression (progressive)*		HP:0030764	https://www.ncbi.nlm.nih.gov/pubmed/26891864	https://www.ncbi.nlm.nih.gov/pubmed/23511227	https://www.ncbi.nlm.nih.gov/pubmed/25940034	https://www.ncbi.nlm.nih.gov/pubmed/30055994							
																				High circulating HGA (homogentisic acid) level		NA	https://www.ncbi.nlm.nih.gov/pubmed/26891864	https://www.ncbi.nlm.nih.gov/pubmed/31296884	https://www.ncbi.nlm.nih.gov/pubmed/31235217	https://www.ncbi.nlm.nih.gov/pubmed/23511227							
																				Joint disesae		HP:0001367											
									N-ACETYL-CYSTEINE	DB06151	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Induced apoptosis in chondrocytes		NA	https://www.ncbi.nlm.nih.gov/pubmed/23704321	https://www.ncbi.nlm.nih.gov/pubmed/20648626	https://www.ncbi.nlm.nih.gov/pubmed/21874298/								
								Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/	ASCORBIC ACID	DB00126	ECO:0000352					Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864 https://www.ncbi.nlm.nih.gov/pubmed/31037385. Dietary restriction of tyrosine and phenylalanine lowers tyrosinaemia associated with nitisinone therapy of alkaptonuria https://www.ncbi.nlm.nih.gov/pubmed/31503358  #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html	C	symptomatic therapeutic procedure		Abnormal chondrocyte growth 		NA	https://www.ncbi.nlm.nih.gov/pubmed/9718357/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/									
																				Disease progression (Rapidly progressive)*		HP:0003678*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/										
																				Abnormality of proteoglycan metabolism (Abnormality of metabolism)*		HP:0004355											
									Methotrexate 	DB00563	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		HGA-induced A-amyloid aggregates		NA	https://www.ncbi.nlm.nih.gov/pubmed/22850426										
26	# 613490	Alpha-1 antitrypsin deficiency 		SERPINA1	alpha-1-antitrypsin (major plasma serine protease inhibitor)	P01009		 The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated. Diphenhydramine Terminated Phase 1 Trials for Alpha-1 Antitrypsin Deficiency Treatment.	ARC-AAT	NA	ECO:0007121					Direct interaction	A	procedure to mitigate dominant effects of a genetically abnormal protein					https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2		https://clinicaltrials.gov/ct2/show/NCT02900183								
									Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Reduced serum alpha-1-antitrypsin HP:0032025		HP:0032025	https://www.ncbi.nlm.nih.gov/pubmed/26067712	https://www.ncbi.nlm.nih.gov/pubmed/30194601	https://www.ncbi.nlm.nih.gov/pubmed/23527792	https://www.ncbi.nlm.nih.gov/pubmed/17115945/	https://www.ncbi.nlm.nih.gov/pubmed/9826709/	https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=101.+Toxicology+and+biodistribution+studies+of+a+recombinant+adeno-associated+virus+2+(rAAV2)+alpha-1+antitrypsin+(AAT)+vector[AST]&author=AE+Poirier&author=LA+Combee&author=AT+Martino&volume=9&publication_year=2004&pages=S40&	https://www.ncbi.nlm.nih.gov/pubmed/12231168/	https://www.ncbi.nlm.nih.gov/pubmed/19706466/			
									Recombinant alpha 1-antitrypsin (rAAT)	DB05481	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Progressive emphysema		HP:0002097	https://www.ncbi.nlm.nih.gov/pubmed/30723781	https://www.ncbi.nlm.nih.gov/pubmed/15978931/	https://www.ncbi.nlm.nih.gov/pubmed/27564673								
																				Decreased lung function 		HP:0005952											
																				Recurrent infection		HP:0002719											
								AAT augmentation therapy has the disadvanyages of protein infusion, and risk of viral contamination and allergic reactions, and is costly	AAT Augmentation Therapy(plasma-derived AAT)	NA	ECO:0000352					Direct interaction		metabolite replacement		Reduced serum alpha-1-antitrypsin HP:0032025		HP:0032025	https://www.ncbi.nlm.nih.gov/pubmed/18413692	https://www.ncbi.nlm.nih.gov/pubmed/20812844/									
									Retinoic acid	DB00755	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Alveoli damage (interstitial pulmonary abnormality)*		HP:0006530	https://www.ncbi.nlm.nih.gov/pubmed/22282548/										
									rAAV-CB-hAAT/rAAV1-AAT 	NA	ECO:0000179/ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Reduced serum alpha-1-antitrypsin HP:0032025		HP:0032025	https://www.ncbi.nlm.nih.gov/pubmed/20812844/	https://clinicaltrials.gov/ct2/show/NCT01054339	https://www.ncbi.nlm.nih.gov/pubmed/21609134/	https://www.ncbi.nlm.nih.gov/pubmed/19706466/	https://www.ncbi.nlm.nih.gov/pubmed/24231351/						
									Beta2-agonists +corticosteroids + anti-cholinergics	R03CC+S03BA+S01FA	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Difficulty breathing		HP:0002098											
																				Lung inflammation (Abnormality of respiratory system)		HP:0002086											
27	* 609458	Alpha-mannosidosis 		MAN2B1	Alpha-mannosidase	 3.2.1.24			Lamazym(rhLAMAN)	DB12374	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Reduced pulmonary function		HP:0005952	https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3	https://www.ncbi.nlm.nih.gov/pubmed/26827607	https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/23494656	https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0		http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/			
																				Low FVC%		HP:0030878*											
																				High NFL (neurofilament light signature ) in CSF		NA											
																				Elevated GFAP (Glial fibrillary acidic protein) level in CSF		NA											
																				Elevated Tau-p level in CSF		NA											
																				High CSF MAN2-oligosaccharides		NA											
																				Cognitive deficits		HP:0100543											
									AAV1vector expressing α-Mannosidase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Neurological abnormality		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode										
28	# 207800	Arginase deficiency 		ARG1	Arginase	3.5.3.1		The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807	Glycerol phenylbutyrate	DB08909	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Low quality of life (Constitutional symptom )*		HP:0025142*	https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/								
									AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Elevated blood arginine levels (Abnorality in arginie metabolism)*		HP:0010909*	https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/26358771									
																				Unstable neurological function (Abnormality of the nervous system)*		HP:0000707*											
																				Disease progression (Rapidly progressive)*		HP:0003678*											
								Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549	Sodium benzoate	DB03793	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/11148549	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title									
									Sodium phenylbutyrate	DB06819	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/11148549										
									AAV-based gene therapy	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Neurotoxicity		NA	https://www.ncbi.nlm.nih.gov/pubmed/25474440		https://www.ncbi.nlm.nih.gov/pubmed/23388701			https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813					
																				Neurological abnormalities		HP:0000707											
																				Cognitive dysfunction		HP:0100543											
29	# 207900	Argininosuccinic aciduria 		ASL	argininosuccinate lyase	4.3.2.1			Nitric oxide supplement	DB00435	ECO:0000179/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertension		HP:0000822	https://www.ncbi.nlm.nih.gov/pubmed/22541557		https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub								
																				Absence of flow-mediated dilatation of brachial artery		NA											
																				Endothelial dysfunction		NA											
																				Left ventricular hypertrophy 		HP:0001712											
																				Cognitive impairment 		HP:0100543											
																																	
									Sodium citrate 	DB09154 	ECO:0000352					Symptomatic	C	functional complementation of a genetically defective protein		Abnormal renal nitrogen elimination		HP:0004364	https://www.ncbi.nlm.nih.gov/pubmed/8582405										
									keto-analogues of essential amino acids	NA	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Seizure		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/668730										
																				High blood ammonia levels		HP:0001987											
																				Defective argininosuccinic acid excretion		HP:0001939*											
									Sodium Phenylbutyrate +Arginin	DB06819+DB00125 	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://clinicaltrials.gov/ct2/show/NCT00345605	https://www.ncbi.nlm.nih.gov/pubmed/8582405									
									Arginine	DB00125 	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormal hepatic function tests		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/19585269	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/	https://www.ncbi.nlm.nih.gov/pubmed/23040521								
																				Low plasma arginine levels		HP:0005961											
																				Acute hyperammonemia		HP:0008281											
30	# 608643	Aromatic L-amino acid decarboxylase deficiency 		 DDC	Aromatic-L-amino-acid decarboxylase	4.1.1.28			AAV2-hAADC ( Gene therapy)	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Motor malperformance		HP:0002275	https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2		https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/						
																				Increased dopamine and serotonin levels (neurotransmitter levels)		HP:0012654											
									Bromocriptine 	DB01200	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		hypokinesia		HP:0002375	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/										
																				Axial hypotonia		HP:0008936											
																				Limb hypertonia		HP:0002509											
																				Dystonia		HP:0001332											
																				Choreoathetosis		HP:0001266											
																				Poor head control		HP:0002421											
																				Oculogyric crises		HP:0010553											
																				Abnormalitilty in voluntary movements (Abnormality of movement)*		HP:0100022*											
																				Autonomic dysfunction		HP:0002459											
									Pyridoxine	DB00165 	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Low residual AADC activity (Abnormal enzyme/coenzyme activity)*		HP:0012379											
								Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/	Pyrodixal 5 phosphate	DB00114	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Low residual AADC activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/25001633/										
									Pramipexole	DB12890	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/	Hypotonia		HP:0001290	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/										
																				Oculogyric crisis		HP:0010553											
																				Poor head control		HP:0002421											
																				Voluntary movement abnormalities (Abnormality of movement)*		HP:0100022*											
																				Autonomic dysfunction		HP:0002459											
								In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.	Rotigotine	DB05271	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypotonia		HP:0001290	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/	https://www.ncbi.nlm.nih.gov/pubmed/23390030/									
																				Oculogyric crisis		HP:0010553											
																				Poor head control		HP:0002421											
																				Voluntary movement abnormalities (Abnormality of movement)*		HP:0100022*											
																				Autonomic dysfunction		HP:0002459											
									Pergolide	DB01186	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypotonia		HP:0001290	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/										
																				Oculogyric crisis		HP:0010553											
																				Poor head control		HP:0002421											
																				Voluntary movement abnormalities (Abnormality of movement)*		HP:0100022*											
																				Autonomic dysfunction		HP:0002459											
									Folinic acid	DB00650	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Cerebral folate depletion		HP:0012446	https://www.ncbi.nlm.nih.gov/pubmed/25001633/										
								From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/	Pargyline	DB01626	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypotonia		HP:0001290	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/										
31	# 301835	Arts Syndrome		PRPS1	Ribose-phosphate diphosphokinase	2.7.6.1			S-adenosylmethionine	DB00118	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		low levels of purines		HP:0004369	https://www.sciencedirect.com/science/article/pii/S0002929707613470	https://www.ncbi.nlm.nih.gov/pubmed/20380929	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/	https://www.ncbi.nlm.nih.gov/pubmed/28967191	https://www.ncbi.nlm.nih.gov/pubmed/17701896						
																				Progression of retinal degeneration (Rapidly Progressive)*		HP:0003678*											
																				Ataxia Progression (Rapid progression)		HP:0002719	https://www.ncbi.nlm.nih.gov/pubmed/23190330										
																				Recurrent infection		HP:0002719											
																				Frequent hospital admission		NA											
																				Hearing impairment progression (Rapid progression)*		HP:0003678*											
																				Noctornal difficulty breathing		HP:0002098											
32	208400	Aspartylglycosaminuria 	As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years	 AGA	N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase	3.5.1.26		Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835 	Amlexanox	DB01025	ECO:0001565	Ser72Pro/Trp168X				Direct interaction	A	activity modification of a genetically defective protein		Low AGA activity (Abnormal enzyme/coenzyme activity)*		HP:0012379		https://www.ncbi.nlm.nih.gov/pubmed/29247835			https://www.ncbi.nlm.nih.gov/pubmed/29247835						
								The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".	betaine	DB06756	ECO:0001565	T122K	Our data show that both T122K and AGU-Fin AGA enzyme variants most likely exhibit a relatively local folding defect that neither completely impairs the structure, nor results in severe destabilization and degradation of the mutant enzyme. These findings are somewhat contradictory to what has been proposed for the AGU-Fin mutated AGA, which has been suggested to become rapidly degraded after synthesis in the ER19,28. However, these previous studies have been based on overexpression of the mutated enzyme mainly in chinese hamster ovarian cells, which may result in ER overload and unfolded protein response, facilitating the degradation of the AGU-Fin mutant precursors. We here show that endogenous T122K and AGU-Fin AGA in patient fibroblasts do not colocalize with the ER marker calnexin, whereas a high degree of colocalization was observed with lysosomal markers. However, it is likely that the misfolding induced by T122K mutation is milder than that of AGU-Fin which impairs the formation of an intramolecular disulfide bond20. This would also be consistent with the data that the PC-like compounds used here showed a higher increase of enzyme activity in the case of T122K than AGU-Fin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/			Direct interaction	A	activity modification of a genetically defective protein		Low AGA activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.nature.com/articles/srep37583/figures/5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/									
																				Unstable AGA enzyme (Abnormal enzyme activity)*		HP:0012379											
																				Misfolded AGA 		NA											
																				Abnormal AGA processing		NA											
									Glycine	DB00145						Direct interaction	A	activity modification of a genetically defective protein		Low AGA activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.nature.com/articles/srep37583/figures/5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/	https://www.ncbi.nlm.nih.gov/pubmed/23601642								
								There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610	Recombinant human Aspartylglucosamidase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Pathology in many somatic tissues (Somatic nervous system abnormalities)*		MP:0002752	https://www.ncbi.nlm.nih.gov/pubmed/10657992	https://www.ncbi.nlm.nih.gov/pubmed/20607610/	https://www.ncbi.nlm.nih.gov/pubmed/15342551/		https://www.ncbi.nlm.nih.gov/pubmed/27906067						
																				Glycoasparagines accumulation (Metaboic abnormality)*		HP:0001939*											
																				High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*		HP:0001939*											
																				High amount of aspartylglucosamine in brain tissue ((Metabolism abnormality)*)		HP:0001939*											
								"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336"	Gene therapy (wild-type Ad-AGA)	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Low expression of AGA enzyme (Abnormality of circulating enzyme level)*		HP:0011021	https://www.ncbi.nlm.nih.gov/pubmed/9930336/										
																				Liver lysosomal storage abnormality (Abnormality of lysosomal metabolism)*		HP:0004356											
																				Brain lysosomal storage disease (Abnormality of lysosomal metabolism)*		HP:0004356											
																				Brain neuronal storage abnormalities -ipsilateral (Abnormality of lysosomal metabolism)*		HP:0004356	https://www.ncbi.nlm.nih.gov/pubmed/16518877/										
33	# 277460	Ataxia with vitamin E deficiency 		TTPA	α-tocopherol transfer protein 	P49638		There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.	Vitamin E	DB00163	ECO:0000352					Functional interaction	B	metabolite replacement		Disease progression (Rapidly progressive)*		HP:0003678*	https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/20301419	https://www.ncbi.nlm.nih.gov/pubmed/17586848	https://www.ncbi.nlm.nih.gov/pubmed/15300460							
																				Abnormal vitamin E level (Vitamin E deficiency)*		HP:0100513*											
																				Ataxia		HP:0001251	https://www.ncbi.nlm.nih.gov/pubmed/9931538	https://www.ncbi.nlm.nih.gov/pubmed/11554913									
																				Neurological abnormalitis		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/11554913	https://www.ncbi.nlm.nih.gov/pubmed/15300460									
									RRR-α-tocopherol	DB14002	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*		HP:0030390*	https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub										
																				Abnormal H50 (The erythrocyte resistance to oxidative stress)		NA											
34	#208900	Ataxia Telangectesia		ATM	ATM serine/threonine kinase	2.7.11.21			Myo-inositol	DB13178	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		neurological malfunction		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/17586848										
																				immune dysfunctions		HP:0002715											
									Alpha lipoic acid 	DB00166	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Neuronal death		HP:0002529	https://www.ncbi.nlm.nih.gov/pubmed/17586848										
																				Oxidative stress 		HP:0025464											
									Nicotinamide	DB02701	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal levels of urine total alkanes		NA	https://www.ncbi.nlm.nih.gov/pubmed/17586848										
																				Oxidative stress 		HP:0025464											
									Alpha-lipoic acid + nicotinamide	DB00166+DB02701	ECO:0007121					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Abnormal serum fast ORAC (oxygen reduced absorbance capacity)		NA											
																				Abnormal lymphocyte counts		HP:0040088	https://www.ncbi.nlm.nih.gov/pubmed/17586848										
									Immunoglobulin replacement therapy	DB00028	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Recurrent infection		HP:0002719	https://www.ncbi.nlm.nih.gov/pubmed/28318010										
									Amantadine	DB00915	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Ataxia		HP:0001251	https://www.ncbi.nlm.nih.gov/pubmed/22550086/										
																				Involuntary movements		HP:0004305											
																				Parkinsonism		HP:0001300											
									Clonazepam	DB01068	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Myoclonuic Jerk		HP:0001336	https://www.ncbi.nlm.nih.gov/pubmed/26232052/										
																				Poor fine motor skills		HP:0007010											
																				Voice tremor		HP:0012477											
																				Poor intelligibility		HP:0001249											
								Study is not yet recruiting. The drug is ment to correct the ataxi	Acetylleucine	DB13226	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure					https://clinicaltrials.gov/ct2/show/NCT03759678										
									4-aminopyridine	DB06637	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Periodic alternating nystagmus (Horizontal nystagmus)*		HP:0000666	https://www.ncbi.nlm.nih.gov/pubmed/23884713/										
																				Abnormal vestibulo-ocular reflex 		HP:0007670											
																				Vertical spontaneous nystagmus (Vertical nystagmus)*		HP:0010544											
							0.1 mg/kg per 24 hours, divided every 12 hours, for 4 weeks then it 	The therapy was started with Betamethasone and followed by Methylprednisolone in an attempt to perform long term therapy.No beneficil effect was obtained when they replaced betamethasone with Methylprednisolone.	Betamethasone	DB00443	ECO:0000352/ECO:0007121/ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		 Abnormal serine-protein kinase ATM activity(Abnormality of circulating enzyme level)*		HP:0011021	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000338-36	https://www.ncbi.nlm.nih.gov/pubmed/31107893	https://www.ncbi.nlm.nih.gov/pubmed/23055520/								
																				Poor head control		HP:0002421	https://www.ncbi.nlm.nih.gov/pubmed/17030666										
																				Gait ataxia 		HP:0002066	https://www.ncbi.nlm.nih.gov/pubmed/17030666	https://www.ncbi.nlm.nih.gov/pubmed/24405665/	https://www.ncbi.nlm.nih.gov/pubmed/22927201/								
																				Oxidative stress 		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/19475758/										
																				Dysarthria		HP:0001260	https://www.ncbi.nlm.nih.gov/pubmed/24405665/	https://www.ncbi.nlm.nih.gov/pubmed/22927201/									
																				Oculomotor impairment (Oculomotor apraxia)*		HP:0000657	https://www.ncbi.nlm.nih.gov/pubmed/24405665/	https://www.ncbi.nlm.nih.gov/pubmed/22927201/									
																				Extrapyramidal disorders		HP:0002071	https://www.ncbi.nlm.nih.gov/pubmed/24405665/										
																				Abnormal kinetic function (Abnormality of movement)*		HP:0100022	https://www.ncbi.nlm.nih.gov/pubmed/24405665/	https://www.ncbi.nlm.nih.gov/pubmed/22927201/									
35	# 208920	Ataxia-oculomotor apraxia type 1 		APTX	Aprataxin	3.1.12.2			CoQ10 	DB09270	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Lack of strenght		HP:0003750	https://www.ncbi.nlm.nih.gov/pubmed/28277561	https://www.ncbi.nlm.nih.gov/pubmed/17242337	https://www.ncbi.nlm.nih.gov/pubmed/18403580								
																				Seizures		HP:0001250											
36	# 209300	Atransferrinemia 		TF	transferrin	P02787			Human apotransferrin	CHEBI:2786	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Hypochromic anemia 		HP:0001931	https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1				https://www.ncbi.nlm.nih.gov/pubmed/8317485						
									Deferoxamine	DB00746	ECO:0000352					Supportive	C	functional complementation of a genetically defective protein		Hypochromic anemia 		HP:0001931	https://www.ncbi.nlm.nih.gov/pubmed/8187613										
								Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280	Ferrous sulfate	DB13257	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Decreased hemoglobin		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/28895280										
																				High ferritin level		HP:0003281											
37	# 162350	Autosomal dominant neuronal ceroid lipofuscinosis 4B 		DNAJC5	DnaJ homolog subfamily C member 5(cysteine string PROTEIN)	Q9H3Z4		Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management	No treatment is available in DDIEM							Symptomatic	C	symptomatic therapeutic procedure															
38	# 256730	Infantile Neuronal Ceroid Lipofuscinosis		PPT1	PALMITOYL-PROTEIN THIOESTERASE	3.1.2.22		Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/	Cystagon	DB00847	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Progression of neurodegeneration		HP:0002344	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/		https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13								
								A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880	N-Acetylcysteine+cysteamine bitartrate	DB06151+DB00847 	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Granular osmiophilic deposits (GROD)		HP:0003657	https://www.ncbi.nlm.nih.gov/pubmed/24997880										
																				Irritability		HP:0000737											
																				Defected alertness		HP:0004372											
																				Isoelectric electroencephalogram		HP:0002353											
									δ-tocopherol (DT)	DB11251	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Cognitive deficits 		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/29631617										
									Hydroxypropyl-β-cyclodextrin (HPBCD)	PubChem CID:14049689 	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Brain atrophy		HP:0012444											
								A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.	δ-tocopherol (DT) + hydroxypropyl-β-cyclodextrin (HPBCD)	DB11251+PubChem CID:14049689 	ECO:0001565					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Lipid accumulation (Abnorality in lipid meabolism)*		HP:0003119*											
																				Lysosomal enlargment (Abnormality of lysosomal metabolism)*		HP:0004356*											
									Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)	NA	ECO:0001565					Direct interaction	A	direct complementation of a genetically defective protein		Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*		HP:0004356*											
39	# 204200	Juvenile Neuronal Ceroid Lipofuscinosis CLN2		CLN3	battenin	Q13286		"The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated https://link.springer.com/chapter/10.1007%2F8904_2018_113. 

However, there were no definite effects on measured autoimmunity or clinical outcomes in the setting of short-term use of CellCept(Mycophenolate mofetil).

The brief exposure to treatment was useful to study short-term safety risks and support future long-term studies, but it “did not allow clinical insights into potential efficacy,” researchers stated in https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/"	Mycophenolate mofetil	DB00688 	ECO:0007121/ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure					https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1	https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7	https://www.ncbi.nlm.nih.gov/pubmed/29923092								
									Carbenoxolone	DB02329	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure	Drug name: Study has been conducted invivo and invitro in mice. https://www.ncbi.nlm.nih.gov/pubmed/29660499	Blood-brain barrier (BBB) impairment 		MP:0005167	https://www.ncbi.nlm.nih.gov/pubmed/29660499										
																				Increased astrocyte endfeet area(Abnormality of the astrocytes )*		HP:0100707											
																				Membrane fluidity alterations		NA											
																				Abnormal endocytosis 		MP:0030951											
																				Disturbed Cdc42 activity(Abnormal enzyme activity)*		HP:0012379											
																				Excessive autofluorescence (Brain imaging abnormality)*		HP:0410263											
																				Cav-1 plasma membrane distribution defects (abnormal plasma membrane sphingolipid content)*		MP:0009587											
																				Extended G1 interval(Abnormality of the cell cycle)*		HP:0011018											
									AAVrh.10hCLN3	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Neurological lysosomal storage defect (Abnormality of lysosomal metabolism)*		HP:0004356	https://www.ncbi.nlm.nih.gov/pubmed/24372003										
																				Astrocyte defect (Abnormality of the astrocytes)*		HP:0100707											
40	# 601780	Late infantile neuronal ceroid lipofuscinoses CLN6		CLN6	CLN6, transmembrane ER protein	NO Human id			scAVV9.CB.CLN6	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	 Drug name: under investgation/ aim is to slow the neurodegeneration progression HP:0002344						https://www.ncbi.nlm.nih.gov/pubmed/31331814		https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14						
41	# 204500	Late infantile neuronal ceroid lipofuscinoses CLN2	A research paper on management strategies for CLN2 disease https://www.ncbi.nlm.nih.gov/pubmed/28335910	TPP1	TRIPEPTIDYL PEPTIDASE I	EC 3.4.14.9			Cerliponase alfa	DB13173	ECO:0007121/ECO:0000352/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Neurologic deficits		HP:0000707	https://clinicaltrials.gov/ct2/show/NCT01907087	https://www.ncbi.nlm.nih.gov/pubmed/28589525/	https://www.ncbi.nlm.nih.gov/pubmed/29688815/		https://www.ncbi.nlm.nih.gov/pubmed/24938720						
																				Cognitive dysfunction		HP:0100543											
																				Brain atrophy		HP:0012444											
																				Loss of ambulation		HP:0002540											
									AAVrh.10CUhCLN2	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	The clinical study is still active, not yet recruiting. No results have been added yet. The aim is to slow the neurdegeneration process.	Progressive neurologic deterioration 		HP:0002344			https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8	https://clinicaltrials.gov/ct2/show/NCT01414985?cond=CLN2&draw=3&rank=8	https://www.ncbi.nlm.nih.gov/pubmed/18473686						
																				Mortality		HP:0040006			https://www.ncbi.nlm.nih.gov/pubmed/18639872?dopt=Abstract								
																																	
									AAV2CUhCLN2	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	The clinical study is still active, not yet recruiting. No results have been added yet. The aim is to slow the neurdegeneration process.	Progressive neurologic deterioration 		HP:0002344			https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9	https://www.ncbi.nlm.nih.gov/pubmed/18473686							
									δ-tocopherol (DT)	DB11251	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Cognitive deficits 		HP:0100543			https://www.ncbi.nlm.nih.gov/pubmed/29631617		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/						
									Hydroxypropyl-β-cyclodextrin (HPBCD)	PubChem CID:14049689 	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Brain atrophy		HP:0012444			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/								
									BMN 190 (recombinant human tripeptidyl peptidase-1 (rhTPP1))	DB13173	ECO:0001565/ECO:0007121/ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Neurological disease 		HP:0000707			https://clinicaltrials.gov/ct2/show/NCT01907087	https://www.ncbi.nlm.nih.gov/pubmed/24938720	https://clinicaltrials.gov/ct2/show/NCT01907087?cond=CLN2&draw=2&rank=3	https://clinicaltrials.gov/ct2/show/NCT02485899?cond=CLN2&draw=2&rank=4	https://clinicaltrials.gov/ct2/show/NCT02678689?cond=CLN2&draw=2&rank=5	https://www.ncbi.nlm.nih.gov/pubmed/25257657?dopt=Abstract			
																				Neurologic deficits		HP:0000707											
																				Cognitive dysfunction		HP:0100543											
																				Brain atrophy		HP:0012444											
																				Loss of ambulation		HP:0002540											
								 One possible limitation might be weight loss that will need to be monitored since NCL patients have weight gain issues.	Gemfibrozil	DB01241	ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Mortality		HP:0040006	https://www.ncbi.nlm.nih.gov/pubmed/28199020										
																				Lipid accumulation in the motor cortex (Upper motor neuron dysfunction )*		HP:0002493	https://www.ncbi.nlm.nih.gov/pubmed/28199020										
																				Low TTP 1 activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/22989886										
									Gemfibrozil+fenofibrate	DB01241+ DB01039	ECO:0000179/ECO:0001565					Direct interaction+Direct interaction	A+A	combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+activity modification of a genetically defective protein by transcriptional or translational modification		Low TTP 1 activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/22989886/										
42	# 612016	COENZYME Q10 DEFICIENCY, PRIMARY, 4		ADCK3/CABC1	Atypical kinase COQ8A, mitochondrial	1.3.5.1			CoQ10 (ubiquinone)	DB09270	ECO:0007121	comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]		E551K /Compound heterozygotes for( R213W,  G272V	E551K  in one patient & A compound heterozygotes for( R213W,  G272V) in another.  https://www.ncbi.nlm.nih.gov/pubmed/18319072                                                                                                                                                                                                       Duplication mutation on ADCK3/CABC1 https://www.ncbi.nlm.nih.gov/pubmed/27793482	Functional interaction	B	functional complementation of a genetically defective protein		Tremor		HP:0001298	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/	https://www.ncbi.nlm.nih.gov/pubmed/28125198	https://www.ncbi.nlm.nih.gov/pubmed/24164873							
																				Drawing inabiliity		MP:0004144	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/										
												comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser								Myoclonus		HP:0002180	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/	https://www.ncbi.nlm.nih.gov/pubmed/24164873									
												comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser								Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/	https://www.ncbi.nlm.nih.gov/pubmed/24164873									
												Hetero c.[1541A→G] + [1750_1752 delACC]								Cerebeller atxia progression (Progressive gait ataxia)*		HP:0007240	https://www.ncbi.nlm.nih.gov/pubmed/18319074										
												G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072 								Exercise intolerance	Although there was a slight improvement of one patient on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/	HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/15326254/										
																				Hyperlactatemia	Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/	HP:0003128	https://www.ncbi.nlm.nih.gov/pubmed/15326254/										
												Homozygous deletion (c.504del_CT) 								Speech problem		HP:0002167	https://www.ncbi.nlm.nih.gov/pubmed/26818466										
																				Gait abnormality		HP:0001288											
																				Neurological abormalities		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/26818466										
												Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)								Fatigue		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/29159460										
																				High ataxia score (Ataxia)*		HP:0001251*											
												homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A								Myoclonic abnormalities (Myoclouns)*		HP:0001336*	https://www.ncbi.nlm.nih.gov/pubmed/29159460	https://www.ncbi.nlm.nih.gov/pubmed/24218524									
																				Ataxic gait		HP:0002066											
																				Dysarthria		HP:0001260											
								Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873																									
									Sodium Valproate	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/										
42	# 607091	B4GALT1-CDG (CDG-IId) 		GALT1	beta-1,4-galactosyl transferase.	 2.4.1.274			No treatment is available in DDIEM																https://clinicaltrials.gov/ct2/show/NCT02955264								
43	# 602579	CDG-Ib		MPI	Mannose-6-phosphate isomerase	5.3.1.8			Mannose supply	DB12907	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Metabolism abnormality		HP:0001939			https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf	https://www.ncbi.nlm.nih.gov/pubmed/12756558							
																				Hypoproteinemia		MP:0005567											
																				Blood coagulation		HP:0001928											
																				Protein-losing enteropathy		HP:0002243											
																				Hypoglycaemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/10484808										
																				Hypoglycosylation of serum glycoproteins		NA	https://www.ncbi.nlm.nih.gov/pubmed/9525984										
																				Urinary tract infection		HP:0000010											
	#614921	PGM1 DEFICIENCY ( PGM1-CDG)		PGM1	Phosphoglucomutase-1	5.4.2.2			D- Galactose	DB11735	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal aPTT level 		HP:0003645	https://www.ncbi.nlm.nih.gov/pubmed/28617415										
																				Abnormal AST level (Abnormal liver enzymes)*		HP:0002910											
																				Abnormal ALT level (Abnormal liver enzymes)*		HP:0002910											
																				Abnormal Antithrombin-III levels		HP:0001976											
																																	
44	# 266265	CDG IIc		SLC35C1	GDP-fucose transporter 1	Q96A29			Fucose therapy	DB03485	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal Golgi located fucosylation		NA	https://www.ncbi.nlm.nih.gov/pubmed/17276979		https://www.ncbi.nlm.nih.gov/pubmed/12409504								
																				Abnormal fucosylation state of glycoconjugates.		NA											
											ECO:0000179									Abnormal selectin ligand function		NA	https://www.ncbi.nlm.nih.gov/pubmed/10590041										
											ECO:0000179									Neutropenia		HP:0001875	https://www.ncbi.nlm.nih.gov/pubmed/12406889										
45	# 241510	Childhood hypophosphatasia 		ALPL	Alkaline phosphatase	3.1.3.1			Asfotase Alfa	DB09105	ECO:0000352/ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Abnormal developmental milestones		HP:0012759			https://www.ncbi.nlm.nih.gov/pubmed/22397652/		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/		ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).		Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.		
																				Pulmonary function deterioration		HP:0005952											
																				Decreased physical function		HP:0025142											
																				Failure-to-thrive		HP:0001508											
																				Dental Defects		HP:0000164			https://www.ncbi.nlm.nih.gov/pubmed/21212313								
									Pyridoxal	DB00147	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Epilepsy 		HP:0001250			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/	https://www.ncbi.nlm.nih.gov/pubmed/15033207						
46	# 308050	CHILD syndrome 		NSDHL	NAD(P) dependent steroid dehydrogenase-like	Q3US15*			Simvastatin	DB00641	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Accumulation of toxic metabolites in cholesterol biosynthetic pathway		HP:0001939*			https://www.ncbi.nlm.nih.gov/pubmed/29687057								
																				Ichthyosiform erythematous plaques		HP:0008064											
																				Waxy scaling plaques		HP:0040189*											
																				Inflammation		MP:0001845											
																				Skin thickening		HP:0100725											
									Lovastatin+Cholesterol 	DB00227+DB04540	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement		Cutaneous abnormalities		MP:00011911			https://www.ncbi.nlm.nih.gov/pubmed/29687057								
										 										Ichthyosiform erythroderma		HP:0007431											
									Ketoconazole	DB01026	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Cutaneous abnormalities		MP:0001191			https://www.ncbi.nlm.nih.gov/pubmed/29687057								
									Simvastatin+Cholesterol	DB00641+ DB04540 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement		Ichthyosiform erythroderma		HP:0007431											
																				Itchy skin		HP:0000989											
																				Scaling Skin 		HP:0040189											
																				Erythema		HP:0010783											
																				Verruciform plaques (verruciform xanthomas)*		HP:0031517*			https://www.ncbi.nlm.nih.gov/pubmed/29341259								
																				Verruciform xanthomas‐like lesions.		NA											
									Retinoids	CHEBI:26537	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Scaling Skin 		HP:0040189			https://www.ncbi.nlm.nih.gov/pubmed/29392821								
									Glycolic acid+lovastatin+cholesterol 	DB03085+DB00227+DB04540	ECO:0000352					Symptomatic+Functional interaction+Functional interaction	C+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement		Verruciform xanthomas		HP:0031517											
47	# 275630	Chanarin-Dorfman syndrome 		ABHD5	adipose triglyceride lipase (ATGL)	3.1.1.3			Emollients +acitretin	 A06AA+DB00459	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Ichthyosis		HP:0008064			https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+Chanarin–Dorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene	https://www.ncbi.nlm.nih.gov/pubmed/23756328							
																				Erythroderma		HP:0001019			https://www.ncbi.nlm.nih.gov/pubmed/21981352/								
																				Diffuse scaling (Skin Scaling)*		HP:0040189*			https://www.ncbi.nlm.nih.gov/pubmed/21981352/								
																				Collodion membrane (Nonbullous congenital ichthyosiform erythroderma)*		HP:0007479*			https://www.ncbi.nlm.nih.gov/pubmed/21981352/								
																				Erythema		HP:0010783			https://www.ncbi.nlm.nih.gov/pubmed/28979034								
																				Scaling		HP:0040189			https://www.ncbi.nlm.nih.gov/pubmed/28979034								
									Emollients	A06AA	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Erythema		HP:0010783			https://www.ncbi.nlm.nih.gov/pubmed/21549082								
																				Ichthyosis		HP:0008064			https://www.ncbi.nlm.nih.gov/pubmed/28636073								
																				Pruritis		HP:0000989			https://www.ncbi.nlm.nih.gov/pubmed/28636073								
																				Scaling		HP:0040189											
									Ursodeoxycholic acid 	DB01586	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Steatohepatitis		HP:0001397			https://www.ncbi.nlm.nih.gov/pubmed/21549082								
									Vitamin E	DB00163	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Steatohepatitis		HP:0001397			https://www.ncbi.nlm.nih.gov/pubmed/21549082								
49	# 213700	Cerebrotendinous xanthomatosis 		CYP27A1	Cholestanetriol 26-monooxygenase	1.14.15.15			Chenodeoxycholic acid	DB06777	ECO:0000352					Functional interaction	B	metabolite replacement		Neurological dysfunctions 		HP:0000707			https://www.ncbi.nlm.nih.gov/pubmed/29260356	https://www.ncbi.nlm.nih.gov/pubmed/25424010	https://www.ncbi.nlm.nih.gov/pubmed/28980151	https://www.ncbi.nlm.nih.gov/pubmed/30804055	https://www.ncbi.nlm.nih.gov/pubmed/15131757	https://www.ncbi.nlm.nih.gov/pubmed/26153518			
																				Cataracts 		HP:0000518											
																				Chronic diarrhoea		MP:0001665											
																				Elevated serum cholesterol		HP:0003124				https://www.ncbi.nlm.nih.gov/pubmed/31115677							
																				EEG abnormalities		HP:0002353											
																				Abnormal gait		HP:0001288					https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Xanthoma		HP:0001114					https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Incoordination 		HP:0002311					https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Movement disorder		HP:0100022					https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Cognitive impairment		HP:0100543					https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Abnormal nerve conduction velocity		HP:0040129				https://www.ncbi.nlm.nih.gov/pubmed/1316120							
																				Seizure		HP:0001250											
									Pravastatin+Chenodeoxycholic acid	DB00175 +DB06777	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement		Xanthoma		HP:0001114			https://www.ncbi.nlm.nih.gov/pubmed/7964884		https://www.ncbi.nlm.nih.gov/pubmed/28590052						
																				Elevated serum cholesterol		HP:0003124											
																				Disease progression (Progressive)*		HP:0003676											
									Coenzyme Q10	DB09270	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		muscle weakness		HP:0001324			https://www.ncbi.nlm.nih.gov/pubmed/20301583								
50	# 613068	Cerebral folate deficiency 		FOLR1	Folate receptor alpha	P15328			Folinic acid	DB00650	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Impaired social interaction		HP:0000735											
																				Movement disorder		HP:0100022											
				MTHFR	Methylenetetrahydrofolate reductase	1.5.1.20														seizure		HP:0001250			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/								
																				Myoclonic seizures		HP:0002123			https://www.ncbi.nlm.nih.gov/pubmed/22734130								
																				Astatic seizures		HP:0010819											
51	# 125700	Central diabetes insipidus 		AVP	Hormone ( Arginine vasopressin)				Desmopressin	DB00035	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Polyuria		HP:0000103			https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1								
									Vasopressin	DB00067						Direct interaction	A	direct complementation of a genetically defective protein		Polydipsia		MP:0001426			https://www.ncbi.nlm.nih.gov/pubmed/23884783								
																				Thirst		HP:0001959											
									Chlorpropamide	DB00672 	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Polyurea		HP:0000103			https://www.ncbi.nlm.nih.gov/pubmed/5563815								
								This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254	Chlorpropamide + carbamazepine	DB00672+DB00564	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	Drug name: This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254	Chlorpropamide-induced hypoglycaemia (Hypoglycemia)*		HP:0001943*			https://www.ncbi.nlm.nih.gov/pubmed/1220254								
																				Polyuria		HP:0000103											
								Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.	Chlorpropamide+Hydrochlorothiazide 	DB00672+DB00999	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	Drug name: Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.	Polyuria		HP:0000103											
																																	
																																	
									Pitressin tannate in oil	NA	ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein	 Drug name: The study was withdrawn.	Polyuria		HP:0000103			https://www.ncbi.nlm.nih.gov/pubmed/3940717								
									Clofibrate	DB00636	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Polyuria		HP:0000103			https://www.ncbi.nlm.nih.gov/pubmed/23884783								
																				Hyposthenuria		HP:0003158											
									Indapamide	DB00808	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High serum osmolality		NA			https://www.ncbi.nlm.nih.gov/pubmed/10510995	https://www.ncbi.nlm.nih.gov/pubmed/12016800							
																				Polyuria		HP:0000103											
																				Reduced urinary osmolality		HP:0003158											
								Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447	dDAVP (1-Desamino-8-D Arginine Vasopressin)	DB00035	ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein	Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447	Increased urine output		HP:0000103			https://www.ncbi.nlm.nih.gov/pubmed/626447								
																																	
																																	
52	# 212138	Carnitine-acylcarnitine translocase deficiency 		SLC25A20 	carnitine-acylcarnitine translocase				Medium-chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Developmental delay		HP:0001263			https://www.ncbi.nlm.nih.gov/pubmed/25614308	https://www.ncbi.nlm.nih.gov/pubmed/19452263/							
									Carnitine	DB00583	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypocarnitinemia		HP:0003234			https://www.ncbi.nlm.nih.gov/pubmed/25614308								
									Carnitine+Medium-chain triglycerides	DB00583+DB13959	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Developmental delay		HP:0001263			https://www.ncbi.nlm.nih.gov/pubmed/17508264								
																				Hypocarnitinemia		HP:0003234											
																				High plasma long-chain acylcarnitines		HP:0045045											
53	* 601987	Carnitine palmitoyltransferase I deficiency , muscle 		CPT1B	carnitine O-palmitoyltransferase 1, muscle isoform	2.3.1.21			Medium-chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Neurological damage		HP:0000707		https://www.ncbi.nlm.nih.gov/pubmed/1922174?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/9048718								
																				Hypoglycemia		HP:0001943											
54	# 255120	Carnitine palmitoyl transferase 1 deficiency 		CPT1A	carnitine palmitoyltransferase 1A	2.3.1.21			Medium-chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/20301700	https://www.ncbi.nlm.nih.gov/pubmed/11350183	https://www.ncbi.nlm.nih.gov/pubmed/6682967	https://www.ncbi.nlm.nih.gov/pubmed/28466427	https://www.ncbi.nlm.nih.gov/pubmed/22301540						
																HP:0002611				Hepatic Dysfunction (Liver disease)		HP:0001392											
																				Muscle Weakness		HP:0001324											
									Cornstarch+Low‐fat diet 	DB11599+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+ dietary supplementation+ dietary regime modification		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/15669684	https://www.ncbi.nlm.nih.gov/pubmed/20301700									
																				Low growth rate (Abnormal growth)*		HP:0001507*											
									High carbohydrate and low fat diet +medium chain triglyceride oil 	NA+DB13959	ECO:0000352					Functional interaction	B	combination therapeutic procedure+ dietary regime modification+ dietary supplementation		Cholestatic hepatitis		HP:0002611	https://www.ncbi.nlm.nih.gov/pubmed/23969540										
	# 600649	Carnitine palmitoyl transferase 2 deficiency 		CPT2	Carnitine O-palmitoyltransferase 2, mitochondrial	2.3.1.21/P23786			Triheptanoin	DB11677	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Exercise intolerance		HP:0003546	https://www.ncbi.nlm.nih.gov/pubmed/14615409	https://www.ncbi.nlm.nih.gov/pubmed/18645163									
																				Muscle pain		HP:0003326											
																				Rhabdomyolysis		HP:0003201											
																				Abnormal SF-36 physical composite scores		NA	https://www.ncbi.nlm.nih.gov/pubmed/18645163										
									Glucose	DB01914	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/14615409	https://www.ncbi.nlm.nih.gov/pubmed/12370460?dopt=Abstract									
																				Exercise intolerance		HP:0003546											
								"The long-term effects of MCT were not elucidated. Other authors have recommended avoidance of C12-fatty acids in the medium-chain triglycerides preparations in addition to tightly regulated doses. https://www.ncbi.nlm.nih.gov/pubmed/9048718?dopt=Abstract

In some other cases, treatment with medium-chain triglycerides has not altered the symptoms. https://www.ncbi.nlm.nih.gov/pubmed/750917?dopt=Abstract "	Medium chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia 		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/1922174?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/14615409									
									Theophylline	DB00277	ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein		Reduced carnitine O-palmitoyltransferase activity		HP:0012380	https://www.ncbi.nlm.nih.gov/pubmed/11578754?dopt=Abstract										
55	# 237300	Carbamoyl phosphate synthetase 1 deficiency 		CPS1	Carbamoyl-phosphate synthase (ammonia	6.3.4.16		The drug works on certain CPS1D mutations.	N-Carbamylglutamate 	DB06775	ECO:0001565/ECO:0000352	p.T471N and p.Y1491H/P1439L/ T1443A and Y1491H/R1371L and T1391M/p.Thr1443Ala	"These mutations might benefit from specific treatment with NAG analogues because they exhibit reduced affinity for NAG.https://www.ncbi.nlm.nih.gov/pubmed/20578160
https://www.ncbi.nlm.nih.gov/pubmed/23649895
https://www.ncbi.nlm.nih.gov/pubmed/26059772
https://www.ncbi.nlm.nih.gov/pubmed/15876373"			Direct interaction	A	activity modification of a genetically defective protein	Active	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/28281899	https://www.ncbi.nlm.nih.gov/pubmed/16126063/	https://www.ncbi.nlm.nih.gov/pubmed/20578160	https://www.ncbi.nlm.nih.gov/pubmed/31392111	https://www.ncbi.nlm.nih.gov/pubmed/23649895/	https://www.ncbi.nlm.nih.gov/pubmed/14213380/	https://www.ncbi.nlm.nih.gov/pubmed/13992367/	https://www.ncbi.nlm.nih.gov/pubmed/30034506	https://www.ncbi.nlm.nih.gov/pubmed/26059772		
									N-acetyl-l-glutamate 	DB04075 	ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein		Acidemia		HP:0001941			https://www.ncbi.nlm.nih.gov/pubmed/23649895								
									HDAd CPS1	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	Under trial	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/29801986/		https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Cell+and+Gene+Therapy+for+Carbamoyl+Phosphate+Synthetase+1+Deficiency&btnG=							
																				Elevated plasma glutamine		HP:0003217	https://www.ncbi.nlm.nih.gov/pubmed/29801986/										
																				Low carbamoyl phosphate synthetase 1 expression(Abnormal enzyme/coenzyme activity)*		HP:0012379											
									Glycerol phenylbutyrate(HPN-100)	DB08909	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://clinicaltrials.gov/ct2/show/NCT00992459	https://www.ncbi.nlm.nih.gov/pubmed/20382058/	https://www.ncbi.nlm.nih.gov/pubmed/22961727	https://www.ncbi.nlm.nih.gov/pubmed/21612962/	https://www.ncbi.nlm.nih.gov/pubmed/23324524	https://clinicaltrials.gov/ct2/show/NCT01347073					
									Sodium phenylbutyrate	DB06819	ECO:0000352/ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/20382058/	https://www.ncbi.nlm.nih.gov/pubmed/22961727	https://clinicaltrials.gov/ct2/show/NCT00992459	https://www.ncbi.nlm.nih.gov/pubmed/21612962/	https://www.ncbi.nlm.nih.gov/pubmed/23324524	https://clinicaltrials.gov/ct2/show/NCT01347073					
									Sodium benzoate	DB03793	ECO:0007121/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/27663197										
								This treatment regimen was introduced to those patient whose ammonia level wasnot reduced by sodium benzote alone. and Regimen was accomapnied by haemofiltration as well. https://www.ncbi.nlm.nih.gov/pubmed/27663197	Sodium phenylacetate + sodium benzoate	DB09269+ DB03793	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/27663197										
									Sodium phenylacetate + sodium benzoate+arginine	DB09269+ DB03793+DB00125	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation		Hyperammonemia		HP:0001987		https://www.ncbi.nlm.nih.gov/pubmed/17538087/	https://www.ncbi.nlm.nih.gov/pubmed/6427608								
									Sodium benzoate + Arginine	DB03793+DB00125	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+dietary supplementation		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/7078580										
56	# 253260	Biotinidase deficiency 		BTD	biotinidase	3.5.1.12		Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss	Biotin	DB00121	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Active	Seizure		HP:0001250			https://clinicaltrials.gov/ct2/show/NCT03269045	https://www.ncbi.nlm.nih.gov/pubmed/28649539	https://www.ncbi.nlm.nih.gov/pubmed/26577040	https://www.ncbi.nlm.nih.gov/pubmed/25638506/	https://www.ncbi.nlm.nih.gov/pubmed/28220409				
									Baclofen	DB00181	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Active	Dystonia		HP:0001332		https://www.ncbi.nlm.nih.gov/pubmed/9285607	https://www.ncbi.nlm.nih.gov/pubmed/28220409								
																				Spasticity		HP:0001257											
57	# 607483	Biotin-thiamine-responsive basal ganglia disease 		SLC19A3	thiamine transporter	not available			Biotin+thiamine	DB00121+DB00152	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein	Active	Seizures 		HP:0001250			https://www.ncbi.nlm.nih.gov/pubmed/27749535	https://www.ncbi.nlm.nih.gov/pubmed/31061755		http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy					
																Symptomatic	C			Encephalopathy		HP:0001298			https://www.ncbi.nlm.nih.gov/pubmed/27749535	https://www.ncbi.nlm.nih.gov/pubmed/31061755	https://www.ncbi.nlm.nih.gov/pubmed/24260777						
																				Signal abnormality of the cortex 		HP:0030178			https://www.ncbi.nlm.nih.gov/pubmed/27749535								
																				Abnormal movement		HP:0100022			https://www.ncbi.nlm.nih.gov/pubmed/27749535								
																				Dystonia		HP:0001332			https://www.ncbi.nlm.nih.gov/pubmed/27749535								
																				Abnormal reflexes		HP:0001347			https://www.ncbi.nlm.nih.gov/pubmed/27749535								
									L-dopa	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Dystonia		HP:0001332			https://www.ncbi.nlm.nih.gov/pubmed/24260777								
58	# 203750	Beta ketothiolase deficiency 		ACAT1	Acetyl-CoA C-acetyltransferase.	2.3.1.9			Glucose	DB09341	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Active	Ketosis		HP:0001946			https://www.ncbi.nlm.nih.gov/pubmed/23163837								
									Carnitine	DB00583 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Organic aciduria		HP:0001992			https://www.sciencedirect.com/science/article/pii/S1110863016300763	https://scholar.google.com/scholar_lookup?journal=+EJMHG&title=Two+Libyan+siblings+with+beta-ketothiolase+deficiency:+A+case+report+and+review+of+literature&author=E+Abdelkreem&author=H+Alobaidy&author=Y+Aoyama&author=S+Mahmoud&author=Aal+MA+El&volume=18&issue=2&publication_year=2017&pages=199-203&							
									Bicitra	DB09154 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Acidosis		HP:0001941			http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency								
									Levertriacetam	DB01202	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Generalized tonic clonic seizures		HP:0002069	https://www.ncbi.nlm.nih.gov/pubmed/23958592										
59	# 601678	Bartter Syndrome 1		SLC12A1	Solute carrier family 12 member 1	Q13621			Spironolactone+potassium+ACE-inhibitor	DB00421+DB14500+C09A	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	Active	Electrolyte disturbances		HP:0003111	https://www.ncbi.nlm.nih.gov/pubmed/30519073			https://www.ncbi.nlm.nih.gov/pubmed/2646391							
									Acetazolamide	DB00819	EC:0007121					Symptomatic	C	symptomatic therapeutic procedure		Metabolic alkalosis		HP:0200114	https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22										
																				Hypokalemia Metabolic Alkalosis		HP:0002900											
																				Hypomagnesemia		HP:0002917	https://www.ncbi.nlm.nih.gov/pubmed/2646391										
60	# 241200	Bartter Syndrome 2		KCNJ1	ATP-sensitive inward rectifier potassium channel 1	P48048			No treatment is available in DDIEM																								
61	# 602522	Bartter Syndrome 4		BSND	barttin	Q8WZ55			Tanespimycin 	DB05134	ECO:0001565/ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein		Low plasma membrane expression of R8Lin kidney(Abnormality of circulating enzyme level HP:0011021		NA	https://www.ncbi.nlm.nih.gov/pubmed/24189473										
																				Hypokalemia		HP:0002900											
																				Metabolic alkalosis		HP:0200114											
																				Sensorineural hearing impairment		HP:0000407											
																				ER-associated degradation of R8L		NA											
																				Mislocalization of R8L		NA											
									Potassium Chloride	DB00761	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypokalemia		HP:0002900	https://www.ncbi.nlm.nih.gov/books/NBK442019/										
									Naproxen	DB00788	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypokalemia		HP:0002900	https://www.nejm.org/doi/full/10.1056/NEJM197807132990214										
									Niflumic acid	DB04552	ECO:0001565	L155/ G345/ A349/L155A, G345S and A349E	Those three mutants are localized in two different protein regions that, based on the crystal structure of bacterial CLC homologs, are expected to be exposed to the extracellular side of the channel, relatively close to each other, and are thus good candidates for being part of the potentiating NFA binding site	G167A / F213A	These two. mutations drastically altered general gating properties and are unlikely to be involved in NFA binding	Functional interaction	B	functional complementation of a genetically defective protein		Abnormal ClC-Ka function		NA	https://www.ncbi.nlm.nih.gov/pubmed/20649569/										
																																	
	# 607364	BARTTER SYNDROME, TYPE 3; BARTS3		CLCNKB	Chloride channel protein ClC-Kb	P51801			Potassium sparing agents	C03D	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Deleterious prognosis		NA	https://www.ncbi.nlm.nih.gov/pubmed/30387909										
																				Decreased life expectancy (Mortality)*		HP:0040006*											
																				Salt wasting		HP:0000127											
																				Growth retardation		HP:0001510											
									Indomethacin	DB00328	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Deleterious prognosis		NA	https://www.ncbi.nlm.nih.gov/pubmed/30387909	https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract									
																				Decreased life expectancy (Mortality)*		HP:0040006*											
																				Salt wasting		HP:0000127											
									Growth hormone	DB00052	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Short stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/30387909	https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report									
																				Decreased serum IGF‐1		HP:0030353											
																				Failure to thrive		HP:0001508											
									Potassium	DB14500	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypokalemia		HP:0002900	https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract										
									Magnesium	DB14513	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypomagnesemia		HP:0002917	https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub										
									Sodium	DB09395	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyponatremia		HP:0002902	https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract										
									Aminoglycoside (Geneticin)	DB04263	ECO:0001565	W610X				Direct Interaction	A	direct complementation of a genetically defective protein by transcriptional or translational modification		Defected ClC-Kb expression		NA	https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract										
									Potassium+Indomethacin±Spironolactone	DB14500+DB00328+ DB00421	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Short stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/28288174										
									Nonsteroidal anti-inflammatory drugs	M01AX	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Elevated prostaglandin E2		HP:0003566	https://www.ncbi.nlm.nih.gov/pubmed/24189473/										
																				Hypokalemia		HP:0002900											
																				High calcium excretion in urine		HP:0002150											
	# 300971	BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5	"Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084"	MAGED2	Melanoma-associated antigen D2	Q9UNF1			Electrolytes	B05BB01	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Renal salt wasting		HP:0000127	https://www.ncbi.nlm.nih.gov/pubmed/27120771										
									Indomethacin	DB00328	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure															
62	302060	Barth syndrome 		TAZ	tafazzin ( Protein)	Not available			Elamipretide	DB11981	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Oxidative stress		HP:0025464	https://clinicaltrials.gov/ct2/show/NCT03098797										
																				Abnormal energy production in damaged mitochondria		HP:0003287	https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1										
																				Fatigue		HP:0012378											
									Granulocyte colony stimulating factor (G‐CSF)	DB00020	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Neutropenia		HP:0001875	https://www.ncbi.nlm.nih.gov/pubmed/15098233/	https://www.ncbi.nlm.nih.gov/pubmed/18632498/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/	https://www.ncbi.nlm.nih.gov/pubmed/18632498/	https://www.ncbi.nlm.nih.gov/pubmed/31239752	https://www.ncbi.nlm.nih.gov/pubmed/23432031					
																				Recurrent infection		HP:0002719	https://www.ncbi.nlm.nih.gov/pubmed/23432031										
									Digoxin	DB00390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name: Temporary improvemnet 	Low ejection fraction		HP:0012664	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/										
																				Tricusped incompetence		HP:0005180											
																				Mitral incomptence		HP:0001653											
									Pantothenic acid	DB01783	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Low myocardial function		HP:0001638	https://www.ncbi.nlm.nih.gov/pubmed/7833193										
																				T wave abnormalities		HP:0005135											
																				Delayed Growth 		HP:0001510											
																				Hypocholesterolaemia		HP:0003146											
																				Hyperuricaemia		HP:0002149											
																				Neutropenia		HP:0001875											
									Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics	C09A/C09CA/C07/C03	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Heart failure		HP:0001635	https://www.ncbi.nlm.nih.gov/pubmed/31239752										
									Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate	C09A/C09CA/C07/C04+B01A	ECO:0000352					Symptomatic	C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Atrial fibrillation		HP:0005110	https://www.ncbi.nlm.nih.gov/pubmed/31239752										
									Bezafibrate 	DB01393	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Cardiac dysfunction		HP:0001635	https://www.ncbi.nlm.nih.gov/pubmed/29695963/	https://www.ncbi.nlm.nih.gov/pubmed/28279226/									
																				Exercise intolerance		HP:0003546	https://www.ncbi.nlm.nih.gov/pubmed/29695963/										
									AAV9-TAZ	NA	ECO:0000179					Direct interaction	A	direct complementatoin of a genetically defective protein by gene therapy		Abnormal cardiac protein (TAZ) expression (Abnormal circulating protein level )*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/30788385/	https://www.ncbi.nlm.nih.gov/pubmed/30070157/									
																				Mitochondrial dysfunction 		HP:0003287	https://www.ncbi.nlm.nih.gov/pubmed/30070157/										
																				Mueculoskeletal dysfunction		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/30070157/										
									Digoxin+furosemide+captopril	DB00390+DB00695+DB01197	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Cardiomegaly		HP:0001640	https://www.ncbi.nlm.nih.gov/pubmed/20981509										
																				Reduced ejection fraction		HP:0012664	https://www.ncbi.nlm.nih.gov/pubmed/20981509										
																				Developmetal delay		HP:0001263	https://www.ncbi.nlm.nih.gov/pubmed/20981509										
																				Abormal liver size		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/20981509										
																																	
63	# 278000	Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY)		LIPA	lysosomal acid lipase 	P38571			Sebelipase alfa	DB11563	ECO:0000352/ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		High plasma cholesterol level*		HP:0003107	https://www.ncbi.nlm.nih.gov/pubmed/29773783	https://www.ncbi.nlm.nih.gov/pubmed/27878737	https://www.ncbi.nlm.nih.gov/pubmed/29374495	https://www.ncbi.nlm.nih.gov/pubmed/28804516							
																				hypertriglycemia		HP:0002155	https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4	https://clinicaltrials.gov/ct2/show/NCT01371825									
																				Abnormal liver function		HP:0002910											
																				Dyslipidemia		HP:0003119											
																																	
									Fenofibrate	DB01039	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Increased plasma triglycerides		HP:0002155	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/										
									Simvastatin	DB00641	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperlipidemia		HP:0003077	https://www.ncbi.nlm.nih.gov/pubmed/16848116										
								Treatment success with statins has been mixed. 	Lovastatin	DB00227	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Increased LDL cholesterol		HP:0003141	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/										
																				Increased plasma triglycerides		HP:0002155											
																				Increased total cholesterol		HP:0003124											
																				Elevated urine mevalonate levels		NA											
									Colestyramine+Simivastatin	DB01432+DB00641	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Dyslipidemia		HP:0003119	https://www.ncbi.nlm.nih.gov/pubmed/1801793	https://www.sciencedirect.com/science/article/pii/S1521691810001101									
																				Abnormal liver function		HP:0002910											
									Ezetimibe 	DB00973	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Dyslipidemia		HP:0003119	https://www.ncbi.nlm.nih.gov/pubmed/29374495										
																				Abnormal liver function		HP:0002910											
64	# 118600	Chondrocalcinosis 2 		ANKH	Progressive ankylosis protein homolog	Q9HCJ1		Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.	Colchicine(COL)	DB01394	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Arthritis		HP:0001369	https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/									
																				Arthralgia		HP:0002829											
								Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/	Prednisone	DB00635	ECO:0000352/ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Arthritis		HP:0001369	https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/27790033/	https://www.ncbi.nlm.nih.gov/pubmed/30891381		https://www.ncbi.nlm.nih.gov/pubmed/21257614/	https://www.ncbi.nlm.nih.gov/pubmed/27586801	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=	https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/			
									Naproxen sodium	DB00788						Symptomatic	C	symptomatic therapeutic procedure		Arthralgia		HP:0002829	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/									
																				Recurrent repisode of flares (Recurrent)*		HP:0025303											
								"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/"	Anakinra/canakinuma	DB00026/DB06168	ECO:0007121/ ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Recurrent repisode of flares (Recurrent)*		HP:0025303	https://www.ncbi.nlm.nih.gov/pubmed/29675606	https://www.ncbi.nlm.nih.gov/pubmed/19289295		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/	https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/22832289	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Anakinra+Compared+to+Prednisone+on+the+Treatment+of+Acute+CPPD+Crystal+Arthritis%2C+a+Randomized%2C+Controlled%2C+Double-Blind+Study&btnG=	https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/		
																				Arthritis		HP:0001369	https://www.ncbi.nlm.nih.gov/pubmed/23022422	https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract								
																				Refractory Arthritis		HP:0031375	https://www.ncbi.nlm.nih.gov/pubmed/22658375										
																				Synovitis		HP:0100769	https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract										
									Rilonacept	DB06372	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Recurrent repisode of flares (Recurrent)*		HP:0025303	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/										
								"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/
  "	Methotrexate	DB00563	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Swollen joint		HP:0001386	https://www.ncbi.nlm.nih.gov/pubmed/29675606	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/	https://www.ncbi.nlm.nih.gov/pubmed/25315665	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/	https://www.ncbi.nlm.nih.gov/pubmed/21102543						
																				Arthralgia		HP:0002829											
									Hydroxychloroquine	DB01611	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Swollen joint		HP:0001386	https://www.ncbi.nlm.nih.gov/pubmed/9195122/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/	https://www.ncbi.nlm.nih.gov/pubmed/21102543								
																				Arthralgia		HP:0002829											
																				Arthropathy		HP:0003040			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/								
									Probenecid	DB01032	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Abnormality of phosphate homeostasis		HP:0100529	https://www.ncbi.nlm.nih.gov/pubmed/7520501										
																																	
65	118610	Chondrocalcinosis due to apatite crystal deposition 							NSAIDs	DB00788	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Acute arthritis		HP:0001369	https://www.ncbi.nlm.nih.gov/pubmed/17541659										
67	# 246700	Chylomicron retention disease 		SAR1B	Sar1b protein				Vitamin E	DB00163	ECO:0000352					Functional interaction	B	metabolite replacement		Neurological abnormalities		HP:0012638	https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/	https://www.ncbi.nlm.nih.gov/pubmed/23329770								
									Alpha-tocopherol	DB11251						Functional interaction	B	metabolite replacement		Neurological abnormalities		HP:0012638											
																				Abnormal Adipose tissue tocopherol level.		NA	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/										
								"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/	Tocofersolan	DB11635	ECO:0000352					Functional interaction	B	metabolite replacement		Disease progression(Progressive)*		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/27520363	https://www.ncbi.nlm.nih.gov/pubmed/20920215	https://www.ncbi.nlm.nih.gov/pubmed/30021760								
									Vitamin A+ Vitamin E	DB00162+DB00163	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement		Minor visual abnormalities		HP:0000505	https://www.ncbi.nlm.nih.gov/pubmed/19285442/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/									
																				Neurological abnormality		HP:0012638	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/										
																				Muscular abnormality		HP:0012638	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/										
									Vitamin D 	DB11094	ECO:0000352					Functional interaction	B	metabolite replacement		osteopenia		HP:0000938											
																				Vitamin D insufficiency		HP:0100512	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/										
									Vitamin K	DB01022	ECO:0000352					Functional interaction	B	metabolite replacement		Bleeding tendency		HP:0001892	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/										
																				Vitamin K insufficiency		HP:0011892	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/										
									Medium-chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	dietary regime modification		Low weight/growth		HP:0004325	https://www.ncbi.nlm.nih.gov/pubmed/27266643										
																				Diarrhea		HP:0002014	https://www.ncbi.nlm.nih.gov/pubmed/20920215										
																				Malnutrition		HP:0004395	https://www.ncbi.nlm.nih.gov/pubmed/20920215										
									Fat emulsion	DB09422	ECO:0000352					Functional interaction	B	metabolite replacement		Fat malabsorption		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/2596948/	https://www.ncbi.nlm.nih.gov/pubmed/20920215									
68	#215720	Citrulline transport defect 							No treatment is available in DDIEM																								
69	# 611209	COG1-CDG (CDG-IIg) 		COG1	component of oligomeric golgi complex 1				No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/21175687										
70	# 615395	Combined oxidative phosphorylation deficiency 16 		MRPL44	mitochondrial ribosomal protein L44	Q9H9J2			L-carnitine +Propranolol	DB00583+DB00571	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		low physical capacity		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/25797485										
71	# 607765	Congenital bile acid synthesis defect, type 1 		HSD3B7	3-beta-hydroxy-delta-5-C27 steroid oxidoreductase 				Cholic acid 	DB02659	ECO:0000352					Functional interaction	B	metabolite replacement		Atypical bile acids 		NA	https://www.ncbi.nlm.nih.gov/pubmed/11067870	https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/	https://www.ncbi.nlm.nih.gov/pubmed/19622360					
																				Defected bile flow		HP:0001396											
																				Cirrhosis		HP:0001394	https://www.ncbi.nlm.nih.gov/pubmed/30373615	https://www.ncbi.nlm.nih.gov/pubmed/30373615									
									Chenodeoxycholic acid	DB06777	ECO:0000352					Functional interaction	B	metabolite replacement		Pruritus		HP:0000989	https://www.ncbi.nlm.nih.gov/pubmed/2072042										
																				Abnormal urinary steroid level		HP:0012030	https://www.ncbi.nlm.nih.gov/pubmed/2072042										
																				Ill-being (Constitutional symptoms)*		HP:0025142*											
									Ursodeoxycholic acid	DB01586	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein															
72	# 235555	Congenital bile acid synthesis defect, type 2 	 UDCA is not recommended for long-term management.	AKR1D1	Aldo-keto reductase family 1 member D1	1.3.1.3		Therapeutic dose requires individualized optimization. UDCA is not recommended for long-term management.	Cholic acid 	DB02659	ECO:0000352					Functional interaction	B	metabolite replacement		Liver biochemical abnormalities (Laboratory abnormalities)*		HP:0001939	https://www.ncbi.nlm.nih.gov/pubmed/30809085	https://www.ncbi.nlm.nih.gov/pubmed/28727657	https://www.ncbi.nlm.nih.gov/pubmed/31337596	https://www.ncbi.nlm.nih.gov/pubmed/15030995/	https://www.ncbi.nlm.nih.gov/pubmed/20522910						
																				Histological abnormalities (Abnormal test result)*		HP:0500014											
																				Disease progression (Rapidly progressive)*		HP:0003678*											
																				Defected bile flow (Cholestasis)*		HP:0001396											
																				Fat soluble vitamin malabsorption*		HP:0002630											
																				Atypical bile acid synthesis 		NA											
																				Production of toxic bile acid metabolic intermediates		NA											
									Chenodeoxycholic acid 	DB06777	ECO:0000352					Functional interaction	B	metabolite replacement		Abnormal liver function		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/28697823										
																				Hepatomegaly		HP:0002240											
								Patients with genetic 5beta-reductase deficiency may respond well to treatment with chenodeoxycholic acid and cholic acid if liver disease is not too advanced.	Cholic acid +chenodeoxycholic acid 	DB02659+DB06777	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement		Hyperbilirubinemia		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/12970144	https://www.ncbi.nlm.nih.gov/pubmed/8707100									
																				Elevated hepatic transaminase		HP:0002910											
																				Cholestasis		HP:0001396											
																				Steatorrhea		HP:0002570											
																				Failure to thrive		HP:0001508											
																																	
73	# 224120	Congenital dyserythropoietic anemia type 1		CDAN1	codanin 1				Interferon α-2a	DB00034	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	controversial	Low hemoglobin concentration		HP:0001931	https://www.ncbi.nlm.nih.gov/pubmed/16141353	https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract	http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract								
																				Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*		HP:0011031*											
									Deferoxamine	DB00746	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		high plasma ferritin		HP:0003281	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/									
									Deferiprone	DB08826	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Elevated serum ferritin concentrations		HP:0003281	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/	https://www.ncbi.nlm.nih.gov/pubmed/16141353									
74	# 220120	D-glycericacidemia 		GLYCTK	d-glycerate kinase 	2.7.1.31 			Sodium bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Active	Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/26247153	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=D-glyceric+aciduria+NÁDIA+W.+DIMER.+PATRÍCIA+F.+SCHUCK.&btnG=	https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract								
75	# 261515	D-bifunctional protein deficiency 	No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/	HSD17B4 	17β-hydroxysteroid dehydrogenase type 4			The study was terminated	Chenodeoxycholic acid+Cholic acid	DB06777+DB02659 	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein					https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/									
								The study was terminated	Cholic acid+Ursodiol	DB02659 +DB14555	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein					https://clinicaltrials.gov/ct2/show/study/NCT00004442										
76	# 600721	D-2-hydroxyglutaric aciduria 		D2HGDH	D-2-hydroxyglutarate dehydrogenase				L- carnitine	DB00583	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		DNA damage (Abnormality of DNA repair)*		HP:0003254*	https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract										
																				oxidative injury*		HP:0025463											
																				Protein oxidation		NA											
																				lipid peroxidation 		NA											
77	# 220110	"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)"			cytochrome c oxidase assembly factor 	1.9.3.1 			Valproic acid	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	better to be avoided	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/22149023										
									Carbamazepine	DB00593	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Phenobarbital	DB01174 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Phenytoin	DB00252	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Oxcarbazepine	DB00776	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Vigabatrin	DB01080	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Gabapentin	DB00996	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Topiramate	DB00273  	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Zonisamide	DB00909	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Ethosuximide	DB00593	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
78	# 219750	Cystinosis, ocular nonnephropathic 		CTNS	cystinosin	O60931			Cysteamine 	DB00847	ECO:0000179/ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Corneal crystals		HP:0000531	https://www.ncbi.nlm.nih.gov/pubmed/12370309/		http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12488257/	https://www.ncbi.nlm.nih.gov/pubmed/1929112/						
79	# 219800	Cystinosis		CTNS	cystinosin	O60931		Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/	Cysteamine 	DB00847	ECO:0000352/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein	Drug name: Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/                                                                                                                                                                                                                                                                                                                                          Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/	Corneal crystals		HP:0000531	https://www.ncbi.nlm.nih.gov/pubmed/11001803	https://www.ncbi.nlm.nih.gov/pubmed/9758713	http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/						
																				Photophobia		HP:0000613	https://www.ncbi.nlm.nih.gov/pubmed/22903658										
																				Kidney disease progression (Progressive disorder)*		HP:0003678*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/	https://www.ncbi.nlm.nih.gov/pubmed/25165189									
																			"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications "	development of extra-renal pathologies (Progressive disorder)*	lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications	HP:0003678*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/	https://www.ncbi.nlm.nih.gov/pubmed/22903658									
																			Phenotypes improved : lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications 	hypothyroidism	lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications	HP:0000821	https://www.ncbi.nlm.nih.gov/pubmed/22903658										
																			"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications "	Delayed growth	lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications	HP:0001510	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/	https://www.ncbi.nlm.nih.gov/pubmed/3550461/	https://www.ncbi.nlm.nih.gov/pubmed/8444253								
																			"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications "	cystine accumulation in muscle parenchyma	lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications	HP:0003358	https://www.ncbi.nlm.nih.gov/pubmed/22903658										
																				Shorter life expectancy (Mortality)*		HP:0040006											
																				Elevated leucocyte cystine levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/27102039										
																				Renal function declines 		HP:0012622	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/										
																				Elevated intralysosomal cystine accumulation (abnormality of cysteine metabolism)		HP:0010918*	https://www.ncbi.nlm.nih.gov/pubmed/23416144										
																				Glomerular damage		HP:0000095*											
								Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/	Indomethacin	DB00328	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name: Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/	Polyuria		HP:0000103	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/										
																				Weight gain		HP:0004324											
																				Proximal tubule salt losses (Proximal tubular defect)		HP:0000114											
																				Renal salt wasting		HP:0000127											
									Bicarbonate+potassium supplements	DB01390+DB01345	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Acidosis		HP:0001941											
									Neutral phosphate+Vitamin D	DB14502 orDB09449 +DB11094	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	Drug name: Substitution with sodium or potassium phosphate and 1–25-(OH)2 cholecalciferol should be initiated from early childhood to compensate for the phosphate imbal- ance and to prevent rickets in patients with preserved GFR https://www.ncbi.nlm.nih.gov/pubmed/27102039	Phosphate imbalance (Abnormality of phosphate homeostasis)*		HP:0100529	https://www.ncbi.nlm.nih.gov/pubmed/27102039										
									Thiazide	DB01324	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name: Usage of Diutics like thiazide to avoid volume expansion, could aggrevate Potassium loss and augments the need for potassium supplements https://emedicine.medscape.com/article/981774-treatment not benefical	Low proximal tubular reabsorption of bicarbonates 		HP:0004910*											
									Growth hormone	DB00052	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Retarded growth		HP:0001510	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/									
																				Low phosphate reabsorption		HP:0000117											
									Thyroxine	DB00451	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypothyroidism		HP:0000821											
									ACE inhibitors	DB01348	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name: Effectivness of the drug is controversial.                                                                                                                                                                                                                     ACE inhibitors must be used with caution in patients with extracellular volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/	Glomerular proteinuria		HP:0000100											
																				Albuminuria		HP:0012592	https://www.ncbi.nlm.nih.gov/pubmed/14690254/										
									Testosterone	DB00624	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug name:  Currently, insufficient data is available on the pathophysiology of the azoospermia observed in male cystinosis patients. Testosterone supplementation is indicated in patients with a primary testicular failure and low plasma testosterone levels https://www.ncbi.nlm.nih.gov/pubmed/19217094/	Low serum testosterone levels		HP:004017	https://www.ncbi.nlm.nih.gov/pubmed/19217094/										
80	# 606785	Crigler Najjar syndrome, type 2 	"Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/"	UGT1A1 	UDP glucuronosyltransferase family 1 member A1 			"""Effectiveness of the drug is controversial, the risk of hypotension and consequent renal function decline, ACE 
ACE inhibitors must be used with caution in patients with extracellular 
volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/"""	Phenobarbital 	DB01174	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		High serum bilirubin level		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/23162302/	https://www.ncbi.nlm.nih.gov/pubmed/1899849	https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/	https://www.ncbi.nlm.nih.gov/pubmed/3306242	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/				
									Orlistat	DB01083	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		High plasma level of unconjugated bilirubin concentration		HP:0008282	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/		https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4								
																				Increased fecal fat excretion (Steatorrhea)		HP:0002570											
																				Low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*		HP:0008282*											
									AT342	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		High serum  bilirubin concentration		HP:0002904			https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3								
									GNT0003 	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		High serum  bilirubin concentration		HP:0002904			https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/							
									Hypericum extract	DB01323	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Hyperbilirubinemia		HP:0002904			https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract								
								Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases	AAV-mediated gene therapy	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Abnormal liver function		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/15753292	https://www.ncbi.nlm.nih.gov/pubmed/10603107/									
																				High serum  bilirubin concentration		HP:0002904											
																				Increased inflammatory response		HP:0012649											
																				Abnormality of metabolism		HP:0001939											
									Chlofibrate	DB00636	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		High serum  bilirubin concentration		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/7483726	https://www.ncbi.nlm.nih.gov/pubmed/19752526/									
								Drug showed an insignificant effect	Fenofibrate	DB01039	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification					https://www.ncbi.nlm.nih.gov/pubmed/16830281										
								Calcium makes phototherapy more efficient 	Calcium 	DB01373	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/10603107/										
																																	
81	# 218800	Crigler Najjar syndrome, type 1		UGT1A1 	uridine diphosphate–glucuronyl transferase 			The drug is effective in conjuction with phototherapy	Tin-protoporphyrin	DB02285	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High serum bilirubin level		HP:0002904	https://www.nature.com/articles/pr1989488	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=TIN-PROTOPORPHYRIN+%28Sn-pP%29+EFFECT+ON+HYPER-+BILIRUBINEMIA+DUE+TO+CRIGLER-NAJJAR+DISEASE+%28CND%29+TYPE+1&btnG=									
								Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.	orlistat	DB01083	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		High plasma level of unconjugated bilirubin concentration		HP:0008282	https://www.ncbi.nlm.nih.gov/pubmed/17957158	https://clinicaltrials.gov/ct2/show/NCT00461799	https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg	https://www.ncbi.nlm.nih.gov/pubmed/15726662							
								Study was suspended based on Sponsor Decision.	AT342	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy					https://clinicaltrials.gov/ct2/show/NCT03223194										
								Information about the Study can be found in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,However study is still recruiting.	GNT0003	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy					https://clinicaltrials.gov/ct2/show/NCT03466463										
									Ad5/CMV/hUG-Br1	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hyperbilirubinemia		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/9525311/	https://www.ncbi.nlm.nih.gov/pubmed/9156798/	https://www.ncbi.nlm.nih.gov/pubmed/15753292								
									Chimeric oligonucleotide (oligonucleotide-based gene therapy)	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		UDP-glucuronosyltransferase gene defect		NA	https://www.ncbi.nlm.nih.gov/pubmed/10468611/										
									Retrovirus 	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hyperbilirubinemia		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/9457971/										
									Ad-hBUGT1	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hyperbilirubinemia		HP:0002904	https://www.ncbi.nlm.nih.gov/pubmed/8900123/										
									Zinc protoporphyrin	CHEBI:28783	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Increased total bilirubin		HP:0003573	https://www.ncbi.nlm.nih.gov/pubmed/29399656										
82	% 608158	CoQ-responsive OXPHOS deficiency 						Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744	Sodium benzoate	DB03793	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Not Active	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/12948744		https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub								
								Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744	Sodium phenylacetate	DB09269	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Not Active	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/12948744										
									CoQ 	DB09270	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal liver function		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/12948744										
83	121270	Copper deficiency, familial benign 							Copper	DB09130	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypocupraemia		HP:0010836	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/										
																				Seizures		HP:0001250											
84	# 263700	Congenital erythropoietic porphyria 		UROS 	uroporphyrinogen III synthase	4.2.1.75			Bortezomib(PS-341)	DB00188 	ECO:0000179/ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein		High porphyrin accumulation in circulating RBCs		HP:0012187	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/	https://www.ncbi.nlm.nih.gov/pubmed/24145442									
																				Skin photosensitivity		HP:0000992											
																				Premature degradation of misfolded UROS mutants		NA	https://www.ncbi.nlm.nih.gov/pubmed/28334762										
																				Abnormal porphyrin accumulation in urine		HP:0010473											
									Beta carotene	DB06755	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		skin photosensitivity		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/1130187	https://scholar.google.com/scholar_lookup?title=Erythropoietic%20protoporphyria&publication_year=1994&author=DJ.%20Todd	https://www.ncbi.nlm.nih.gov/pubmed/12534613	https://www.ncbi.nlm.nih.gov/pubmed/677933							
									Ascorbic acid + α-tocopherol	DB00126+DB00163	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative stress		HP:0025464											
																				Reduced RBCs level		HP:0001903											
																				Low hemaoglobin		HP:0001903											
								Studies that reported a charcoal for producing unexpected unexplained results or for lack of efficiecy  https://www.ncbi.nlm.nih.gov/pubmed/8369205/ https://www.ncbi.nlm.nih.gov/pubmed/8127352	Charcoal	DB09278	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal circulating porphyrin concentration 		HP:0010472	https://www.ncbi.nlm.nih.gov/pubmed/3100953	https://www.ncbi.nlm.nih.gov/pubmed/2084460	https://www.ncbi.nlm.nih.gov/pubmed/3338705								
																				Porphyrinuria 		HP:0010473											
									Hematin	DB13387	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Acute prophyria attack(Acute)*		HP:0011009	https://www.ncbi.nlm.nih.gov/pubmed/449661	https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Congenital+erythropoietic+porphyria&draw=5&rank=39	https://ashpublications.org/blood/article/126/2/130/34473/Iron-and-erythropoietic-porphyrias								
									Afamelanotide	DB04931	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Severe photosensitivity 	The drug is considered for treating CEP due to its protective effects against UVR.	HP:0007537	https://clinicaltrials.gov/ct2/show/NCT00979745?cond=Congenital+erythropoietic+porphyria&draw=6&rank=45	https://clinicaltrials.gov/ct2/show/NCT01097044?cond=Congenital+erythropoietic+porphyria&draw=6&rank=44	https://clinicaltrials.gov/ct2/show/NCT01605136?cond=Congenital+erythropoietic+porphyria&draw=6&rank=43	https://www.ncbi.nlm.nih.gov/pubmed/?term=Advances+in+the+management+of+erythropoietic+protoporphyria+–+role+of+afamelanotide	https://www.ncbi.nlm.nih.gov/pubmed/26132941	https://www.ncbi.nlm.nih.gov/pubmed/19144952	https://clinicaltrials.gov/ct2/show/NCT04053270?cond=Congenital+erythropoietic+porphyria&draw=5&rank=40				
																				Painful photosenstivity (Pain)*		HP:0012531	https://www.ncbi.nlm.nih.gov/pubmed/26132941										
																				Affected quality of life(Constitutional symptom)*		HP:0025142	https://www.ncbi.nlm.nih.gov/pubmed/26132941										
																				Phototoxicity	The drug indication is to prevent phototoxicity	MP:0005653	https://www.ncbi.nlm.nih.gov/pubmed/26979527										
									MT-7117	NA	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Phototoxicity	The drug indication is to prevent phototoxicity	MP:0005653	https://clinicaltrials.gov/ct2/show/NCT03520036?cond=Congenital+erythropoietic+porphyria&draw=6&rank=42										
									Cysteine hydrochloride	DB00151	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Severe photosensitivity 		HP:0007537	https://clinicaltrials.gov/ct2/show/NCT00004831?cond=Congenital+erythropoietic+porphyria&draw=5&rank=38	https://clinicaltrials.gov/ct2/show/NCT00004940	https://www.ncbi.nlm.nih.gov/pubmed/7727280								
									Deferasirox	DB01609	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Porphyrinuria 		HP:0010473	https://www.ncbi.nlm.nih.gov/pubmed/25972160										
																				Cutaneous photosensitivity 		HP:0000992											
									Hydroxyurea	DB01005	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Abnormal circulating porphyrin concentration 		HP:0010472	https://www.ncbi.nlm.nih.gov/pubmed/8127351										
																				Cutaneous photosensitivity 		HP:0000992											
									Zinc oxide/Titanium dioxide	"DB09321/DB09536
"	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Cutaneous photosensitivity 		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/16365260										
								The clinical trial was terminated (Interim analysis demonstrated the treatment was not effective) and anthoer pilot study showed that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in human.	Isoniazid	DB00951	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein					https://clinicaltrials.gov/ct2/show/NCT01550705?cond=Congenital+erythropoietic+porphyria&draw=5&rank=35	https://www.ncbi.nlm.nih.gov/pubmed/31395332									
									Colestipol	DB00375	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Sun sensitivity		HP:0000992	https://clinicaltrials.gov/ct2/show/NCT01422915?cond=Congenital+erythropoietic+porphyria&draw=4&rank=29	https://www.ncbi.nlm.nih.gov/pubmed/24438965									
									Proteasome inhibitor MG132	CHEBI:75142	ECO:0001565/ECO:0000179							activity modification of a genetically defective protein		Abnormal enzyme activity		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/21343304	https://www.ncbi.nlm.nih.gov/pubmed/24145442									
									Lentivirus-mediated transfer of the human UROS cDNA 	NA	ECO:0000179							direct complementation of a genetically defective protein by gene therapy		Skin photosensitivity		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/18601879	https://www.ncbi.nlm.nih.gov/pubmed/11320408									
85	# 610198	DCMA syndrome (3-methylglutaconic aciduria, type V)		DNAJC19	DnaJ heat shock protein family (Hsp40) member C19 	Q96DA6			Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide	C09C+DB00390+DB00695	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Reduced ejection fraction		HP:0012664	https://www.ncbi.nlm.nih.gov/pubmed/27928778	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/								
86	261750	GLYCOGEN STORAGE DISEASE IXb; GSD9B		PHKB	Phosphorylase b kinase regulatory subunit beta	Q93100			Dextrothyroxine	DB00509	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Hepatomegaly		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/280544										
																				Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/280544										
																				Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/280544										
																				Mild asymptomatic hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/280544										
									Complex Carbohydrates	NA	ECO:0000352					Functional interaction	B	dietary regime modification		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
																				Short Stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									Complex carbohydrates+Beneprotein+Low fats	NA+NA+NA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+dietary regime modification+dietary supplementation+dietary regime modification		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
	306000	GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 )		PHKA2	Phosphorylase b kinase regulatory subunit alpha, liver isoform	P46019			Uncooked cornstarch+ Beneprotein+Low fats diet	DB11599+NA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+dietary supplementation+dietary supplementation+dietary regime modification		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									Uncooked cornstarch+ Beneprotein	DB11599+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+dietary supplementation+dietary supplementation		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
																				Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									Uncooked cornstarch	DB11599	ECO:0000352					Functional interaction	B	dietary supplementation		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
																				Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate)	DB11599+NA+NA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+dietary supplementation+dietary supplementation+dietary regime modification		Elevated hepatic transaminases	On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.	HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									CoCarbs + HPro	NA+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+dietary regime modification+dietary regime modification		Elevated hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
	# 613027	GLYCOGEN STORAGE DISEASE IXc; GSD9C		PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	P15735			Uncooked cornstarch+ Beneprotein	DB11599+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+dietary supplementation+dietary supplementation		Elevated hepatic transaminases	Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917	HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922	https://www.ncbi.nlm.nih.gov/pubmed/12930917									
																				Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/12930917										
87	# 240600	Glycogen storage disease type 0, liver 	"GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/"	GYS2	glycogen synthase 2	2.4.1.11			Glycosade	NA	ECO:0007121					Functional interaction	B	dietary supplementation		Nocturnal Hypoglycemia (Hypoglycemia)*		HP:0001943*	https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/29223626									
																				Poor sleep quality (Sleep disturbance)*		HP:0002360*	https://www.ncbi.nlm.nih.gov/pubmed/29223626										
								Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/	Cornstarch	DB11599	ECO:0000352					Functional interaction	B	dietary supplementation		MorningHypoglycemia (Hypoglycemia)*		HP:0012051	https://www.ncbi.nlm.nih.gov/pubmed/12794686										
																				Ketosis		HP:0001946											
88	#611881	Glycogen storage disease type 12 		ALDOA	aldolase, fructose-bisphosphate A	4.1.2.13			No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/28932990										
89	#612932	Glycogen storage disease type 13 		ENO3	enolase 3	4.2.1.11			No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/28932990										
90	# 232200	Glycogen storage disease type 1A 		G6PC	Glucose 6-phophatase	3.1.3.9		The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level. 	DTX401	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy					https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/20163245									
									FIV-hAAT-G6Pase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/										
									Ad-mG6Pase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Growth retardation		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
																				Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
																				Hyperuricemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
																				Hyperlipidemia		HP:0003077	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
																				Enlarged kidney		HP:0000105	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
																				Hepatomegaly		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/10625614										
									AAV-cG6PGH	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Growth Failure		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/16672983										
																				Hyperlipidemia		HP:0003077	https://www.ncbi.nlm.nih.gov/pubmed/16672983	https://www.ncbi.nlm.nih.gov/pubmed/17430128									
																				Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/16672983	https://www.ncbi.nlm.nih.gov/pubmed/17430128									
								Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292	HDAd-G6Pase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/17505475										
									Glycosade	NA	ECO:0007121					Functional interaction	B	dietary supplementation		Fasting hypoglycemia		HP:0003162	https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6	https://www.ncbi.nlm.nih.gov/pubmed/29223626	https://www.ncbi.nlm.nih.gov/pubmed/18996862	https://www.ncbi.nlm.nih.gov/pubmed/17514432							
																				Sleep disturbance/Poor sleep quality	The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862	HP:0002360	https://www.ncbi.nlm.nih.gov/pubmed/29223626	https://www.ncbi.nlm.nih.gov/pubmed/18996862									
																				Low quality of life (Constitutional symptoms)*		HP:0025142*											
									L-carnitine	DB00583	ECO:0007764					Symptomatic	C	symptomatic therapeutic procedure		mitochondrial dysfunction		HP:0003287	http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract	https://www.nature.com/articles/srep44408									
									Tempol	DB12449	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Abnormal renal function		HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/20195241										
																				Renal disease progression (Progressive disorder)*		HP:0003676*	https://www.ncbi.nlm.nih.gov/pubmed/20195241										
																				Nephropathy		HP:0000112	https://www.ncbi.nlm.nih.gov/pubmed/20195241										
									ACE‐inhibitors	C09C	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Glomerular hyperfilteration (Abnormal glomerular filtration rate)		HP:0012212	https://www.ncbi.nlm.nih.gov/pubmed/15963056	https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580									
									Antioxidant + ACE inhibitors 	DB12449+C09C	ECO:0007764					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Nephropathy		HP:0000112											
									Glucose	DB01914	ECO:0000352					Functional interaction	B	metabolite replacement		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/26835382	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/									
									Uncooked cornstarch	DB11599	ECO:0000352					Functional interaction	B	dietary supplementation		Hypoglycemia		HP:0001943	https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome	https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580	https://www.ncbi.nlm.nih.gov/pubmed/20975743/								
									Allopurinol	DB00437	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High plasma uric acid levels		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/26835382										
								Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.	Calcium+ vitamin D3	DB01373+DB00169	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Osteoporosis	Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.	HP:0000939	https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580										
									Medium chain triglycerides	DB13959	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperuricemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/20357432										
																				Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/20357432										
																				Growth failure		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/20357432										
																																	
91	# 232220	Glycogen storage disease type 1b		SLC37A4	Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)	O43826		Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382	Human granulocyte-colony-stimulating-factor	DB00099	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Neutropenia		HP:0001875	https://www.ncbi.nlm.nih.gov/pubmed/26835382	https://www.ncbi.nlm.nih.gov/pubmed/25288127	https://www.ncbi.nlm.nih.gov/pubmed/8447561	https://www.ncbi.nlm.nih.gov/pubmed/19066956							
																				Recurrent bacterial infection		HP:0002718	https://www.ncbi.nlm.nih.gov/pubmed/1709246	https://www.ncbi.nlm.nih.gov/pubmed/1719175									
																				Frequent, severe infections		HP:0002719	https://www.ncbi.nlm.nih.gov/pubmed/1709246	https://www.ncbi.nlm.nih.gov/pubmed/1719175									
								Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585	G‐CSF + 5‐aminosalicylic acid 	DB00099+DB00244	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Neutropenia with IBD		HP:0001875+HP:0002037	https://www.ncbi.nlm.nih.gov/pubmed/12373585	https://www.ncbi.nlm.nih.gov/pubmed/25288127	https://www.ncbi.nlm.nih.gov/pubmed/19541498								
									Adalimumab	DB00051	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		GSD-associated enterocolitis (enterocolitis)		HP:0004387	https://www.ncbi.nlm.nih.gov/pubmed/18172743										
									Glycosade	NA	ECO:0007121					Functional interaction	B	dietary supplementation		Fasting hypoglycemia		HP:0003162	https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6	https://www.ncbi.nlm.nih.gov/pubmed/29223626	https://www.ncbi.nlm.nih.gov/pubmed/18996862	https://www.ncbi.nlm.nih.gov/pubmed/17514432							
																				Sleep disturbance/Poor sleep qaulity	The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862	HP:0002360	https://www.ncbi.nlm.nih.gov/pubmed/29223626	https://www.ncbi.nlm.nih.gov/pubmed/18996862									
																				Low quality of life (Constitutional symptoms)*		HP:0025142*											
									rAAV-GPE-G6PT 	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Hyperlipidemia		HP:0003077	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
																				Hypoglycemia		HP:0001943	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
																				Hyperuricemia		HP:0002149	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
																				Lactic acidemia		HP:0003128	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
																				Age-related insulin resistance (Insulin resistance)*		HP:0000855*	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
																				Obesity		HP:0001513	http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract										
								"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment."	Galactose+Uridine	DB11735+DB02745	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Partial correction of neutrophil dysfunction	In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract	HP:0011990	http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract										
									Vitamin E	DB00163	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Neutropenia		HP:0001875	https://www.ncbi.nlm.nih.gov/pubmed/19066956										
																				Frequent, severe infections		HP:0002719	https://www.ncbi.nlm.nih.gov/pubmed/19066956										
								"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated."	Testosterone	DB00624	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Decreased male libido		HP:0040306	https://www.ncbi.nlm.nih.gov/pubmed/28160246										
																				Low physical activity		HP:0025142											
																				decrease muscle strenght		HP:0001324											
									Medium chain triglycerides	DB13959	ECO:0000352					Functional interaction	B	dietary supplementation		Hyperuricemia 		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/20357432										
																				Hypertriglyceridemia		HP:0002155											
																				Growth failure		HP:0001510											
92	# 232400	Glycogen storage disease type 3	Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546	AGL	Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)	2.4.1.25 +3.2.1.33			Cornstarch 	DB11599	ECO:0000352					Functional interaction	B	dietary supplementation		Linear growth velocity (Abnormality of body height)*		HP:0000002*		https://www.ncbi.nlm.nih.gov/pubmed/20631546	https://www.ncbi.nlm.nih.gov/pubmed/25153581	https://www.ncbi.nlm.nih.gov/pubmed/24613482							
																				Hypoglycemic seizures		HP:0002173											
																				Enlarged size of the liver		HP:0002240											
									Calcium+Vitamin D	DB01373 + DB11094	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Osteoporosis		HP:0000939											
									Glycosade	NA	ECO:0007121					Functional interaction	B	dietary supplementation		Fasting hypoglycemia		HP:0003162	https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6	https://www.ncbi.nlm.nih.gov/pubmed/29223626	https://www.ncbi.nlm.nih.gov/pubmed/17514432								
																				Sleep disturbance		HP:0002360	https://www.ncbi.nlm.nih.gov/pubmed/29223626										
	# 232400	Glycogen storage disease type IIIa		AGL	Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)	2.4.1.25 +3.2.1.33			Rapamycin	DB00877 	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by inhibition	Drug name:   Study was done in a canine model.	High glycogen levels in muscles		HP:0009051	https://www.ncbi.nlm.nih.gov/pubmed/24509886										
																				Liver fibrosis progression		HP:0001395	https://www.ncbi.nlm.nih.gov/pubmed/24509886										
									Fructose	DB04173	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Exercise intolerance		HP:0003546	https://www.ncbi.nlm.nih.gov/pubmed/25832663										
									High protein diet	NA						Functional interaction	B	dietary regime modification	Drug name: A dietary tretament	Delayed growth		HP:0001510	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/	https://www.ncbi.nlm.nih.gov/pubmed/8245377									
																				Myopathy		HP:0003198											
																				Cardiomyopathy		HP:0001638											
									Modified Atkins diet	NA	ECO:0000352					Functional interaction	B	dietary regime modification	Drug name: A dietary tretament	Abnormal blood levels of ketone bodies		HP:0001939	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/	https://www.ncbi.nlm.nih.gov/pubmed/20631546/									
																				Abnormal blood levels of  fatty acids		HP:0004359											
																				High creatine kinase		HP:0003236											
																				Cardiomyopathy		HP:0001638											
																				Low energetic state of heart (Abnormality of cardiovascular system physiology)*		HP:0011025*											
																				Low energetic state of skeletal muscle		HP:0011804											
																				Increased creatine kinase activity		HP:0003236											
93	# 232600	Glycogen storage disease type 5 		PYGM	Glycogen phosphorylase, Muscle form	2.4.1.1			Sodium Valproate	DB00313	ECO:0007121/ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein by stimulation	Drug name:	Difficulty walking		HP:0002355		https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/25762569							
									Triheptanoin	DB11677	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Abnormal fat metabolism		HP:0004359	https://www.ncbi.nlm.nih.gov/pubmed/28932990	https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1									
																				Abnormal carbohydrate metabolism*		HP:0011013											
									Creatine	DB00148	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Exercise intolerance		HP:0003546	https://www.ncbi.nlm.nih.gov/pubmed/25391139	http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/17490880	https://www.ncbi.nlm.nih.gov/pubmed/24493026	https://www.ncbi.nlm.nih.gov/pubmed/19019309						
									Sucrose	DB02772	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Exercise intolerance		HP:0003547	http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/25391139	https://www.ncbi.nlm.nih.gov/pubmed/17490880	https://www.ncbi.nlm.nih.gov/pubmed/24493026	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/			https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract			
									Vitamin B6	DB00165 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Insufficient anaerobic glycolysis of skeletal muscle		NA	https://www.ncbi.nlm.nih.gov/pubmed/22334182	https://www.ncbi.nlm.nih.gov/pubmed/17490880	https://www.ncbi.nlm.nih.gov/pubmed/24493026	https://www.ncbi.nlm.nih.gov/pubmed/19019309							
																				Exercise intolerance		HP:0003546											
																				Abnormal muscle phosphorylase activity(Abnormal enzyme activity)*		HP:0012379											
									Ramipril 	DB00178	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Disability (Functional motor problems)*		HP:0004302*	https://www.ncbi.nlm.nih.gov/pubmed/18098237	https://www.ncbi.nlm.nih.gov/pubmed/24493026	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/								
																				Abnormal exercise physiology		HP:0009020											
								Drug has been proven to be unsuccessful	GENTAMICIN 	DB04729	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein	Drug name: ineffective/ further study is needed				https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/19019309									
									PTC124	DB05016	ECO:0007764							activity modification of a genetically defective protein		Exercise intolerance		HP:0003546											
94	# 232700	Glycogen storage disease type 6 		PYGL	Glycogen phosphorylase, liver form	2.4.1.1			Cornstarch (Uncooked)	DB11599	ECO:0000352					Functional interaction	B	dietary supplementation	Drug name: Uncooked cornstarch administartion can result in avoidance of ketosis, hypoglycemia and hepatomegaly. https://www.ncbi.nlm.nih.gov/pubmed/20301760	Short stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/25266922	https://www.ncbi.nlm.nih.gov/pubmed/25266922									
																				Abnormal blood glucose concentration		HP:0011015	https://www.ncbi.nlm.nih.gov/pubmed/20301760										
																				Low energy level (Tiredness)*		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/20301760										
																				Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
																				Elevated Hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									Beneprotein	NA	ECO:0000352					Functional interaction	B	dietary supplementation		Short stature		HP:0004322			https://www.ncbi.nlm.nih.gov/pubmed/25266922								
									Uncooked cornstarch+Beneprotein	DB11599+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+dietary supplementation+dietary supplementation		Elevated Hepatic transaminases		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/25266922										
									D-Thyroxine	DB00509	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hepatomeglay		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/3483883										
																				Elevated Hepatic transaminases		HP:0002910											
																				Failure to thrive		HP:0001508											
																				Increased erythrocyte glycogen content		HP:0001939											
																				Hypertriglyceridemia		HP:0002155											
95	# 232800	Glycogen storage disease type 7 	The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272	PFKM	ATP-dependent 6-phosphofructokinase, muscle type	2.7.1.11		A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process(in the Recruiting stage. ). https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1	Triheptanoin	DB11677	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure					https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1										
																																	
96	# 606664	Glycine N-methyltransferase deficiency 	Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.	GNMT 	glycine N-methyltransferase	2.1.1.20		An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/	Nicotinamide	DB02701 	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein	"Disease name: Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high.

https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.  Drug name: An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/"	Liver steatosis		HP:0001397	https://www.ncbi.nlm.nih.gov/pubmed/20578266/	https://www.ncbi.nlm.nih.gov/pubmed/27207470	https://www.ncbi.nlm.nih.gov/pubmed/19585268								
																				Fatty liver		HP:0001397											
																				Liver fibrosis		HP:0001395											
																				DNA hypermethylation		NA											
96	# 231950	Glutathionuria 		GGT1	Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase	3.4.19.13/2.3.2.2			OTZ (L-2-oxothiazoline-4-carboxylic acid)	NA	ECO:0000179					Functional interaction	B	metabolite replacement	Disease name : In 2007 Ristoff et al.   mentioned in their paper  that there is no treatment that has been recommended. https://www.ncbi.nlm.nih.gov/pubmed/17397529?dopt=Abstract. Drug name: These drugs have been tested on mice. 	Low intracellular cysteine(Abnormal cysteine level)*		MP:0030621			http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract								
																				Behavioral abnormalities 		HP:0000708											
																				GSH deficiency		HP:0003343											
									N-acetylcysteine	DB06151	ECO:0000179					Functional interaction	B	metabolite replacement	Drug name: These drugs have been tested on mice.	Delayed growth		HP:0001510	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/		https://www.ncbi.nlm.nih.gov/pubmed/20868666								
																				Cataract		HP:0000518	https://www.ncbi.nlm.nih.gov/pubmed/11095909										
																				Low reproductive capacity (infertility)		HP:0000144	https://www.ncbi.nlm.nih.gov/pubmed/11089562										
97	# 266130	Glutathione synthetase deficiency 		GSS	glutathione synthetase	6.3.2.3			Ascorbic acid	DB00126	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/8301428/		https://www.ncbi.nlm.nih.gov/pubmed/17397529								
									Ascorbate + N-acetylcysteine	DB00126+DB06151 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High erythrocyte turnover (Abnormality of erythrocytes)*		HP:0001877*	https://www.ncbi.nlm.nih.gov/pubmed/8301428/										
								Polycitra (Citric acid +Potassium citrate + Sodium citrate)	Polycitra +vitamin C+vitamin E+selenium	NA+DB00126+DB00163+DB11135	ECO:0000352					Symptomatic+Functional interaction+Functional interaction+Functional interaction	C+B+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Oxidative stress		HP:0025464	http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract										
									Alpha-tocopherol	DB00163	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal microtubule assembly 		NA	https://www.ncbi.nlm.nih.gov/pubmed/29340523	https://www.ncbi.nlm.nih.gov/pubmed/7375069									
																				Short erythrocyte survival (Abnormality of erythrocytes)*		HP:0001877*	https://www.ncbi.nlm.nih.gov/pubmed/29340523										
																				Abnormal polymorphonuclear leukocyte function		HP:0001874											
																				Neutropenia		HP:0001875											
																				Susceptibility to Bacterial infection		HP:0002718											
																				Retinal dystrophy		HP:0000556	https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract										
																				CNS damage progression		HP:0007367											
									L-carnitine+Vitamin E+Vitamin B1+Cobalamin	DB00583+DB00163+DB00152+DB14098	ECO:0000352					Symptomatic+Functional interaction+Symptomatic+Symptomatic	C+B+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Hypersomnia		HP:0100786	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Jaundice		HP:0000952	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Carnitine deficiency		HP:0003234	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Hypotonia		HP:0001290	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
									L-carnitine+vitamin B1+B2+ B12+ C+E + Sodium bicarbonate	DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Symptomatic+Functional interaction+Functional interaction+Symptomatic	C+C+C+C+B+B+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure		Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Elevated urine 5-oxoproline		NA	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Decreased blood free carnitine		HP:0008315	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
									L-carnitine+ Vitamin B1+B12+C+E	DB00583+DB00152+DB00115+DB00126+DB00163	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Functional interaction+Functional interaction	C+C+C+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Elevated urine 5-oxoproline		NA	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
																				Decreased blood free carnitine		HP:0008315	https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract										
									Sodium Bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/29340523	https://www.ncbi.nlm.nih.gov/pubmed/26669244/									
									Coenzyme Q10	DB09270	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High-anion gap acidosis 		HP:0001941*	http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract										
									Dorzolamide+acetazolamide	DB00869+DB00819	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Cystoid macular edema		HP:0011505	https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract										
									Erythropoietin + iron+folic acid + vitamin B12	DB00016+DB01592+DB00158+DB00165	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Symptomatic	C+C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Anaemia		HP:0001903	http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/16435214									
98	# 231670	Glutaric acidemia type I 	It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622	GCDH	glutaryl-CoA dehydrogenase, mitochondrial	1.3.8.6		This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918	Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements	DB00583+DB00130+DB09393	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation		Brain damage	Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622	HP:0001298	https://www.ncbi.nlm.nih.gov/pubmed/23326493										
																				Cerebral palsy	Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918	HP:0100021	https://www.ncbi.nlm.nih.gov/pubmed/10630918										
																				Secondary Carnitine deficiency (Carnitine deficiency)*		HP:0003234*											
									Carnitine+ Riboflavin+baclofen	DB00583+DB00130+DB00181	ECO:0000352					Functional interaction+Direct interaction+Functional interaction	B+A+B	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		Disease progression		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/3335963	http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract									
																Symptomatic	C			Secondary Carnitine deficiency (Carnitine deficiency)*		HP:0003234*				https://www.ncbi.nlm.nih.gov/pubmed/16368216							
																				Metabolic acidosis		HP:0001942											
									Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen	DB00583+DB00679+DB01563+DB00181	ECO:0000352					Functional interaction+Symptomatic+Symptomatic+Functional interaction	B+C+C+B	combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein		Dystonia	The phenotype has been reported in association to treatment with baclofen as 	HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/8881997										
									Chlorpromazine	DB00477	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperpyrexia in case of acute encephalopathic crises (Fever)*		HP:0001945*	https://www.ncbi.nlm.nih.gov/pubmed/10222465										
								The combination was accompanied by Low L-lysine diet	Carnitine+Riboflavin+L-Arginine+clofibrate	DB00583+DB00130+DB00125+DB00636	ECO:0000179					Functional interaction+Direct interaction+Functional interaction+Symptomatic	B+A+B+C	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure		Glutaric acidemia	Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787 	HP:0003530	https://www.ncbi.nlm.nih.gov/pubmed/20923787										
99	# 231680	Glutaric acidemia type II 		ETFA,ETFB,ETFDH	electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase			Synergism inmproves results	Carnitine+ riboflavin	DB00583+DB00140	ECO:0000352					Functional interaction+Direct interaction	B+A	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein		High serum creatine kinase		HP:0003236	https://www.ncbi.nlm.nih.gov/pubmed/10723193	https://www.ncbi.nlm.nih.gov/pubmed/19249206	https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract								
																			synergism inmproves results	Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/10723193										
																				Secondary Carnitine deficiency (Carnitine deficiency)*		HP:0003234	https://www.ncbi.nlm.nih.gov/pubmed/10723193										
									Carnitine+ riboflavin+Coenzyme Q	DB00583+DB00140+DB09270	ECO:0000352					Functional interaction+Direct interaction+Functional interaction	B+A+B	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		Dysphagia		HP:0002015	https://www.ncbi.nlm.nih.gov/pubmed/26236614										
																				Difficulty walking		HP:0002355											
																				Secondary Carnitine deficiency (Carnitine deficiency)*		HP:0003234	https://www.ncbi.nlm.nih.gov/pubmed/10723193										
									Glycine+Riboflavin+Carnitine	DB00145+DB00140+DB00583	ECO:0000352					Functional interaction+Direct interaction+Functional interaction	B+A+B	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/3229565										
									Sodium-d,l-3-hydroxybutyrate 	CHEBI:113373	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Progressive leukodystrophy		HP:0002415	https://www.ncbi.nlm.nih.gov/pubmed/12727399	http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract									
																				Paralysis		HP:0003470	https://www.ncbi.nlm.nih.gov/pubmed/12727399										
																				Cardiomyopathy 		HP:0001638	https://www.ncbi.nlm.nih.gov/pubmed/12727399										
																				Impaired myocardial contractility		HP:0006670	https://www.ncbi.nlm.nih.gov/pubmed/12727399										
									Riboflavin+Carnitine+Corticosteroid	DB00140+DB00583+S03BA 	ECO:0000352					Direct interaction*+Functional interaction+Symptomatic	A	combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure		Myopathy		HP:0003198	https://www.ncbi.nlm.nih.gov/pubmed/10581232										
																				Muscle weakness		HP:0001324											
																				Elevated serum creatine kinase		HP:0003236											
																				Ketonuria		HP:0002919											
100	# 231690	Glutaric acidemia type III 		SUGCT	succinate-hydroxymethylglutarate coA-transferase	2.8.3.13			Metronidazole	DB00140	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Cyclic vomiting (Vomiting)*		HP:0002013	https://www.ncbi.nlm.nih.gov/pubmed/28766179										
																				Bacterial glutric acid production		NA											
101	# 266130	Glutathione synthetase deficiency 		GLUL	Glutamine synthetase	6.3.1.2			L-glutamine	DB00130	ECO:0007121					Functional interaction	B	metabolite replacement		Abnormal plasma glutamine levels		HP:0010903	https://www.ncbi.nlm.nih.gov/pubmed/22830360		https://www.ncbi.nlm.nih.gov/pubmed/27775558	https://www.ncbi.nlm.nih.gov/pubmed/22830360							
																				Low CSF glutamine level		HP:0030980*											
																				Unalertness		HP:0002329											
																				Lack of emotional expressions		HP:0030213											
																				Abnormal EEG results		HP:0002353											
																				Low brain glutamine concentration		HP:0030980											
																Symptomatic				Secondary NAD+ deficiency in leucocytes		NA	https://www.ncbi.nlm.nih.gov/pubmed/22830360	https://www.ncbi.nlm.nih.gov/pubmed/25896882/									
									Nicotinamide 	DB02701	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Secondary NAD+ deficiency in leucocytes		NA	https://www.ncbi.nlm.nih.gov/pubmed/25896882/										
									Vitamin C+Vitamin E+Selenium	DB00126+DB00163+DB11135	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/26984560										
									Citric acid+Sodium citrate+ Potassium citrate	DB04272+DB09154+DB09125	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/26984560										
102	# 229100	Glutamate formiminotransferase deficiency 	The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726	FTCD	formiminotransferase cyclodeaminase				Pyridoxine +Folic acid	DB00165+DB00158	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement		Megaloblastic anemia		HP:0001889	https://www.ncbi.nlm.nih.gov/pubmed/5301410										
103	# 606824	Glucose-galactose malabsorption 	Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187	SLC5A1	sodium/glucose cotransporter protein called SGLT1			The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940	Fructose +Carbohydrate free formula	DB04173+NA	ECO:0000352					Symptomatic+Functional interaction	C+B	combination therapeutic procedure+symptomatic therapeutic procedure+dietary regime modification		Watery Diarrhea		HP:0002014	https://www.ncbi.nlm.nih.gov/pubmed/10404446	https://www.ncbi.nlm.nih.gov/pubmed/20486940		https://www.ncbi.nlm.nih.gov/pubmed/28283348	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/						
																				Dehydration		HP:0001944											
104	# 606777	Glucose transporter type 1 deficiency syndrome 	"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract "	SLC2A1	glucose transporter protein type 1 (GLUT1)				UX007 (triheptanoin)	DB11677	ECO:0007121/ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1	https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2	https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3	https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5	https://www.ncbi.nlm.nih.gov/pubmed/29303961	https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9	https://www.ncbi.nlm.nih.gov/pubmed/23196212/				
																				EEG with focal spike waves		HP:0011197											
																				Nonepileptic paroxysmal abnormalities		NA											
																	C			Seizures 		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/22812641/	https://www.ncbi.nlm.nih.gov/pubmed/23196212/	https://www.ncbi.nlm.nih.gov/pubmed/22812641/								
																	C			Movement disorders		HP:0100022											
																				Dyskinesia		HP:0100660			https://www.ncbi.nlm.nih.gov/pubmed/26982753								
									AAV-GLUT1	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein by gene therapy		Abnormal CSF glucose levels 		HP:0031884			https://www.ncbi.nlm.nih.gov/pubmed/29624790								
																				Abnormal motor function		HP:0004302											
																				Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)		HP:0007166											
105	# 263800	Gitelman syndrome 		SLC12A3 / CLCNKB	sodium chloride co-transporter/ chloride channel called ClC-Kb	P51801		The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411	Rofecoxib	DB00533	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Refractory hypokalemia		HP:0002900*	https://www.ncbi.nlm.nih.gov/pubmed/12141411				https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub						
																				Abnormally reduced levels of aldosterone 		HP:0004319											
																				Abnormal serum renin level		HP:0040084											
								"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083

"	Indometacin/Amiloride/Eplerenone+Potassium	(DB00328/DB00594/DB00700)+DB00761	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Refractory hypokalemia		HP:0002900*	https://www.ncbi.nlm.nih.gov/pubmed/25012174		https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/25012174	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/	https://www.ncbi.nlm.nih.gov/pubmed/21503667/	https://www.ncbi.nlm.nih.gov/pubmed/28381550/				
									Indometacin	DB00328	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Developmental delay		HP:0001263	https://www.ncbi.nlm.nih.gov/pubmed/25852896/		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/								
																				High plasma RAAS activity		HP:0000847*											
																Symptomatic	C			Abnormally reduced levels of aldosterone 		HP:0004319	https://www.ncbi.nlm.nih.gov/pubmed/25012174										
																Symptomatic	C			Abnormal serum renin level		HP:0040084	https://www.ncbi.nlm.nih.gov/pubmed/25012174										
									Magnesium	DB14513	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Hypomagnesemia	In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications	HP:0002917	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/										
																				Chondrocalcinosis		HP:0000934											
									Potassium chloride	DB00761	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Hypokalemia		HP:0002900											
106	# 230800	Gaucher disease type 1		GBA 	beta-glucocerebrosidase	3.2.1.45			Taliglucerase alfa	DB08876	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Hepatomegaly		HP:0002240	https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all	https://www.ncbi.nlm.nih.gov/pubmed/29471850	https://www.ncbi.nlm.nih.gov/pubmed/29388611	https://www.ncbi.nlm.nih.gov/pubmed/27839981							
																				Splenomegaly		HP:0001744	https://www.ncbi.nlm.nih.gov/pubmed/28131618			https://www.ncbi.nlm.nih.gov/pubmed/27102949	https://www.ncbi.nlm.nih.gov/pubmed/27499018						
																				Thrombocytopenia		HP:0001873											
																				Low mean hemoglobin concentration 		HP:0025547											
																				Low bone marrow fat fraction value		NA			https://www.ncbi.nlm.nih.gov/pubmed/30066229								
									Imiglucérase (ISU302)	DB00053	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Primary low heamoglobin level		HP:0001903*	https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr										
																				Thrombocytopenia		HP:0001873											
																				Splenomegaly		HP:0001744											
																				Hepatomegaly		HP:0002240											
																				High angiotensin- converting enzyme		HP:0000841											
																				High  Chitotriosidase Level (Abnormality of lysosomal metabolism)*		HP:0004356											
																				Elevated Chemokine Ligand (CCL-18) Level [ng/mL]		NA											
								Trial is no longer available 	prGCD	DB08876	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein	Study is no longer available				https://clinicaltrials.gov/ct2/show/NCT00705939	https://www.ncbi.nlm.nih.gov/pubmed/19277123	https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25	https://clinicaltrials.gov/ct2/show/NCT00376168?cond=NCT00376168&draw=2&rank=1							
																																	
									Eliglustat tartrate	DB09039	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Low mean hemoglobin level 		HP:0001903	https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26	https://www.ncbi.nlm.nih.gov/pubmed/20439622									
																				Thrombocytopenia		HP:0001873											
																				Hepatomegaly		HP:0002240											
																				Splenomegaly		HP:0001744											
																				Low lumbar spine bone mineral density (abnormality of bone mineral density)*		HP:0004348											
									N-acetylcysteine	DB06151 	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://clinicaltrials.gov/ct2/show/NCT01427517	https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9		https://www.ncbi.nlm.nih.gov/pubmed/23860343							
																				Low blood glutathione redox ratios		MP:0012604*											
																				Inflammation		HP:0012649	https://www.ncbi.nlm.nih.gov/pubmed/23860343										
																				Concentration of myo-inositol in brain		HP:0025460											
																				Concentration of TNF-alpha in plasma 		HP:0011118*											
									Elelyso 	DB08876	ECO:0000352/ ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Hepatomegaly		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/22916340	https://www.ncbi.nlm.nih.gov/pubmed/29471850	https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7								
																				Splenomegaly		HP:0001744											
																				thrombocytopenia		HP:0001873											
																				Anaemia		HP:0001903											
									Velaglucerase alfa	DB06720	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Changes in lumbar spine (LS)		HP:0100712	https://www.ncbi.nlm.nih.gov/pubmed/29503270		https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14	https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15	https://www.ncbi.nlm.nih.gov/pubmed/25801797	https://clinicaltrials.gov/ct2/show/NCT04120506?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=17					
																				Abnormality in bone mineral density 		HP:0004348											
																				Anaemia		HP:0001903											
																				Thrombocytopenia		HP:0001873											
																				Hepatosplenomegaly		HP:0001433											
																				Growth faliure		HP:0001510											
																				Avascular osteonecrosis		HP:0010885	https://www.ncbi.nlm.nih.gov/pubmed/29503270										
																				Bone pain		HP:0002653	https://www.ncbi.nlm.nih.gov/pubmed/29503270										
								The drug was used in a pilot study.	Ambroxol	DB06742	ECO:0007121					Direct interaction 	A	activity modification of a genetically defective protein		Anemia		HP:0001903	https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17	https://www.ncbi.nlm.nih.gov/pubmed/23085429	https://clinicaltrials.gov/ct2/show/NCT03950050								
																				Splenomegaly		HP:0001744	https://www.ncbi.nlm.nih.gov/pubmed/23085429										
																				Thrombocytpenia		HP:0001873	https://www.ncbi.nlm.nih.gov/pubmed/23085429										
																				Hepatomegaly		HP:0002240	https://www.ncbi.nlm.nih.gov/pubmed/23085429										
									Miglustat (NB-DNJ)(OGT 918)	DB00419	ECO:0007121/ECO:0000179/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Splenomegly		HP:0001744			https://www.ncbi.nlm.nih.gov/pubmed/11227045	https://www.ncbi.nlm.nih.gov/pubmed/12064906		https://www.ncbi.nlm.nih.gov/pubmed/15505381	https://www.ncbi.nlm.nih.gov/pubmed/15895716				
																				Hepatomegly		HP:0002240			https://www.ncbi.nlm.nih.gov/pubmed/16199246	https://www.ncbi.nlm.nih.gov/pubmed/16285070							
																				High chitotriosidase level		NA											
									PEG-Glucocerebrosidase(Lysodase)	NA	ECO:0007121					Direct interaction (ERT)	A	direct complementation of a genetically defective protein		Fatigue		HP:0012378	https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9	https://www.ncbi.nlm.nih.gov/pubmed/7814809									
																				Asthenia		HP:0025406											
																				Pancytopenia		HP:0001876											
																				Hepatosplenomegaly		HP:0001433											
109	# 230900	Gaucher disease type 2	" By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury."	GBA 	beta-glucocerebrosidase			The treatment was done via convection-enhanced delivery, however, no results were added to the result section.	Glucocerebrosidase	DB06667	ECO:0007121/ ECO:0000352					Direct interaction (ERT)	A	direct complementation of a genetically defective protein					https://www.ncbi.nlm.nih.gov/pubmed/18952590	https://www.ncbi.nlm.nih.gov/pubmed/17065591	https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/24441827		https://www.ncbi.nlm.nih.gov/pubmed/7814809					
																																	
110	# 231005	Gaucher disease type 3 		GBA 	beta-glucocerebrosidase				Miglustat (Substrate reduction therapy)+imiglucerase	DB00419+DB00053	ECO:0007121					Functional interaction+Direct interaction	B+A	combination therapeutic procedure+functional complementation of a genetically defective protein+direct complementation of a genetically defective protein		Neuropathy		HP:0009830	https://www.ncbi.nlm.nih.gov/pubmed/17433057	https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2									
																				Generalized tonic-clonic seizures		HP:0002069											
																				Speech impairment		HP:0002167											
									Eliglustat(Substrate reduction therapy)	DB09039	ECO:0007121	CYP2D6				Functional interaction	B	functional complementation of a genetically defective protein		Abnormal glucocerebroside level		HP:0003656	https://www.ncbi.nlm.nih.gov/pubmed/29680197	https://www.ncbi.nlm.nih.gov/pubmed/30264864	http://clinicaltrials.gov/show/NCT00358150	https://www.ncbi.nlm.nih.gov/pubmed/30247105	https://www.ncbi.nlm.nih.gov/pubmed/29358012	https://www.ncbi.nlm.nih.gov/pubmed/29326879					
																				Hepatosplenomegaly 		HP:0001433	https://www.ncbi.nlm.nih.gov/pubmed/28935503										
																				Thrombocytopenia		HP:0001873											
																				Low mean hemoglobin concentration 		HP:0025547											
									Velaglucerase alfa	DB06720	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Decreased hemoglobin		HP:0001903	https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18	https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all									
																				Thrombocytopenia		HP:0001873											
																				High spleen volume		HP:0001744											
																				High liver volume		HP:0002240											
									PEG-Glucocerebrosidase(Lysodase)	NA	ECO:0007121					Direct interaction (ERT)	A	direct complementation of a genetically defective protein		Glucocerebroside accumulation in blood stream (Abnormal circulating lipid concentration)*		HP:0003119	https://clinicaltrials.gov/ct2/show/NCT00001410?cond=Gaucher+Disease%2C+Type+3&draw=2&rank=9										
107	# 608013	Gaucher disease perinatal lethal 		GBA 	beta-glucocerebrosidase	3.2.1.45			No treatment is available in DDIEM																								
111	# 219500	Gamma-cystathionase deficiency 	Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897	CTH	cystathionine gamma-lyase	4.4.1.1			Pyridoxine	DB00165	ECO:0000352					Direct interaction 	A	activity modification of a genetically defective protein		Cystathioninuria		HP:0003153	http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/417288	https://www.ncbi.nlm.nih.gov/pubmed/5707897							
																				Tremor 		HP:0001337											
																				Impaired fine motor skillls		HP:0007010											
																				EEG abnormality		HP:0002353											
																				High total homocysteine level		HP:0010919											
112	# 613163	Gamma aminobutyric acid transaminase deficiency		ABAT	GABA-transaminase	2.6.1.19			Flumazenil	DB01205	ECO:0007121/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Unalertness		HP:0002329	http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract		https://www.ncbi.nlm.nih.gov/pubmed/29480352								
																				EEG abnormality		HP:0002353	http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract										
																				Functional motor deficit		HP:0004302	http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract										
																				Excessive adventitious movements		HP:0100022*	http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract										
																				Hypersomnolence 		HP:0100786	http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract										
																				Oculomotor apraxia		HP:0000657	https://www.ncbi.nlm.nih.gov/pubmed/29480352										
																				Developmental delay		HP:0012758	https://www.ncbi.nlm.nih.gov/pubmed/29480352										
								Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/	Phenobarbital/clonazepam/valproate/ midazolam	DB01174/DB01068/DB00313/DB00683	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
									Rapamycin	DB00877	ECO:0007764/ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Elevated CSF GHB levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/25485164	https://www.ncbi.nlm.nih.gov/pubmed/24578415/									
																				Oxidative stress		HP:0025464											
113	# 256540	Galactosialidosis 		CTSA	Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase	3.4.16.5			 rAAV-PPCR 	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein		Edematous		HP:0000969		https://www.ncbi.nlm.nih.gov/pubmed/22008912/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/	https://www.ncbi.nlm.nih.gov/pubmed/15084520/							
																				Infertility		HP:0000789											
																				Incoordination		HP:0002311											
																				Gait abnormality		HP:0001288											
																																	
									N-octyl-4-epi-β-valienamine (NOEV)	NA	ECO:0001565	"SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all
"				Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Low β-gal activity (Abnormal enzyme/coenzyme activity )*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/21520340	https://www.ncbi.nlm.nih.gov/pubmed/20826101	https://www.ncbi.nlm.nih.gov/pubmed/26259553								
114	# 230200	Galactokinase deficiency 		GALK1	galactokinase 1	2.7.1.6			No treatment is available in DDIEM																								
115	# 606812	Fumarase deficiency 	The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812	FH	Fumarate hydratase, mitochondrial	4.2.1.2			No treatment is available in DDIEM																								
116	253800	Fukuyama type muscular dystrophy 		FKTN	fukutin	O75072			Antisense oligonucleotide (VMO AED cocktail)	NA	ECO:0000179/ECO:0001565					Direct interaction 	A	activity modification of a genetically defective protein by transcriptional or translational modification		Abnormal fukutin mRNA expression		HP:0030098	https://www.nature.com/articles/nature10456	https://www.ncbi.nlm.nih.gov/pubmed/27421908									
																				Pathogenic exon trapping 		NA											
									AAV9-MCK-fukutin	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein by gene therapy		Imapired muscle function		HP:0011804	https://www.ncbi.nlm.nih.gov/pubmed/21102543										
									Corticosteroid	DB00288	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Muscle weakness 		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/21726969										
																				Muscle necrosis 		HP:0003713											
																				Muscle inflammation		HP:0100614											
117	# 230000	Fucosidosis		FUCA1	a-L-fucosidase	3.2.1.51			Recombinant canine α-l-fucosidase enzyme	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein		High level of fucosyl-oligosaccharide accumulation (Increased urinary fucosylated oligosaccharide)*		HP:0410350	https://www.ncbi.nlm.nih.gov/pubmed/21575633	https://www.ncbi.nlm.nih.gov/pubmed/27491218	https://www.ncbi.nlm.nih.gov/pubmed/26537923								
																				Neuronal vacuolation (Granulovacuolar degeneration )*		HP:0002528		https://www.ncbi.nlm.nih.gov/pubmed/26537923									
																				Vacuolated lymphocytes		HP:0001922	https://www.ncbi.nlm.nih.gov/pubmed/21575633										
																				Pyramidal neuron loss		HP:0002062*											
																				Astrocytosis		MP:0003354											
																				Microgliosis		HP:0100708											
																				Purkinje cells apoptosis		MP:0000880											
																				Oligodendrocyte loss		HP:0100709											
																				Hypomyelination		MP:0013438											
																				Lysosomal expansion in neurons of deep cortex		HP:0004356*											
																				Astrocytosis in cerebral cortex		HP:0002446											
																				Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression (Abnormality of lysosomal metabolism )*		HP:0004356											
																				Abnormal neurololgical function		HP:0000707											
									Tocilizumab	DB06273	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Arthritis		HP:0001369	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/										
118	# 229700	Fructose-1,6-bisphosphatase deficiency 	"The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9"	FBP1	Fructose-1,6-bisphosphatase 1	3.1.3.11		Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193	Glucose	DB01914	ECO:0000352					Functional interaction	B	metabolite replacement		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/29203193		https://www.ncbi.nlm.nih.gov/pubmed/29390242								
119	# 136120	Fish-eye disease 	"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146"	LCAT	lecithin-cholesterol acyltransferase 	2.3.1.43			Statin	DB00175	ECO:0000352					Functional interaction	B	functional complementation of a defective protein		Decreased cholesterol absorption		MP:0002647	https://www.ncbi.nlm.nih.gov/pubmed/24636183										
								The drug was accomapined with fat-restricted diet 	Angiotensin II receptor blockers (ARBs)	C09C	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal lipoprotein profile		HP:0010979	https://www.ncbi.nlm.nih.gov/pubmed/23522979										
																				Abnormal renal function		HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/23522979										
																				Proteinuria		HP:0000093	https://www.ncbi.nlm.nih.gov/pubmed/23522979										
																				Low serum HDL-cholesterol		HP:0003233	https://www.ncbi.nlm.nih.gov/pubmed/23522979										
								rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512	r LCAT	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein		Abnormal lipoprotein profile		HP:0010979	https://www.ncbi.nlm.nih.gov/pubmed/20605907										
																				Low HDL-C  level		HP:0003233	https://www.ncbi.nlm.nih.gov/pubmed/20605907										
120	# 612319	Fatty acid hydroxylase-associated neurodegeneration 		FA2H	fatty acid 2-hydroxylase				Baclofen/Tizanidine/Trihexyphenidyl/Benzodiazepine/Dantrolene	DB00182/DB00697/DB00376/DB12537/DB01219	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/21735565										
																				Spasticity		HP:0001257	https://www.ncbi.nlm.nih.gov/pubmed/21735565										
									Botulinum toxin 	DB00083	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal muscular co-contraction		HP:0001257	https://www.ncbi.nlm.nih.gov/pubmed/21735565										
									Nimodipine	DB00393	ECO:0000305/ECO:0001565					Direct interaction 	A	activity modification of a genetically defective protein		Abnormality of circulating enzyme level		HP:0011021	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/										
								Iron Chelation is one of the therapies under investigation.	Deferiprone	DB08826	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/21735565										
																																	
121	# 616896	Fatal infantile encephalomyopathy 		OPA1	mitochondrial dynamin like GTPase 				No treatment is available in DDIEM																								
122	# 228000	Farber's disease 		ASAH1	acid ceramidase	3.5.1.23			Human recombinant acid ceramidase/human ACDase-encoding lentivector	NA	ECO:0000179/ECO:0001565					Direct interaction (ERT)	A	direct complementation of a genetically defective protein		Delayed growth		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				High cermaide level		MP:0020582	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/							
																				High intracellular cermaid level		MP:0020582*	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				Abnormal spleen size		HP:0001744	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				Abnormal sphingosine level (Abnormality of lipid metabolism)*		MP:0009587	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				high plasma MCP-1		NA	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				High macrophage infiltration into tissues (Abnormal inflammatory response)*		HP:0012647*	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				Abnormal tissue lipid profiles (Abnormality of lipid metabolism)*		HP:0003119	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
																				Joint inflammation		HP:0001369	https://www.ncbi.nlm.nih.gov/pubmed/23681708/	https://www.ncbi.nlm.nih.gov/pubmed/28275553	https://www.ncbi.nlm.nih.gov/pubmed/27155573								
								The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs. 	Amitriptyline	DB00321	ECO:0000305/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Abnormal pulmonary ceramide level(Abnormal circulating lipid concentration )*		HP:0003119	https://www.ncbi.nlm.nih.gov/pubmed/18376404										
																																	
123	# 227810	Fanconi Bickel syndrome 		SLC2A2	Solute carrier family 2, facilitated glucose transporter member 2	P11168		 Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet	Uncooked Cornstarch	DB11599	ECO:0000352					Functional interaction	B	Dietary supplementation		Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/24912437	https://www.ncbi.nlm.nih.gov/pubmed/7564233/									
																				Fasting hypoglycemia		HP:0003162	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Late+Diagnosis+of+Fanconi-Bickel+Syndrome%3A+Challenges+With+the+Diagnosis+and+Literature+Review&btnG=										
									Vitamin D	DB11094	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Short stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/24912437										
									Phosphorus	DB14151	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Rickets		HP:0002748	https://www.ncbi.nlm.nih.gov/pubmed/24912437										
									Bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Renal tubular acidosis		HP:0001947	https://www.ncbi.nlm.nih.gov/pubmed/24912437										
									Insulin	DB00030 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Diabetes mellitus		HP:0000819	http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/23456528									
124	151660	Familial partial lipodystrophy type 2 	Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/ 	LMNA	lamins ( Lamins A and C)	P02545			ISIS 703802 (AKCEA-ANGPTL3-LRx)	PubChem SID: 384573165	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		High fasting triglycerides		HP:0002155*	https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1										
									Metreleptin (A-100)	DB09046	ECO:0007121/ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal free fatty acid levels		HP:0040300	https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2	https://www.ncbi.nlm.nih.gov/pubmed/25734254									
																				High facial soft tissue volume		HP:0000287	https://www.ncbi.nlm.nih.gov/pubmed/28993984										
																				Abnormal fasting glucose		MP:0013277	https://www.ncbi.nlm.nih.gov/pubmed/29044799	https://www.ncbi.nlm.nih.gov/pubmed/26584826									
																				High  HbA1c levels		HP:0040217											
									Albiglutide (glucagon-like peptide-1 receptor agonist)	DB09043						Symptomatic	C	symptomatic therapeutic procedure		Abnormal fasting glucose		MP:0013277											
																				High HbA1c levels		HP:0040217											
									Volanesorsen (IONIS-APOCIIIRx)	NA	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Abnormal fasting triglycerides		HP:0002155*	https://clinicaltrials.gov/ct2/show/NCT02300233	https://clinicaltrials.gov/ct2/show/NCT02211209	https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2								
									Obeticholic Acid	DB05990	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Hepatic steatosis		HP:0001397	https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3										
																				High liver triglyceride level (hyperlipidemia)*		HP:0003077*											
									Gemcabene	DB05123	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Hypertriglyceridemia		HP:0002155	https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6										
																				Hepatic steatosis		HP:0001397											
								Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616	Fibrates + Omega-3 fatty acids (OMG-3) 	DB00636 +DB11133	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/27710244										
																																	
125	# 245900	Familial LCAT deficiency 		LCAT	lecithin-cholesterol acyltransferase 	2.3.1.43			Recombinant human LCAT (ACP-501)	NA	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Anemia		HP:0001903	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/	https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1									
																				Abnormal lecithin:cholesterol acyltransferase activity		MP:0011598											
																				Abnormal plasma lipids levels		HP:0003119											
																				Low HDL level		HP:0003233											
																				Low HDL-C level		HP:0003233											
																				Abnormal cholesterol efflux from cells		MP:0003193											
																				Dyslipidemia		MP:0003949											
																				Low APO A level		HP:0025201*											
																				Low Apo B protein level		HP:0025201*											
																				Proteinuria		HP:0000093											
									Captopril	DB01197	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypertension		HP:0000822	https://www.ncbi.nlm.nih.gov/pubmed/23391322										
									Thiazide	DB01324	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Oedema		HP:0000969											
126	# 162000	Familial juvenile hyperuricaemic nephropathy 		UMOD	uromodulin	P07911			Probenecid	DB01032	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperurecemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/20301530	https://www.ncbi.nlm.nih.gov/pubmed/8842764									
									Probenecid+Allopurinol	DB01032+DB00437	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Hyperurecemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/8842764										
								In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.	Allopurinol	DB00437	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperurecemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/12205338	https://www.ncbi.nlm.nih.gov/pubmed/11068651									
																				Mortality		HP:0040006	https://www.ncbi.nlm.nih.gov/pubmed/12205338										
																				Disease progression (Progressive)*		HP:0003676	https://clinicaltrials.gov/ct2/show/NCT03098797										
									Allopurinol+Benzbromarone	DB00437+DB12319	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Hyperurecemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/9678437										
127	# 145980	Familial hypocalciuric hypercalcemia type 1 	In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511	CASR	calcium-sensing receptor 	P41180			Cinacalcet	DB01012	ECO:0000352					Direct interaction 	A	activity modification of a genetically defective protein		Hypercalcemia		HP:0003072	https://www.ncbi.nlm.nih.gov/pubmed/28459040	https://www.ncbi.nlm.nih.gov/pubmed/16882283/	https://www.ncbi.nlm.nih.gov/pubmed/17803689/	https://www.ncbi.nlm.nih.gov/pubmed/22142470/	https://www.ncbi.nlm.nih.gov/pubmed/21289269/	https://www.ncbi.nlm.nih.gov/pubmed/20495831/					
																				Elevated circulating parathyroid hormone level		HP:0003165	https://www.ncbi.nlm.nih.gov/pubmed/20495831/	https://www.ncbi.nlm.nih.gov/pubmed/21289269/									
																				Impaired renal uric acid clearance		HP:0004732	https://www.ncbi.nlm.nih.gov/pubmed/28459040										
																				Polydipsia		HP:0001959	https://www.ncbi.nlm.nih.gov/pubmed/28459040										
128	# 145981	Familial hypocalciuric hypercalcemia type 2 		GNA11	guanine nucleotide-binding protein (Gα11)	P21278			Cinacalcet	DB01012	ECO:0000352					Direct interaction 	A	activity modification of a genetically defective protein		High serum ionized calcium concentrations		HP:0003072*	https://www.ncbi.nlm.nih.gov/pubmed/22142470/		https://www.ncbi.nlm.nih.gov/pubmed/28833550								
																				Abnormal parathyroid hormone level		HP:0003165											
129	# 600740	Familial hypocalciuric hypercalcemia type 3 		AP2S1	adaptor protein-2 σ-subunit 	 P53680			Cinacalcet	DB01012 	ECO:0000352					Direct interaction 	A	activity modification of a genetically defective protein		High serum ionized calcium concentrations		HP:0003072*	https://www.ncbi.nlm.nih.gov/pubmed/27050234/	https://www.ncbi.nlm.nih.gov/pubmed/22142470/	https://www.ncbi.nlm.nih.gov/pubmed/25993639								
																				Abnormal parathyroid hormone level		HP:0003165											
																				Low calcium urine excretion		HP:0003127	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/										
	# 145750	HYPERTRIGLYCERIDEMIA, FAMILIAL		APOA5	Apolipoprotein A-V	Q6Q788			Gemfibrozil+Dietary fat restriction 	DB01241+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+dietary exclusion		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/15251700/										
																																	
									Fenofibrate +niacin+omega‐3 fatty acids	DB01039+DB00627 +DB11133	ECO:0000352					Direct interaction+Functional interaction+Functional interaction	A+B+B	combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/24524914										
									Omega 3 FA	DB11133	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/10925336?dopt=Abstract										
									Omega-3-acid ethyl esters	DB09539	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/16390715?dopt=Abstract										
									Insulin	DB01306	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/28225998									
								Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965	Heparin	DB01109	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/1800965	https://www.ncbi.nlm.nih.gov/pubmed/12114919	https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/28225998							
																				Acute pancreatitis		HP:0001735											
									Chenodeoxycholic acid	DB06777	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Hypertriglyceridemia		HP:0002155	https://clinicaltrials.gov/ct2/show/NCT00465751?cond=Familial+hypertriglyceridemia&draw=3&rank=2										
									Rosuvastatin	DB01098	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/23323877										
																				High LDL level		HP:0003141											
																																	
130	# 604091	Familial HDL deficiency (Tangier Disease)		ABCA1	Phospholipid-transporting ATPase ABCA1	7.6.2.1			Niacin	DB00627	ECO:0007121					Direct interaction 	A	activity modification of a genetically defective protein		Hypoalphalipoproteinemia 		HP:0003233	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/	https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10									
																				Low HDL cholesterol concentration		HP:0003233	https://www.ncbi.nlm.nih.gov/pubmed/18993152										
									Gemfibrozil	DB01241	ECO:0000179					Direct interaction 	A	activity modification of a genetically defective protein		Low HDL cholesterol concentration		HP:0003233	https://www.ncbi.nlm.nih.gov/pubmed/9493705										
									Pravastatin	DB00175	ECO:0007121	R219K				Direct interaction 	A	activity modification of a genetically defective protein		Increased low-density lipoprotein cholesterol concentration		HP:0003141	https://www.ncbi.nlm.nih.gov/pubmed/24854628/										
								Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152	Atorvastatin/ Fenofibrate/ Niacin	DB01076/DB01039/DB00627	ECO:0007121					Direct interaction 	A	activity modification of a genetically defective protein		Hypoalphalipoproteinemia 		HP:0003233	https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3	https://www.ncbi.nlm.nih.gov/pubmed/18993152									
																	A			Low HDL cholesterol concentration	Niacin was the only effective drug to increase HDL cholesterol.	HP:0003233											
									CER 001, a recombinant high-density lipoprotein (HDL)	NA	ECO:0007121/ECO:0000179/ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Decreased apolipoprotein AI level		HP:0031799	https://www.ncbi.nlm.nih.gov/pubmed/25561459/		https://www.ncbi.nlm.nih.gov/pubmed/28213743	https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8							
																				Vasculitis		HP:0002633											
																				Decreased plasma HDL-c levels		HP:0003233											
																				Arterial pluque		HP:0002621											
131	# 301500	Fabry disease 		GLA	alpha-galactosidase A				Fabrazyme ( agalsidase beta) + pegunigalsidase alfa ( PRX-102)	DB00103+DB14992	ECO:0007121					Direct interaction+Direct interaction	A+A	combination therapeutic procedure+direct complementation of a genetically defective protein+direct complementation of a genetically defective protein		Abnormal kidney function		HP:0012211		https://clinicaltrials.gov/ct2/show/study/NCT02795676?term=PRX-102&cond=Fabry+Disease&show_locs=Y#locn	https://www.ncbi.nlm.nih.gov/pubmed/25885911				https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8				
									REPLAGAL (Agalsidase Alfa)	DB00103	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Cardiomegaly		HP:0001640	https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7	https://www.ncbi.nlm.nih.gov/pubmed/25885911									
																				Low renal glomerular filtration rate		HP:0012213											
																				Pain		HP:0012531											
								Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy	Pegunigalsidase alfa ( PRX-102)	DB14992	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Abnormal kidney function		HP:0012211	https://clinicaltrials.gov/ct2/show/NCT03180840?term=PRX-102&cond=Fabry+Disease	https://clinicaltrials.gov/ct2/show/NCT01678898?term=PRX-102&cond=Fabry+Disease	https://clinicaltrials.gov/ct2/show/NCT01769001?term=PRX-102&cond=Fabry+Disease	https://clinicaltrials.gov/ct2/show/NCT01981720?term=PRX-102&cond=Fabry+Disease							
									Lucerastat	DB14872	ECO:0007121/ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		High Gb3 (globotriaosylceramide) accumulation.		NA	https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2	https://clinicaltrials.gov/ct2/show/NCT03425539	https://clinicaltrials.gov/ct2/show/NCT03737214	https://www.ncbi.nlm.nih.gov/pubmed/28088251	https://www.ncbi.nlm.nih.gov/pubmed/29982630						
								"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/"	Migalastat hydrochloride (AT1001)	DB05018	ECO:0007121/ECO:0001565	p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W  		E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S		Direct interaction	A	activity modification of a genetically defective protein		High plasma lyso-globotriaosylsphingosine level		NA	https://www.ncbi.nlm.nih.gov/pubmed/30875019	https://www.ncbi.nlm.nih.gov/pubmed/30765910	https://www.ncbi.nlm.nih.gov/pubmed/27509102/	https://clinicaltrials.gov/ct2/show/NCT00925301	https://clinicaltrials.gov/ct2/show/NCT01458119	https://www.ncbi.nlm.nih.gov/pubmed/30723321					
																				High mean number of GL-3 inclusions/kidney interstitial capillary(KIC) 		NA											
																				Left ventricular hypertrophy		HP:0001712	https://www.ncbi.nlm.nih.gov/pubmed/27834756/	https://www.ncbi.nlm.nih.gov/pubmed/30723321									
132	# 612073	MITOCHONDRIAL DNA DEPLETION SYNDROME 5		SUCLA2	Succinyl-CoA synthetase ( beta subunit)				Carbamazepine	DB00564 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		seizures		HP:0001250			https://www.ncbi.nlm.nih.gov/books/NBK6803/								
									Riboflavin+thiamine	DB00140+DB00152  	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/19666145										
								The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.	L-DOPA 	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal facial expression		HP:0005346	https://www.ncbi.nlm.nih.gov/pubmed/19666145										
																				Functional motor deficit		HP:0004302											
																																	
133	# 249900	Encephalopathy due to prosaposin deficiency		PSAP 	prosaposin			https://www.ncbi.nlm.nih.gov/pubmed/8370580	No treatment is available in DDIEM																								
134	# 177000	Erythropoietic protoporphyria 		FECH	ferrochelatase				Vitamin D	DB11094	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Concommitant low vit D level(Low levels of vitamin D)*		HP:0100512*			https://www.ncbi.nlm.nih.gov/pubmed/24137761								
									Afamelanotide (Scenesse)	DB04931	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Erythema		HP:0010783	https://www.ncbi.nlm.nih.gov/pubmed/28003770	https://www.ncbi.nlm.nih.gov/pubmed/25402764	https://www.ncbi.nlm.nih.gov/pubmed/19656325/	https://www.ncbi.nlm.nih.gov/pubmed/25402764	https://www.ncbi.nlm.nih.gov/pubmed/26979527	https://www.ncbi.nlm.nih.gov/pubmed/23884489/					
																				Cutaneous photosensitivity		HP:0000992											
									Corticosteroids	DB00288 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Pain		HP:0012531	https://www.ncbi.nlm.nih.gov/pubmed/27139922	https://www.ncbi.nlm.nih.gov/pubmed/19744342									
																				Pruritus		HP:0000989											
									Zinc 	DB01593	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Increased ROS formation		HP:0025464	http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract			https://www.ncbi.nlm.nih.gov/pubmed/22092997							
								"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/"	β-carotene	DB06755	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure	No significant difference was found in the controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/341955/	intolerance to sunlight		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/341955/	https://www.ncbi.nlm.nih.gov/pubmed/22791288									
																				Pain in the skin		HP:0025280*											
									Cholestyramine	DB01432	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal  protoporphyrin enterhepatic circulation		HP:0012187	https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract									
								Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract	Activated charcoal	DB09278	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal liver function test		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract									
																				Abdominal pain		HP:0002027	https://www.ncbi.nlm.nih.gov/pubmed/20375647										
																				Photosenstivity		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/20375647	https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract								
																				Pruritis		HP:0000989	https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract										
																				Hepatotoxicity		NA	https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract										
																				Fluid retention		HP:0000969	https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract										
									Hemin	DB03404	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Hepatic prophyria (Abnormality of the heme biosynthetic pathway)*		HP:0010472*	https://www.ncbi.nlm.nih.gov/pubmed/23016163										
									Cysteine hydrochloride	DB00151 	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		photosensitivity		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/12535027	https://clinicaltrials.gov/ct2/show/NCT00004940	https://clinicaltrials.gov/ct2/show/NCT00004831								
								"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal، model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332
Study was Terminated (Interim analysis demonstrated the treatment was not effective)"	Isoniazid	DB00951	ECO:0000179/ECO:0007121					Symptomatic	C	functional complementation of a genetically defective protein by inhibition	Terminated				https://www.ncbi.nlm.nih.gov/pubmed/31395332		https://clinicaltrials.gov/ct2/show/NCT01550705								
									Iron	DB01592	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		High erythrocyte protoporphyrin levels		HP:0012187			https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10								
135		Erythropoietic uroporphyria associated with myeloid malignancy 							No treatment is available in DDIEM																https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub								
136	# 602473	Ethylmalonic encephalopathy		ETHE1	persulfide dioxygenase				Acetylcysteine	DB06151	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein/functional complementation of a genetically defective protein by inhibition		High Lactic acid		HP:0003648	https://www.ncbi.nlm.nih.gov/pubmed/16376514	https://www.ncbi.nlm.nih.gov/pubmed/27830356		https://www.ncbi.nlm.nih.gov/pubmed/29526615							
								Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)	Neomycin+Acetylcysteine	DB00994+DB06151	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition		Abnormal thiosulfates level		HP:0011943	https://www.ncbi.nlm.nih.gov/pubmed/29526615										
									Metronidazole+Acetylcysteine+Dietary restricting sulfur containing amino acids treatment	(DB00916+DB06151)+NA	ECO:0000352					(Functional interaction+Functional interaction)+Functional interaction	(B+B)+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition+dietary exclusion		Hypotonia		MP:0004144	https://www.ncbi.nlm.nih.gov/pubmed/29526615	https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract									
																				Diarrhea		HP:0002014											
																				High EMA levels		HP:0003219											
									Ascorbic acid	DB00126	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Decreased activity of cytochrome C oxidase in muscle tissue		HP:0003688	https://www.ncbi.nlm.nih.gov/pubmed/29526615										
								A drug regimen that was used as a postoperative therapy after liver transplataion surgery to maintain the achieved metabolic results.	Carnitine+metronidazole	DB00583+DB00916	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Disease progression (Progressive)*		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/26917598										
									Riboflavin and/orCoenzyme Q10	DB00140+DB09270	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Functional motor deficit		HP:0004302	https://www.ncbi.nlm.nih.gov/pubmed/11916321	https://www.ncbi.nlm.nih.gov/pubmed/17712735									
																				Cognitive impairment		 HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/17712735										
																				Elevated plasma acylcarnitine levels		HP:0045045	https://www.ncbi.nlm.nih.gov/pubmed/17712735										
																				Chronic mucoid diarrhea		HP:0002028	https://www.ncbi.nlm.nih.gov/pubmed/17712735	https://www.ncbi.nlm.nih.gov/pubmed/17712735									
																				Petechiae 		HP:0000967	https://www.ncbi.nlm.nih.gov/pubmed/17712735										
																				Psychomotor retardation		HP:0025356	https://www.ncbi.nlm.nih.gov/pubmed/17712735										
								It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria. 	Dehydroascorbic acid	DB08830	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Sulfide toxicity		NA	https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230										
137	# 237500	Dubin-Johnson syndrome	DJS is a benign disease that does not require treatment.https://www.ncbi.nlm.nih.gov/pubmed/20955959 https://www.ncbi.nlm.nih.gov/pubmed/28923092	ABCC2 	Multidrug resistance protein-2				No treatment is available in DDIEM																								
138	# 608799	DPM1-CDG (CDG-Ie) 		DPM1	dolichol-P-mannose synthase 1			https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/	No treatment is available in DDIEM																								
139	# 615042	DPM2-CDG 		DPM2	dolichyl-phosphate mannosyltransferase subunit 2				No treatment is available in DDIEM																								
140	# 612937	DPM3-CDG (CDG-Io) 		DPM3	dolichyl-phosphate mannosyltransferase subunit 3				No treatment is available in DDIEM																								
141	# 179850	Dowling-Degos disease 		KRT5/POGLUT1	keratin 5/protein O-glucosyltransferase			"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428"	No treatment is available in DDIEM																								
142	# 223360	Dopamine beta hydroxylase deficiency 		DBH	dopamine beta (β)-hydroxylase				Droxidopa	DB06262	ECO:0007121					Functional interaction	B	metabolite replacement		Orthostatic hypotension		HP:0001278	https://www.ncbi.nlm.nih.gov/pubmed/20301647	https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency	https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10								
143	# 128230	Dopa-responsive dystonia		GCH1/TH/SPR	GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase				Levedopa/carbidopa	DB01235/DB00190	ECO:0007121					Functional interaction	B	metabolite replacement		Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/9886460/	https://www.ncbi.nlm.nih.gov/pubmed/11346370/	https://www.ncbi.nlm.nih.gov/pubmed/16891685	https://www.ncbi.nlm.nih.gov/pubmed/1899474	https://www.ncbi.nlm.nih.gov/pubmed/16891685	https://www.ncbi.nlm.nih.gov/pubmed/8163996	https://www.ncbi.nlm.nih.gov/pubmed/1899474	https://www.ncbi.nlm.nih.gov/pubmed/12084887			
																				Parkinsonism		HP:0001300											
																				Fatigue		HP:0012378											
																				Cerebellar dysfunction		NA	https://www.ncbi.nlm.nih.gov/pubmed/16908750										
									Serotonin reuptake inhibitors	N06AB	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Depression		HP:0000716	https://www.ncbi.nlm.nih.gov/pubmed/16361586										
																				Obsessive-compulsive behavior 		HP:0000722											
									5‐hydroxytryptophan	DB02959 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Depression		HP:0000716	https://www.ncbi.nlm.nih.gov/pubmed/16361586										
																				Serotonin deficiency		HP:0003117*											
	# 605407	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE		TH	Tyrosine hydroxylase	1.14.16.2			Selegiline+L-dopa	DB01037+DB01235	ECO:0000352					Functional interaction	B	combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement		Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/20399390	https://www.ncbi.nlm.nih.gov/pubmed/11241071	https://www.ncbi.nlm.nih.gov/pubmed/10753262								
																				lack of eye contact		HP:0000817											
																				Delayed motor skills		HP:0002194											
																				Poor head control		 HP:0002421											
																				Delayed mental development		HP:0001263											
																				lack of gross motor function		HP:0002194											
								There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107	L- dopa	DB01235	ECO:0000352			(926T>C		Functional interaction	B	metabolite replacement		Decreased CSF homovanillic acid		HP:0003785	https://www.ncbi.nlm.nih.gov/pubmed/8817341	https://www.ncbi.nlm.nih.gov/pubmed/10585338	https://www.ncbi.nlm.nih.gov/pubmed/10407773	https://www.ncbi.nlm.nih.gov/pubmed/9732974							
																				Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/22815559										
																				Myoclonus jerk		HP:0001336	https://www.ncbi.nlm.nih.gov/pubmed/22815559										
																				Abnormal epinephrine/norepinephrin ratio		NA	https://www.ncbi.nlm.nih.gov/pubmed/10585338										
																				Hypokinesia		HP:0002375											
																																	
144	# 614921	PGM1-CDG 		PGM1	Phosphoglucomutase-1	5.4.2.2			D-galactose	DB11735	ECO:0007121/ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal alanine transaminase		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/28617415	https://clinicaltrials.gov/ct2/show/NCT02955264	https://www.ncbi.nlm.nih.gov/pubmed/24499211/								
																				Abnormal aspartate transaminase		HP:0002910											
																				Abnormal activated partial thromboplastin time		HP:0003645											
																				Abnormal Antithrombin-III levels		HP:0001976											
																				Abnormal nucleotide sugars		NA											
145	# 266265	SLC35C1-CDG (CDG-IIc) 		SLC35C1	guanosine 5'-diphosphate (GDP)-fucose transporter	Q96A29			Fucose	DB03485	ECO:0001565/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Defected phagocytic function		HP:0010977	https://www.ncbi.nlm.nih.gov/pubmed/29702557	https://www.ncbi.nlm.nih.gov/pubmed/17276979	https://www.ncbi.nlm.nih.gov/pubmed/10590041								
																				low neutrophil count		HP:0001875											
																				recurrent infection		HP:0002719											
																				abnormal expression of E- and P-selectin ligands		NA											
																				Atypical psychomotor development		HP:0001263*											
146	# 610768	DOLK-CDG		DOLK	dolichol kinase	2.7.1.108			Vigabatrin	DB01080	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/23890587	https://www.ncbi.nlm.nih.gov/pubmed/23890587									
									Carbamazepine	DB00564	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Generalized tonic–clonic seizure		HP:0002069											
																				Focal seizures		HP:0007359											
									Clonazepam+Vigabatrin	DB01068+DB01080	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Seizures		HP:0001250											
147		Dipsogenic diabetes insipidus	Behavioural therapy was a successful treatmemnt for primary polydipsia.https://www.ncbi.nlm.nih.gov/pubmed/2373769?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/12102585?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/3392224?dopt=Abstract					Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.	Desmopressin 	DB00035 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Polyuria		HP:0000103	https://www.ncbi.nlm.nih.gov/pubmed/16544179		https://www.ncbi.nlm.nih.gov/pubmed/16544179								
																				Affected functional activity (Constitutional symptom)*		HP:0025142*											
148	# 274270	Dihydropyrimidine dehydrogenase (DPD) deficiency		DPYD 	dihydropyrimidine dehydrogenase	1.3.1.2			Uridine triacetate	DB09144 	ECO:0000179/ECO:0000305					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Mortality		HP:0040006	https://www.ncbi.nlm.nih.gov/pubmed/29908244	https://www.ncbi.nlm.nih.gov/pubmed/27622829									
																				Weight loss		HP:0001824				https://www.ncbi.nlm.nih.gov/pubmed/28275972							
									Valproic acid 	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Generalized muscular hypotonia		 HP:0001290	https://www.ncbi.nlm.nih.gov/pubmed/28275972										
																				EEG with parito-occipital spike waves		HP:0012011											
																				Developmental impairment		HP:0001270											
																				Speech and languague delay		HP:0000750											
									Valproic acid+Carbamazepine	DB00313+DB00564	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/30349988										
149	# 261630	Dihydropteridine reductase deficiency		QDPR	quinoid dihydropteridine reductase	1.5.1.34			L-dopa/carbidopa+BH4+5-hydroxytryptophan+ Folinic acid	DB01235/DB00190+DB00360+DB02959+DB00650 	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High plasma phenylalanine level		HP:0004923			https://www.ncbi.nlm.nih.gov/pubmed/23430801	https://www.ncbi.nlm.nih.gov/pubmed/26817292							
																				Developmental delay		HP:0001263											
																				Unalertencess		HP:0002329*											
																				Receptive language delay		HP:0010863											
									Phe-restricted diet +Folinic acid+L-dopa+5-hydroxytryptophan	NA+DB00650 +DB01235+DB02959 	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+dietary exclusion+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High plasma phenylalanine level		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/26817292	https://www.ncbi.nlm.nih.gov/pubmed/7760062	https://www.ncbi.nlm.nih.gov/pubmed/18425437								
																				High serum  prolactin		HP:0040086											
																				Neurological abnormalities		HP:0000707											
																				Abnormal blood Phe levels		HP:0010893											
									L‐dopa+5-hydroxytryptophan+BH4+Entacapone	DB01235+DB02959+DB00360+DB00494	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Supportive	B+B+B+C	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+metabolite replacement+symptomatic therapeutic procedure		high plasma phenylalanine level		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/25667865										
									Levetiracetam 	DB01202	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/25667865										
									Phenobarbital + Valproate 	DB01174+DB00313	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Spastic tetraparesis		HP:0001285	https://www.ncbi.nlm.nih.gov/pubmed/18060820										
																				Epilepsy		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/18060820										
																																	
																																	
									L‐dopa+carbidopa+5-hydroxytryptophan+selegiline	DB01235+DB00190+DB02959+DB01037	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Supportive	B+B+B+C	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic therapeutic procedure		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/18425437										
									Pramipexole	DB00413	ECO:0000352					Supportive	C	symptomatic therapeutic procedure		Dopamine deficiency		HP:0012656	https://www.ncbi.nlm.nih.gov/pubmed/22325981	https://www.ncbi.nlm.nih.gov/pubmed/25707872	https://www.ncbi.nlm.nih.gov/pubmed/27423595								
																				Movement disability		HP:0100022											
																				Behavioral disability		HP:0000708											
																				Hyperprolactinemia		HP:0000870											
								Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.	Rotigotine+L-dopa+carbidopa	DB05271+DB01235+DB00190	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Parkinsonian symptoms		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/27423595										
																				Postural tremor		HP:0002174											
																				Kinetic tremor 		HP:0030186											
																				Bradykinesia		HP:0002067											
																				Dystonia		HP:0001332											
150	# 222748	Dihydropyrimidinase deficiency 		DPYS	dihydropyrimidinase	3.5.2.2			No treatment is available in DDIEM											Dyskinesias		HP:0100660											
151	# 246900	Dihydrolipoamide dehydrogenase deficiency 		DLD	dihydrolipoamide dehydrogenase	1.8.1.4			Riboflavin	DB00140	ECO:0000352/ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein		Exercise intolerance		HP:0003546			https://www.ncbi.nlm.nih.gov/pubmed/25251739	https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/10970889						
																				Myopathy		HP:0003198											
																				Fatiguability		HP:0003750											
									Biotin+Coenzyme Q+Carnitine+Riboflavin	DB00121+DB09270+DB00148+DB00140	ECO:0000352					Supportive+Supportive+Supportive+Direct interaction	C+C+C+A	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+activity modification of a genetically defective protein		Repeated vomiting		HP:0002572	https://www.ncbi.nlm.nih.gov/pubmed/14765544										
																Supportive	C			Encephalopathy		HP:0001298											
																Supportive	C			Lactic acidosis		HP:0003128											
									Sodium bicarbonate+Dichloroacetate+Carnitine+Thiamine+Coenzyme Q+Riboflavin	DB01390+DB08809+DB00583+ DB00152+DB09270+DB00140 	ECO:0000352					Supportive+Functional interaction+Supportive+Direct interaction+Direct interaction	C+B+C+A+A	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition+symptomatic therapeutic procedure+activity modification of a genetically defective protein+symptomatic therapeutic procedure+activity modification of a genetically defective protein		Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/10448086										
									Thiamine	DB00152	ECO:0000352	p.I480M				Direct interaction	A	activity modification of a genetically defective protein		Recurrent vomiting		HP:0002572			https://www.ncbi.nlm.nih.gov/pubmed/25032271	https://www.ncbi.nlm.nih.gov/pubmed/10448086							
																				Ptosis		HP:0000508	https://www.ncbi.nlm.nih.gov/pubmed/20652410										
																				Increased muscle fatiguability		HP:0003750	https://www.ncbi.nlm.nih.gov/pubmed/20652410										
								Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022	Sodium dichloroacetate	DB08809	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Lactic acidemia 		HP:0003128	https://www.ncbi.nlm.nih.gov/pubmed/8652022	https://www.ncbi.nlm.nih.gov/pubmed/11687750	https://www.ncbi.nlm.nih.gov/pubmed/23478190	https://www.ncbi.nlm.nih.gov/pubmed/25032271							
									Lipoic acid	DB00166 	ECO:0000352					Functional interaction	B	functional complementation of a defective protein		Lactic acidemia 		HP:0003128	https://www.ncbi.nlm.nih.gov/pubmed/6418873										
																				Pyruvic acidemia		HP:0001941					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/						
152	# 222730	Dicarboxylic aminoaciduria		SLC1A1	Excitatory amino acid transporter 3	P43005 			No treatment is available in DDIEM																								
154	# 125370	Dentatorubral-pallidoluysian atrophy 		ATN1 	atrophin 1	P54259			Levetiracetam	DB01202 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tonic-clonic seizures		HP:0002069			https://www.ncbi.nlm.nih.gov/pubmed/25558587	https://www.ncbi.nlm.nih.gov/pubmed/24816443							
																				Myoclonus		HP:0001336											
																				EEG abnormality		HP:0002353											
																				Poor appetite		HP:0004396											
																				Low quality of life (Constitutional symptom)*		HP:0025142											
																			The drug reduces the frequency of the epileptic seizures.	Epileptic seizures		HP:0001250											
								"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138	Olanzapine	DB00334 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Psychosis		HP:0000709			https://www.ncbi.nlm.nih.gov/pubmed/29739138								
																				Hallucinatory-paranoid state		HP:0011999*											
																				Auditory hallucinations		HP:0008765											
								The treatment regimen resulted in neuroleptic malignant syndrome.	Haloperidol +Levomepromazine	DB00502+DB01403	ECO:0000352					Symptomatic+Functional interaction	C+B	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein by inhibition		Psychosis		HP:0000709	https://www.ncbi.nlm.nih.gov/pubmed/11449034/										
									Perampanel	DB08883	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Diminished intellectual abilities		HP:0001249	https://www.ncbi.nlm.nih.gov/pubmed/28856097										
																				Myoclonic seizures		HP:0002123											
																				Inability to walk		HP:0002540											
155	# 602398	Desmosterolosis 		DHCR24	3-beta-hydroxysterol delta-24-reductase	1.3.1.72			Riboflavin+Nicotinamide+Thiamine	DB00140+DB02701+DB00152	ECO:0007764/ECO:0007121					Direct interaction+Direct interaction+Direct interaction	A+A+A	combination therapeutic procedure+activity modification of a genetically defective protein+activity modification of a genetically defective protein+activity modification of a genetically defective protein		High desmosterol levels (Abnormality of cholesterol metabolism)*	The change was not statistically significant.	HP:0003107*			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/								
																				High desmosterol/cholesterol ratio	The change was not statistically significant.	HP:0003107*											
																																	
								There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.	Cholesterol	DB04540 	ECO:0000352					Functional interaction	B	metabolite replacement		High desmosterol levels (Abnormality of cholesterol metabolism)*		HP:0003107*	https://www.ncbi.nlm.nih.gov/pubmed/10959439										
156	# 105650	Diamond-Blackfan anemia 		RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1	40S ribosomal protein S19	P39019			L-leucine	DB00149	ECO:0007121/ECO:0000179/ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		low heamoglobin level		HP:0001903			https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/22734070	https://www.ncbi.nlm.nih.gov/pubmed/25098371	https://www.ncbi.nlm.nih.gov/pubmed/17562599	https://www.ncbi.nlm.nih.gov/pubmed/22791294				
																				Defect in protein synthesis (Abnormality of circulating protein level)*		HP:0010876*											
																				Decreased red blood cell production 		HP:0012133*			https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4								
									Antithymocyte globulin+Cyclosporine	DB00098+DB00091	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+functional complementation of a genetically defective protein by inhibition	In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia. No results were posted in the website to tell what was the actual responce to the treatment. https://clinicaltrials.gov/ct2/show/NCT00001749	Pure red blood cell aplasia		HP:0012410	https://www.ncbi.nlm.nih.gov/pubmed/15813920		https://clinicaltrials.gov/ct2/show/NCT00001749								
									Rituximab	DB00073	ECO:0007121/ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Low RBC count		HP:0001877			https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156								
									Daclizumab	DB00111 	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Low RBC count		HP:0001877			https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1								
									Lenalidomide	DB00480	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Low RBC count		HP:0001877			https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9								
									Prednisolone	DB00635	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Low Hb level		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/27329125	http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract	http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract	http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/26305041	https://www.ncbi.nlm.nih.gov/pubmed/28883274					
																				Low quality of life		HP:0025142*											
																				Abnormal apoptosis		NA											
																				Erythroid progenitor depletion		HP:0025034*											
																				Premature differentiation of erythroid cells		HP:0012130*											
									Prednisone+Cyclosporine	DB00635+DB00091 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition		Low Hb level		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/27329125	https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract						
																				Reticulocytopenia		HP:0001896											
									Metoclopramide	DB01233	ECO:0000352					Functional interaction		functional complementation of a genetically defective protein by stimulation		Low Hb level		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/15795909	https://www.ncbi.nlm.nih.gov/pubmed/12351372/	https://www.ncbi.nlm.nih.gov/pubmed/17921858/	https://www.ncbi.nlm.nih.gov/pubmed/24744655							
																				Reduced hematocrit		HP:0031851											
									Metoclopramide+prednisolone	DB01233+DB00635	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by stimulation+functional complementation of a genetically defective protein		Low Hb level		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/24744655										
									Eltrombopag	DB06210	ECO:0007121/ECO:0000352	(c.356+3>C)				Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Low Hb level		HP:0001903	http://www.bloodjournal.org/content/128/22/2682	https://clinicaltrials.gov/ct2/show/NCT01328587	https://www.ncbi.nlm.nih.gov/pubmed/29684566								
																				Thrombocytopenia		HP:0001873											
157	# 258870	Gyrate atrophy of the choroid and retina 		OAT	ornithine aminotransferase	2.6.1.13			Vitamin B6 	DB00165	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		High ornithine level		HP:0012026	https://www.ncbi.nlm.nih.gov/pubmed/29757052	https://www.ncbi.nlm.nih.gov/pubmed/17565677/	https://www.ncbi.nlm.nih.gov/pubmed/7028650/	https://www.ncbi.nlm.nih.gov/pubmed/24082780	https://www.ncbi.nlm.nih.gov/pubmed/29654911						
									Lysine supplementation	DB00123 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High ornithine level              		HP:0012026	https://www.ncbi.nlm.nih.gov/pubmed/11486915	https://www.ncbi.nlm.nih.gov/pubmed/11486915	https://www.ncbi.nlm.nih.gov/pubmed/10896280								
									Low protein intake (arginine-restricted diet)+pyridoxine	NA+DB00165	ECO:0000352					Functional interaction+Direct interaction	B+A	combination therapeutic procedure+dietary exclusion+activity modification of a genetically defective protein		Cystoid macular edema 		HP:0011505	https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract										
																				Low visual acuity		HP:0007663											
									Arginine-restricted diet	NA	ECO:0000352					Functional interaction	B	dietary exclusion		Disease progresssion		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/16601905	https://www.ncbi.nlm.nih.gov/pubmed/15159649	https://www.ncbi.nlm.nih.gov/pubmed/1755734	https://www.ncbi.nlm.nih.gov/pubmed/7356686	https://www.ncbi.nlm.nih.gov/pubmed/7254778/						
																				High ornithine plasma level		HP:0012026											
																				Low visual acuity		HP:0007663											
									Topical NSAIDs +Systemic CAI	DB00586+DB00311	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Cystoid macular edema 		HP:0011505	https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract										
									Intravitreal bevacizumab	DB00112	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Choroidal neovascularization		HP:0011506	https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract										
																				Decreased visual acuity 		HP:0007663											
																				Abnormal central vision		HP:0000504											
									Alpha-aminoisobutyric acid	DB02952	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High ornithine plasma level		HP:0012026	https://www.ncbi.nlm.nih.gov/pubmed/7356686	https://www.ncbi.nlm.nih.gov/pubmed/7254778/									
									Gene therapy *	NA	ECO:0007121/ECO:0001565					Direct interaction 	A	direct complementation of a genetically defective protein by gene therapy		Abnormal enzyme/coenzyme activity		 HP:0012379	https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/9414260	https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1								
158	# 612736	Guanidinoacetate methyltransferase deficiency		GAMT	guanidinoacetate methyltransferase	 2.1.1.2			Creatine-monohydrate	DB00148	ECO:0000352					Functional interaction	B	metabolite replacement		Extrapyramidal movement disorders		HP:0002071	https://www.ncbi.nlm.nih.gov/pubmed/24268530	https://www.ncbi.nlm.nih.gov/pubmed/18652077	https://www.sciencedirect.com/science/article/pii/S1096719213003107	https://www.sciencedirect.com/science/article/pii/S1096719213003661	https://www.ncbi.nlm.nih.gov/pubmed/29506905	https://www.sciencedirect.com/science/article/pii/S1096719212002971	https://www.ncbi.nlm.nih.gov/pubmed/8813986				
								A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation	L-ornithine+Arginine restriction	DB00129+NA	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+dietary exclusion		Epileptic seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/11749046	https://www.ncbi.nlm.nih.gov/pubmed/9686828									
																				Slow background activity in the EEG (EEG abnormality)*		HP:0002353*											
																				Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*		HP:0002453*											
								"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys"	Sodium benzoate+ornithine+creatine	DB03793+DB00129+DB00148	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition+metabolite replacement		High CSF guanidinoacetate levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/24071436	https://www.ncbi.nlm.nih.gov/pubmed/12557293									
																				High plasma guanidinoacetate levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/24071436										
								This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203	Creatine+l-ornithine+Arginine restriction	DB00148+DB00129+NA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein by inhibition+dietary exclusion		Epilepsy		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/24268530	https://www.ncbi.nlm.nih.gov/pubmed/12557293									
																				Low urinary creatine excretion		HP:0012113	https://www.ncbi.nlm.nih.gov/pubmed/16855203										
																				Low brain creatine phosphate		NA	https://www.ncbi.nlm.nih.gov/pubmed/16855203	https://www.ncbi.nlm.nih.gov/pubmed/15625559									
																				Low cerebral creatine		HP:0025051	https://www.ncbi.nlm.nih.gov/pubmed/16855203										
																				High plasma guanidinoacetate levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/16855203										
																				Abnormal coordination of movements		HP:0011443	https://www.ncbi.nlm.nih.gov/pubmed/24268530	https://www.ncbi.nlm.nih.gov/pubmed/16855203	https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency								
																				Behavioral abnormalities		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/24268530	https://www.ncbi.nlm.nih.gov/pubmed/16855203									
								Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530	Sodium phenylbutyrate+L-ornithine+Arginine restriction	DB06819+DB00129+NA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein by inhibition+dietary exclusion		High plasma guanidinoacetate levels		NA	https://www.ncbi.nlm.nih.gov/pubmed/24268530										
159	# 233910	GTP cyclohydrolase I deficiency 		GCH1	GTP cyclohydrolase 1	3.5.4.16			Tetrahydrobiopterin	DB00360	ECO:0007121/ECO:0000352					Functional interaction	B	metabolite replacement	Mechanistic (A)	High serum phenylalanine 		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/9667588	https://www.ncbi.nlm.nih.gov/pubmed/12003346	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES	https://www.ncbi.nlm.nih.gov/pubmed/16275037							
									L-dopa	DB01235	ECO:0000352					Functional interaction	B	metabolite replacement	Symptomatic ©	Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/12391354	https://www.ncbi.nlm.nih.gov/pubmed/12003346	https://www.ncbi.nlm.nih.gov/pubmed/18276179		https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10078749	https://www.ncbi.nlm.nih.gov/pubmed/21937252			
									benserazide	DB12783	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Oromandibular dystonia 		HP:0012048	https://www.ncbi.nlm.nih.gov/pubmed/10078749	https://www.ncbi.nlm.nih.gov/pubmed/12003346									
									5-hydroxytryptophane	DB04159 	ECO:0000352					Functional interaction	B	metabolite replacement		Spasticity		HP:0001257											
																				Abnormal motor development		HP:0001270											
																				Sleep disturbance		HP:0002360											
																				Defected neurotransmitter homeostasis in the CNS		HP:0012535	https://www.ncbi.nlm.nih.gov/pubmed/22729819										
									Folinic acid	DB00650	ECO:0000352					Functional interaction	B	metabolite replacement		Depletion of cerebral folate		HP:0012446	https://www.ncbi.nlm.nih.gov/pubmed/12003346	https://www.ncbi.nlm.nih.gov/pubmed/18276179									
																				Abnormal folate homeostasis in the CNS		HP:0012335											
								The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.	Amantadine	DB00915	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Levodopa‐induced choreic dyskinesia (Dyskinesia)*		HP:0100660*	https://www.ncbi.nlm.nih.gov/pubmed/15389992										
169	# 215140	Greenberg dysplasia 		LBR	lamin B receptor	Q14739			No treatment is available in DDIEM																								
170	# 603358	GRACILE syndrome 		BCS1L	ubiquinol-cytochrome c reductase complex chaperone	Q9Y276			Sodium bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Symptomatic ©	Lactic acidosis		HP:0003128			https://www.ncbi.nlm.nih.gov/pubmed/22970607	https://www.ncbi.nlm.nih.gov/pubmed/24655110							
171	# 609056	GM3 synthase deficiency 		ST3GAL5	GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase	2.4.99.9			Gangliosides	DB12351	ECO:0007121					Functional interaction	B	metabolite replacement	Mechanistic (A)	Delayed Develoment		HP:0001263			https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1								
									CoQ10	DB09270	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Poor eye contect		HP:0000817			https://www.ncbi.nlm.nih.gov/pubmed/22990144								
																				Abnormal interactivity		HP:0012433											
172	# 230500	GM1 gangliosidosis type 1 		GLB1	beta-galactosidase	3.2.1.23			(5aR)-5a-C-Pentyl-4-epi-isofagomine	NA	ECO:0001565					Direct interaction 	A	activity modification of a genetically defective protein	Mechanistic (B)	Neurologic abnormalities		HP:0000707			https://www.ncbi.nlm.nih.gov/pubmed/27750150								
									β-galactosidase:RTB lectin fusion	NA	ECO:0001565					Direct interaction 	A	direct complementation of a genetically defective protein		Decreased beta-galactosidase activity		HP:0008166	https://www.ncbi.nlm.nih.gov/pubmed/26766614										
									N-octyl 4-epi-β-valienamine	NA	ECO:0000179							functional complementation of a defective protein		Intracellular ganglioside accumulation		NA											
																				Short survival time (Mortality)*		HP:0040006	https://www.ncbi.nlm.nih.gov/pubmed/22436580										
173	# 230600	GM1 gangliosidosis type 2 		GLB1	beta-galactosidase	3.2.1.23			6S-NBI-DGJ	PubChem CID:76070514 	ECO:0001565					Direct interaction 	A	activity modification of a genetically defective protein	Mechanisitic (B)	Brain pathology		HP:0001298			https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract								
174	# 230650	GM1 gangliosidosis type 3 		GLB1	beta-galactosidase	3.2.1.23			Cyclodextrin	CHEBI:23456	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure	Mechanistic (	CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis 		NA			https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract								
																				Elevated intraneuronal cholesterol		NA											
									AAV-treated βgal	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein	Mechanisitic(A)	Abnormally decreased rate of beta-galactosidase activity		HP:0008166			https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract								
									Miglustat	DB00419 	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein by inhibition	Mechanisitic (B)	High ganglioside accumulation 		HP:0004345			https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1								
																				Ataxic gait		HP:0002066											
175	# 607625	Niemann-Pick disease type C2 		NPC2	NPC intracellular cholesterol transporter 2	P61916			2-hydroxypropyl-beta-cyclodextrin	DB15146	ECO:0000352					Functional interaction	B	functional complementation of a defective protein	Mechanistic (B)	Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*		HP:0003107*		https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Use+of+2-Hydroxypropyl-Beta-Cyclodextrin+for+Niemann-Pick+Type+C+Disease&btnG=	https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease								
																				High intraneuronal GSL storage		NA											
																				Increased free sphingosine accumulation (Abnormality of lipid metabolism)*		HP:0003119*											
176	# 257220	Niemann-Pick disease type C1 		NPC1	NPC intracellular cholesterol transporter 1	O15118			N-butyldeoxynojirimycin+allopregnanolone	DB00419 +DB11859	ECO:0000179					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement	Mechanistic (B)	elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*		HP:0003107*	https://www.ncbi.nlm.nih.gov/pubmed/11227045/			https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract							
								One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824	2-hydroxypropyl-beta-cyclodextrin (Adrabetadex)	DB15146	ECO:0007121/ECO:0000352/ECO:0000179					Functional interaction	B	functional complementation of a defective protein		High intraneuronal GSL storage		NA	https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/11787939/	https://www.ncbi.nlm.nih.gov/pubmed/29429782	https://clinicaltrials.gov/ct2/show/NCT02534844	https://www.ncbi.nlm.nih.gov/pubmed/28803710/	https://www.ncbi.nlm.nih.gov/pubmed/19415691/	https://www.ncbi.nlm.nih.gov/pubmed/25717099/				
																				Increased free sphingosine accumulation (Abnormality of lipid metabolism)*		HP:0003119*											
																				Neurodegeneration		HP:0002180											
																				Poor swallowing		HP:0002015			https://www.ncbi.nlm.nih.gov/pubmed/29429782								
																				Cognitive impairment		HP:0100543			https://www.ncbi.nlm.nih.gov/pubmed/29429782								
																				Fine motor impairment		HP:0007010			https://www.ncbi.nlm.nih.gov/pubmed/29429782								
																				Liver injury		HP:0001392			https://www.ncbi.nlm.nih.gov/pubmed/26027824								
																				Cholesterol sequestration (Abnormality of cholesterol metabolism)*		HP:0003107*			https://www.ncbi.nlm.nih.gov/pubmed/26027824								
																				Reduced life span (Mortality)*		HP:0040006*			https://www.ncbi.nlm.nih.gov/pubmed/26027824								
																				Rapid progression		HP:0003678											
									Miglustat+Allopregnanolone+Cyclodextrin	DB00419+DB11859+CHEBI:23456	ECO:0000179					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+metabolite replacement+functional complementation of a genetically defective protein		Motor function impairment		HP:0002275	https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract		https://www.ncbi.nlm.nih.gov/pubmed/23948640								
																				Cerebeller neurodegeneration (neurodegeneration)*		HP:0002180*			https://www.ncbi.nlm.nih.gov/pubmed/25400034								
																				Abnormality of lipid metabolism		HP:0003119			https://www.ncbi.nlm.nih.gov/pubmed/31248418								
																				Splenomegaly		HP:0001744			https://www.ncbi.nlm.nih.gov/pubmed/31248418								
																				Increased number of splenic myeloid cells 		NA			https://www.ncbi.nlm.nih.gov/pubmed/31248418								
									Allopregnanolone	DB11859	ECO:0000179					Functional interaction	B	metabolite replacement		Mortality 		HP:0040006			https://www.ncbi.nlm.nih.gov/pubmed/15208706/								
																				Disease progression		HP:0003678											
																				cortical GM2 ganglioside accumulation 		HP:0003495											
																				GM3 ganglioside accumulation (Ganglioside accumulation)*		HP:0004345											
																									https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771135/								
																																	
																																	
																																	
																																	
																																	
																																	
177	# 245010	Haim-Munk syndrome		CTSC	Dipeptidyl peptidase 1	3.4.14.1			(Trimethoprim+Sulfamethoxazole)+Acitretin	(DB00440+DB01015)+DB00459	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	Symptomatic ©	Palmoplantar keratoderma		HP:0000982			https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract								
																				Periodontitis		HP:0000704											
									Acitretin	DB00459	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Periodontitis		HP:0000704			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/								
									Etretinate	DB00926	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Keratoderma 		HP:0000982			https://www.ncbi.nlm.nih.gov/pubmed/10738634/								
																				Aggressive periodontitis (Sever periodontitis)		HP:0000166											
									Salicylic acid+Urea	DB00936+DB03904	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Palmoplantar hyperkeratosis		HP:0000972			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/								
178	# 234500	Hartnup disease 		SLC6A19	Sodium-dependent neutral amino acid transporter B(0)AT1	Q695T7			Niacin	DB00627	ECO:0000352					Functional interaction	B	metabolite replacement	Mechanistic (A)	Chronic diarrhea		HP:0002028		https://www.ncbi.nlm.nih.gov/pubmed/6236384	https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract								
																				Hypoalbuminemia		HP:0003073											
																				Exfoliative erythema		HP:0001019											
179	# 140350	Hawkinsinuria		HPD	4-hydroxyphenylpyruvate dioxygenase	1.13.11.27			Ascorbic acid	DB00126	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Low activity of the immature 4-HPPD enzyme (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/26226126	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=The+Incidence+of+Transient+Neonatal+Tyrosinemia+Within+a+Mexican+Population&btnG=	https://www.ncbi.nlm.nih.gov/pubmed/14206878								
									N-acetyl-L-cysteine	DB06151	ECO:0000352					Symptomatic (Functional)	C (B)	functional complementation of a genetically defective protein		Secondary glutathione deficiency (Abnormality of metabolism/homeostasis)*		HP:0001939*	https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract		https://www.ncbi.nlm.nih.gov/pubmed/27488560								
																				Pyroglutamic aciduria (Organic aciduria)*		HP:0001992*											
																				Metabolic acidosis		HP:0001942											
																				Decreased appetite		HP:0004396											
									Medium-chain triglyceride oil 	DB13959	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Symptomatic ©	Failure to thrive		HP:0001508			https://www.ncbi.nlm.nih.gov/pubmed/27488560								
																				Growth delay		HP:0001510											
																				Hemolytic anemia		HP:0001878											
																				Low β2 microglobulin/creatinine ratio		NA											
									Phosphate	DB14573	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypophosphatemia		HP:0002148			https://www.ncbi.nlm.nih.gov/pubmed/27488560								
									Sodium bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Metabolic acidosis		HP:0001942											
									Nitisinone (NTBC)	DB00348	ECO:0000179					Direct interaction	A	procedure to mitigate dominant effects of a genetically abnormal protein		Extreme frailty (Fatigue)*		HP:0012378*			https://www.ncbi.nlm.nih.gov/pubmed/20677779								
	# 235200	HEMOCHROMATOSIS, TYPE 1; HFE1		HFE	Hereditary hemochromatosis protein	Q30201			Pantoprazole	DB00213	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		High serum ferritin		HP:0003281			https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7	https://www.ncbi.nlm.nih.gov/pubmed/28624580							
																																	
																																	
180	# 602390	Hemochromatosis type 2		HJV/HAMP	hemojuvelin/hepcidin				Deferoxamine	DB00746  	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Iron overload (Abnormality of iron homeostasis)*		HP:0011031*	https://www.ncbi.nlm.nih.gov/pubmed/14632789		https://www.ncbi.nlm.nih.gov/pubmed/17124037								
									hepcidin	NA	ECO:0007764 					Direct interaction	A	direct complementation of a genetically defective protein		Increased plasma iron concentration (Increased serum iron)		HP:0003452			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/	https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives	http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true						
181	# 604250	Hemochromatosis type 3 		TFR2 	transferrin receptor 2				Deferoxamine	DB00746  	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure	Symptomatic ©	Iron overload (Abnormality of iron homeostasis)*		HP:0011031*			https://www.ncbi.nlm.nih.gov/pubmed/29134618	https://clinicaltrials.gov/ct2/show/NCT00001203	https://www.ncbi.nlm.nih.gov/pubmed/14632789						
									hepcidin	NA	ECO:0007764 					Functional interaction	B	metabolite replacement		Increased plasma iron concentration (Increased serum iron)		HP:0003452			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/								
									LJPC-401(Synthetic human hepcidin)	NA	ECO:0007121					Functional interaction	B	metabolite replacement		High serum iron		HP:0003452			https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13								
									Deferiprone (L1)	DB08826	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Elevated liver iron concentration		HP:0040134			https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23	https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39							
									Nifedipine	DB01115 	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Iron overload (Abnormality of iron homeostasis)*		HP:0011031*			https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30								
								Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927	flavanols	NA	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Iron overload (Abnormality of iron homeostasis)*		HP:0011031*			https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34								
183	* 151670	Hepatic lipase deficiency		LIPC	hepatic lipase	3.1.1.3		Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447	Rosuvastatin	DB01098	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Symptomatic ©	High atherogenic lipoprotein (Abnormality of lipid metabolism)*		HP:0003119*	https://www.ncbi.nlm.nih.gov/pubmed/22798447	https://www.ncbi.nlm.nih.gov/pubmed/26194979	https://www.ncbi.nlm.nih.gov/pubmed/12547874								
																				High low-density lipoprotein (LDL)-C (Abnormality of lipid metabolism)*		HP:0003119*											
																				High Apolipoprotein B (ApoB) (Abnormality of lipid metabolism)*		HP:0003119*											
184	 # 176100	PORPHYRIA CUTANEA TARDA		UROD/HEF	uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein	4.1.1.37/Q30201			Hemin	DB03404	ECO:0000179/ECO:0001565					Functional interaction	B	metabolite replacement		Acute episodic abdominal pain		HP:0002574	https://www.ncbi.nlm.nih.gov/pubmed/24652768	https://www.ncbi.nlm.nih.gov/pubmed/24175354									
																				Low pancreatic zymogens		NA											
								The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.	Chloroquine 	DB00608	ECO:0000352			C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)	https://www.ncbi.nlm.nih.gov/pubmed/12622622. https://www.ncbi.nlm.nih.gov/pubmed/4739135	Symptomatic	C	symptomatic therapeutic procedure		Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*		HP:0010472*	https://www.ncbi.nlm.nih.gov/pubmed/12622622	https://www.ncbi.nlm.nih.gov/pubmed/5080345	https://www.ncbi.nlm.nih.gov/pubmed/7324107	https://www.ncbi.nlm.nih.gov/pubmed/22985607							
																				Increased liver iron level		HP:0012465	https://www.ncbi.nlm.nih.gov/pubmed/5080345	https://www.ncbi.nlm.nih.gov/pubmed/4744026	https://www.ncbi.nlm.nih.gov/pubmed/4811840/	https://www.ncbi.nlm.nih.gov/pubmed/6173993/	https://www.ncbi.nlm.nih.gov/pubmed/4744026/						
																				Abnormal liver function		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/4739135			https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract							
																				Increased serum ferritin		HP:0003281	https://www.ncbi.nlm.nih.gov/pubmed/4739135										
																				Elevated transferrin saturation		HP:0012463	https://www.ncbi.nlm.nih.gov/pubmed/4739135										
																				"Increased serum iron
"		HP:0003452											
	# 176100																																
185	# 241500	Hypophosphatasia, INFANTILE		 ALPL	tissue-nonspecific alkaline phosphatase (TNSALP)	3.1.3.1			Asfotase alfa	DB09105	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Defect of bone mineralisation		HP:0004348	https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/29405935	https://www.ncbi.nlm.nih.gov/pubmed/30811537	https://www.ncbi.nlm.nih.gov/pubmed/30288020	https://www.ncbi.nlm.nih.gov/pubmed/30576866						
																				Growth delay		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/29405935									
																				Poor skeletal mineralization		HP:0006462	https://www.ncbi.nlm.nih.gov/pubmed/30083035										
																				Respiratory insufficiency		HP:0002093	https://www.ncbi.nlm.nih.gov/pubmed/30083035										
																				Rickets 		HP:0002748	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Caused+by+Alkaline+Phosphatase+Deficiency+Hypophosphatasia%3A+A+Systemic+Skeletal+Disorder+Caused+by+Alkaline+Phosphatase+Deficiency&btnG=										
																				Gross motor dysfunction		HP:0007015	https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract										
																				Fine motor dysfunction		HP:0007010											
																				Cognitive impairment		HP:0100543											
																				Muscle weakness		HP:0001324											
																				Fatigue		HP:0012378											
																				Delayed growth (stature)		HP:0000002											
								Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).	Vitamin D 	DB11094						Direct interaction 	A	activity modification of a genetically defective protein		Secondary hyperparathyrodism		HP:0000867		https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Caused+by+Alkaline+Phosphatase+Deficiency+Hypophosphatasia%3A+A+Systemic+Skeletal+Disorder+Caused+by+Alkaline+Phosphatase+Deficiency&btnG=									
									NSAID	S01BC	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Lower limb pain		HP:0012514	https://www.ncbi.nlm.nih.gov/pubmed/16803637	https://www.ncbi.nlm.nih.gov/pubmed/10574582	https://www.ncbi.nlm.nih.gov/pubmed/10574582								
																				Abnormal prostaglandin level		HP:0011023	https://www.ncbi.nlm.nih.gov/pubmed/10574582										
																				Low quality of life (Constitutional symptoms)*		HP:0025142*	https://www.ncbi.nlm.nih.gov/pubmed/10574582										
																				Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/10574582										
																				Abnormal walking distance (low or weak muscle tone)*		HP:0001252	https://www.ncbi.nlm.nih.gov/pubmed/10574582										
																																	
								"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_
"	Teriparatide 	DB06285		D378V /G339R/E191K/A176T/V423A		N461L		Functional interaction	B	activity modification of a genetically defective protein		Stress fractures (Pathologic fracture)*		HP:0002756*	https://www.ncbi.nlm.nih.gov/pubmed/26245849	https://www.ncbi.nlm.nih.gov/pubmed/27042741	https://www.ncbi.nlm.nih.gov/pubmed/22218563								
												Ala176Thr/Val423Ala/Val522Ala								Metatarsal stress fractures		HP:0001832	https://www.ncbi.nlm.nih.gov/pubmed/20089612	https://www.ncbi.nlm.nih.gov/pubmed/17213282?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract								
												compound heterozygotes for a p.G339R and p.E191K ALPL mutation								Proximal femur pseudofractures		HP:0100036	https://www.ncbi.nlm.nih.gov/pubmed/20739387	https://www.ncbi.nlm.nih.gov/pubmed/20739387									
																				High bone turnover markers		HP:0003260*		https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract									
																				Defect in skeletal mineralization		HP:0006462											
																				Pain		HP:0012531											
																				Mobility problems		HP:0001376											
																				High urine phosphoethanolamine		HP:0003239	https://www.ncbi.nlm.nih.gov/pubmed/20089612										
																				High serum pyridoxal 5'-phosphate 		NA	https://www.ncbi.nlm.nih.gov/pubmed/20089612										
									Vitamin B6	DB00165 										Seizure		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract										
									BPS804 (setrusumab)	DB14778	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Bone weakness (Osteomalacia)*		HP:0002749	https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/									
																				Bone fructure		HP:0002757											
																				Low bone formation biomarkers		HP:0031429 											
																				Low bone mineral density		HP:0004349	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/										
186	# 615558	Hypolipoproteinemia (Familial hypobetalipoproteinemia)		 APOB	apolipoprotein B-48 + apolipoprotein B-100				Vitamin A	DB00162	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Fat soluble vitamin  Malabsorption		HP:0002630	https://www.ncbi.nlm.nih.gov/pubmed/24751931	https://www.ncbi.nlm.nih.gov/pubmed/24288038									
																				Progressive ataxic retinopathy		HP:0000488	https://www.ncbi.nlm.nih.gov/pubmed/26086616										
									Vitamin E	DB00163	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Central nervous degeneration		HP:0007009	https://www.ncbi.nlm.nih.gov/pubmed/24751931	https://www.ncbi.nlm.nih.gov/pubmed/24288038									
																				Retinal degeneration		HP:0000546											
																				Neuromuscular degeneration		HP:0002180											
																				Oxidative stress		HP:0025464											
																				Progressive ataxic neuropathy 		HP:0003434	https://www.ncbi.nlm.nih.gov/pubmed/26086616										
187	# 615558	Homozygous Hypolipoproteinemia		 APOB	apolipoprotein B-48 + apolipoprotein B-100				Vitamin A	DB00162	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Fat soluble vitamin  Malabsorption (Fat malabsorption)*		HP:0002630	https://www.ncbi.nlm.nih.gov/pubmed/24751931	https://www.ncbi.nlm.nih.gov/pubmed/24288038									
																				Progressive ataxic retinopathy		HP:0000488	https://www.ncbi.nlm.nih.gov/pubmed/26086616										
									Vitamin E	DB00163	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Central nervous degeneration		HP:0007009	https://www.ncbi.nlm.nih.gov/pubmed/24751931	https://www.ncbi.nlm.nih.gov/pubmed/24288038									
																				Retinal degeneration		HP:0000546											
																				Neuromuscular degeneration		HP:0002180											
																				Oxidative stress		HP:0025464											
																				Progressive ataxic neuropathy 		HP:0003434	https://www.ncbi.nlm.nih.gov/pubmed/26086616										
188	# 600627	Hypertryptophanemia 	Hypertryptophanemia should be regarded as a benign condition	TDO2	tryptophan 2,3-dioxygenase 	1.13.11.11			No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/22081291	https://www.ncbi.nlm.nih.gov/pubmed/28285122									
																							https://www.ncbi.nlm.nih.gov/pubmed/12822831										
																							https://www.ncbi.nlm.nih.gov/pubmed/15036384										
																																	
189	# 239500	Hyperprolinemia 		PRODH	proline dehydrogenase 1	1.5.5.2			Vitamen B6	DB00165	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	"However vitamin B6 and/or PP supplementation was not clinically effective in our patient group. In one patient it seemed to give a temporary improvement, in another patient however, it even seemed to result in a deterioration of the epilepsy
"	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/24173411										
									Pyridoxine phosphate	DB02209	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/24173411										
									Olanzapine	DB00334	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Behavioural disturbance		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/28202261										
									Lithium	DB14507 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Psychotic  disorder		HP:0000725											
									Green tea extract	DB14307	ECO:0000179					Supportive	C	symptomatic therapeutic procedure		Oxidative Stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/27589827	https://www.ncbi.nlm.nih.gov/pubmed/24980685									
									Vitamin D	DB11094	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Schizophrenia	The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.	HP:0100753	https://www.ncbi.nlm.nih.gov/pubmed/24787057										
								"α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .
"	α-Tocopherol+ascorbic acid	DB14476+DB00126	ECO:0000179					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Impairment of spatial memory (Memory impairment)*		HP:0002354 	https://www.ncbi.nlm.nih.gov/pubmed/16214240										
																				Oxidative stress		HP:0025464											
																				Cerebral cortex acetylcholinesterase inhibition		NA											
																				Hippocampal Na+, K+-ATPase reduced activity(Abnormal enzyme activity)*		HP:0012379											
190	# 239510	Hyperprolinemia type 2		ALDH4A1	Δ1-pyrroline 5-carboxylate dehydrogenase 	1.2.1.88			No treatment is available in DDIEM																								
191	# 264070	Hyperphenylalaninemia due to dehydratase deficiency 	Protein and phenylalanine restriction should be maintained in order to avoid disease progression.	PCBD1	pterin-4 alpha-carbinolamine dehydratase	4.2.1.96			Tetrahydrobiopterin	DB00360	ECO:0000352					Functional interaction	B	metabolite replacement		Muscular hypotonia		HP:0001252	https://www.ncbi.nlm.nih.gov/pubmed/22729819										
																				Dystonia 		HP:0001332											
																				Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/9585615	https://www.ncbi.nlm.nih.gov/pubmed/24204001									
																				Growth failure		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/9760199										
																				Primapterinuria		NA	https://www.ncbi.nlm.nih.gov/pubmed/24204001										
									Sulfonylureas	DB01124	ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		PCBD1-diabetes (Noninsulin-dependent diabetes)*		HP:0005978*	https://www.ncbi.nlm.nih.gov/pubmed/24848070										
																																	
																																	
																																	
																																	
																																	
																																	
192	# 238700	Hyperlysinemia 	"Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588
"	AASS	Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase	1.5.1.8+1.5.1.9			Botulinum toxin	DB00083	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Delayed motor development		HP:0001270	https://www.ncbi.nlm.nih.gov/pubmed/23570448										
									Valproate+Carbamazepine	DB00313+DB00564	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/23570448										
																Symptomatic	C			Generalized tonic convulsions		 HP:0010818	https://www.ncbi.nlm.nih.gov/pubmed/23570448										
								The drug was accompanied with lysin restricted diet	Valproic acid+Lysine restricted diet	DB00313+NA	ECO:0000352					Symptomatic+Functional interaction	C+B	combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/23570448										
								No remarkable clinical improvement was observed and therefore, treatment was discontinued	pyridoxine	DB00165	ECO:0000352					Functional interaction	B	dietary supplementation					https://www.ncbi.nlm.nih.gov/pubmed/23890588										
193	# 144650	Hyperlipoproteinemia type V		APOA5	apolipoprotein A5	Q6Q788			Rosuvastatin	DB01098 	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia 		HP:0002155	https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2										
																				High LDL level		HP:0003141											
																				High total cholesterol		HP:0003124											
																				High Apoliporprotein B level (Abnormal abpolipoprotein level)*		HP:0025201*											
									Fenofibrates 	DB13873	ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		hypertriglyceridemia 		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/22129523	https://www.ncbi.nlm.nih.gov/pubmed/2653622	https://www.ncbi.nlm.nih.gov/pubmed/12709436	https://www.ncbi.nlm.nih.gov/pubmed/23633496							
																				High level of very low-density lipoprotein		HP:0003362											
																				High total cholesterol		HP:0003124											
																				Low HDL-cholesterol		HP:0003233											
								Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523	Nicotinic acid 	DB00627 	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Hypertriglyceridemia 		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/1894760	https://www.ncbi.nlm.nih.gov/pubmed/18001312	https://www.ncbi.nlm.nih.gov/pubmed/5679950	https://www.ncbi.nlm.nih.gov/pubmed/4883477							
																				High total plasma cholesterol		HP:0003124											
																				Elevated LDL-C level		HP:0003141											
																				High VLDL-triglycerides 		HP:0003362											
																				Low HDL-C 		HP:0003233											
								Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265	Strong statins (atorvastatin, pitavastatin, and rosuvastatin)	DB01076 or DB08860 or DB01098	ECO:0000352	TT-1131		 C-1131		Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia 		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/22129523	https://www.ncbi.nlm.nih.gov/pubmed/19530961/	https://www.ncbi.nlm.nih.gov/pubmed/29695967								
									Gemfibrozil	DB01241	ECO:0000352/ ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Tuberoeruptive xanthomas	The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860	HP:0001013*	https://www.ncbi.nlm.nih.gov/pubmed/2702860	https://www.ncbi.nlm.nih.gov/pubmed/2681858									
																				Hyperchylomicronemia		HP:0012238	https://www.ncbi.nlm.nih.gov/pubmed/2681858										
																				High total plasma cholesterol leve		HP:0003124	https://www.ncbi.nlm.nih.gov/pubmed/2681858										
																				Elevated LDL-C level		HP:0003141	https://www.ncbi.nlm.nih.gov/pubmed/2681858										
																				High VLDL-triglycerides 		HP:0003362	https://www.ncbi.nlm.nih.gov/pubmed/2681858										
																				Low HDL-C 		HP:0003233	https://www.ncbi.nlm.nih.gov/pubmed/2681858										
194	617347	HYPERLIPOPROTEINEMIA, TYPE III		 APOE	apolipoprotein E	P02649			Rosuvastatin+Pravastatin	DB01098 +DB00175	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Hypertriglycernemia		HP:0002155	https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2										
								Study was terminated due to safety issues.	Torcetrapib/atorvastatin	DB06281/DB01076	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein					https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3										
								In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.	Simvastatin	DB00641	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High non-HDL-C (Abnormality of lipid metabolism)*		HP:0003119*	https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/25768710	https://www.ncbi.nlm.nih.gov/pubmed/28098593	https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract							
																				High VLDL triglycerides (Increased VLDL cholesterol concentration)*		HP:0003362											
								In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.	Gemfibrozil	DB01241	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		high non-HDL-C (Abnormality of lipid metabolism)*		HP:0003119*	https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/25768710	https://www.ncbi.nlm.nih.gov/pubmed/28098593	https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract							
																				High VLDL triglycerides 		NA											
									Lovastatin 	DB00227 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High non-HDL-C (Abnormality of lipid metabolism)*		HP:0003119*	https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/25768710	https://www.ncbi.nlm.nih.gov/pubmed/28098593	https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract							
									Clofibrate	DB00636	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		High non-HDL-C (Abnormality of lipid metabolism)*		HP:0003119*	https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/25768710	https://www.ncbi.nlm.nih.gov/pubmed/28098593								
								clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710	Lovastatin+Clofibrate	DB00227+DB00636	ECO:0000352					Functional interaction+Direct interaction	B+A	combination therapeutic procedure+functional complementation of a genetically defective protein+activity modification of a genetically defective protein		Hypercholesterolemia		HP:0003124	https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub	https://www.ncbi.nlm.nih.gov/pubmed/25768710	https://www.ncbi.nlm.nih.gov/pubmed/28098593								
									Fenofibrate	DB13873	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/25079293	https://www.ncbi.nlm.nih.gov/pubmed/25079293									
									Niacin	DB00627 	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hypertriglyceridemia		HP:0002156	https://www.ncbi.nlm.nih.gov/pubmed/25079293	https://www.ncbi.nlm.nih.gov/pubmed/25079293									
									Fish oil	DB13961	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypertriglyceridemia		HP:0002157	https://www.ncbi.nlm.nih.gov/pubmed/25079293	https://www.ncbi.nlm.nih.gov/pubmed/25079293	https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract								
									Fenofibrate + Atorvastatin	DB13873+ DB01076	ECO:0000352					Direct interaction+Functional interaction	A+B	combination therapeutic procedure+activity modification of a genetically defective protein+functional complementation of a genetically defective protein		Xanthomas		HP:0000991	https://www.ncbi.nlm.nih.gov/pubmed/25079293	https://www.ncbi.nlm.nih.gov/pubmed/25079293									
																				Stenotic coronary atherosclerosis 		HP:0001677											
																				Angina pectoris		HP:0001681											
									Atrovastatin	DB01076	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		High serum total cholesterol		HP:0003124	https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract									
																				High serum triglyceride 		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract									
																				High remnant-like particle (RLP)-cholesterol 		NA	https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract										
																				High remnant-like particle (RLP)-TG 		NA	https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract										
																				Elevated VLDL-cholesterol/serum TG ratio 		HP:0003362	https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract										
																				Elevated apolipoprotein B level		HP:0031798	https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract										
								"Although  probucol effectively lowers the total plasma cholesterol levels in the apoE /  mice, but unexpectedly it accelerates the development of their aortic atherosclerotic plaquesis. 
Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703"	Probucol	DB01599	ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein		High total plasma cholesterol		HP:0003124	https://www.ncbi.nlm.nih.gov/pubmed/9185508										
																				Increased LDL cholesterol concentration 		HP:0003141											
																																	
																																	
								Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.	Bezafibrate/ atorvastatin	DB01393/DB01076	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Atherogenic dyslipidemia (Dyslipidemia)*		HP:0003119*	https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract										
									Recombinant apolipoprotein A-I	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Atherosclerosis		HP:0002621	https://www.ncbi.nlm.nih.gov/pubmed/11425766/										
195	606762	Hyperinsulinism-hyperammonemia syndrome	Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/ 	GLUD1	Glutamate dehydrogenase, mitochondrial	1.4.1.3			Diazoxide	DB01119	ECO:0000352					Functional interaction	B	procedure to mitigate dominant effects of a genetically abnormal protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/23295286	https://www.ncbi.nlm.nih.gov/pubmed/20936362	https://www.ncbi.nlm.nih.gov/pubmed/25781533	https://www.ncbi.nlm.nih.gov/pubmed/26962538							
																				Epileptic seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/	https://www.ncbi.nlm.nih.gov/pubmed/28621098									
																				Hyperinsulinism		HP:0000842	https://www.ncbi.nlm.nih.gov/pubmed/10969108	https://www.ncbi.nlm.nih.gov/pubmed/10453735/									
									Carglumic acid + diazoxide+ Glucose	DB06775+DB01119+DB01914	ECO:0000352					Symptomatic+Functional interaction+Functional interaction	C+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein+functional complementation of a genetically defective protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/26962538										
									Levetiracetam	DB01202	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/26962538										
																				Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/10969108										
196	602485	Hyperinsulinism due to glucokinase deficiency		GCK	glucokinase-4	2.7.1.1			Diazoxide	DB01119	ECO:0000352	T65I		GK-Y214C(De novo muttation)		Functional interaction	B	procedure to mitigate dominant effects of a genetically abnormal protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/15277402	https://www.ncbi.nlm.nih.gov/pubmed/19336674	https://www.ncbi.nlm.nih.gov/pubmed/9435328								
												(Val455Met) at codon 455											https://www.ncbi.nlm.nih.gov/pubmed/15133749	https://www.ncbi.nlm.nih.gov/pubmed/15133749									
												M197I		Y214C									https://www.ncbi.nlm.nih.gov/pubmed/19336674										
												A456V		ins454A 									https://www.ncbi.nlm.nih.gov/pubmed/19336674										
												W99R											https://www.ncbi.nlm.nih.gov/pubmed/19336674										
												S64Y											https://www.ncbi.nlm.nih.gov/pubmed/19336674										
												V452L											https://www.ncbi.nlm.nih.gov/pubmed/19336674										
												"M197I/G68V
W99L"	W99Lwas partially responsive to diazoxide.https://www.ncbi.nlm.nih.gov/pubmed/19336674										https://www.ncbi.nlm.nih.gov/pubmed/19336674										
								The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/	Octreotide 	DB00104	ECO:0007121					Functional interaction	B	procedure to mitigate dominant effects of a genetically abnormal protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/8410522/										
									Dextrose +Diazoxide	DB09341+DB01119	ECO:0000352					Symptomatic+Functional interaction	C+B	combination therapeutic procedure+symptomatic therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/30026763										
197	307030	Hyperglycerolemia (Isolated glycerol kinase deficiency)		GK	Glycerol kinase 	2.7.1.30			Rosuvastatin	DB01098	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/									
198	610293	Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency		PIGM	GPI mannosyltransferase 1	2.4.1.-			Antithrombotic agents	B01	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Thrombosis		HP:0001977	https://www.ncbi.nlm.nih.gov/pubmed/16767100										
									Sodium phenylbutyrate	DB06819	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/17442906										
199	237400	HYPER-BETA-ALANINEMIA			beta-alanine-alpha-ketoglutarate transaminase. 				Taurine	DB01956	ECO:0001565					Symptomatic	C	symptomatic therapeutic procedure		Mitochondrial toxicity (Mitochondrial abnormalities)*		HP:0012103	https://www.ncbi.nlm.nih.gov/pubmed/27023909	https://www.ncbi.nlm.nih.gov/pubmed/28718066	https://www.ncbi.nlm.nih.gov/pubmed/7936305								
									Pyridoxine	DB00165	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	??	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/7936305	https://www.ncbi.nlm.nih.gov/pubmed/6198500	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=β-Alanine-α-Ketoglutarate+Aminotransferase+Deficiency&btnG=								
																				somnolence		HP:0002360	https://www.ncbi.nlm.nih.gov/pubmed/7936305										
200	260920	Hyperimmunoglobulinemia D		MVK	mevalonate kinase 	2.7.1.36			Anti-TNF-alpha (Adalimumab)+Etanercept	DB00051+DB00005 	ECO:0000352					Symptomatic	C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Periodic fever		HP:0001954	https://www.ncbi.nlm.nih.gov/pubmed/24935455										
																Symptomatic	C			Abnormality of immune system physiology		HP:0010978	https://www.ncbi.nlm.nih.gov/pubmed/24935455										
									Anakinra	DB00026	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Arthralgia		HP:0002829	https://www.ncbi.nlm.nih.gov/pubmed/20712835	https://www.ncbi.nlm.nih.gov/pubmed/25758134/									
																				joint swelling		HP:0001386											
									Canakinumab	DB06168	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Fever		HP:0001945	https://www.ncbi.nlm.nih.gov/pubmed/25758134/	https://www.ncbi.nlm.nih.gov/pubmed/22740624/									
																				High serum amyloid A protein (Abnormal circulating protein level)*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/22740624/										
																				Elevated C-reactive protein		HP:0011227	https://www.ncbi.nlm.nih.gov/pubmed/22740624/										
									prednisolone + azathioprine + immunoglobulins	DB00860+DB00993+DB00028	ECO:0000352	compound V377I and I126T mutations				Symptomatic	C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Periodic fever		HP:0001954	https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract										
								Limited Efficacy of the drug. Drug has been withdrawn , it resulted in negative effects.	Thalidomide	DB01041	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract										
									Steroids + Simvastatin	DB00641+S02BA	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Periodic fever		HP:0001954	https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract										
									Infliximab	DB00065	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Nummular keratitis (keratitis)*		HP:0000491	https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract										
																				Corneal scar		HP:0000559	https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract										
																				Decreased visual acuity		HP:0007663											
									Tocilizumab	DB06273	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Fever		HP:0001945	https://www.ncbi.nlm.nih.gov/pubmed/30225156	https://www.ncbi.nlm.nih.gov/pubmed/24561416	https://www.ncbi.nlm.nih.gov/pubmed/26516243								
																				Fatigue		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/30225156										
																				Pain		HP:0012531	https://www.ncbi.nlm.nih.gov/pubmed/30225156										
																				Oral ulceration		HP:0000155	https://www.ncbi.nlm.nih.gov/pubmed/30225156										
									Anakinra+ tocilizumab	DB00026+DB06273	ECO:0001565/ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Abnormal inflammatory response		HP:0012647	https://www.ncbi.nlm.nih.gov/pubmed/25173351										
201	236800	hydroxykynureninuria		KYNU	kynureninase	3.7.1.3			Niacin	DB00627	ECO:0000352					Functional interaction	B	metabolite replacement		Dermatitis 		HP:0011123	https://www.ncbi.nlm.nih.gov/pubmed/14169454										
																				Diarrhoea 		HP:0002014	https://www.ncbi.nlm.nih.gov/pubmed/14169454										
																				Dementia 		HP:0000726	https://www.ncbi.nlm.nih.gov/pubmed/17334708										
																				Sensitivity to sunlight		HP:0000992	https://www.ncbi.nlm.nih.gov/pubmed/10540864										
									Pyridoxal phosphate	DB00114	ECO:0000352					Direct interaction 	A	activity modification of a genetically defective protein		Low enzyme activity		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/5586569										
202	607015	Hurler-Scheie syndrome		IDUA 	alpha-L-iduronidase				Laronidase	DB00090	ECO:0007121					Direct interaction 	A	direct complementation of a genetically defective protein		Low Forced Vital Capacity		HP:0002111	https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2	https://www.ncbi.nlm.nih.gov/pubmed/31434105	https://www.ncbi.nlm.nih.gov/pubmed/31211405	https://www.ncbi.nlm.nih.gov/pubmed/31196723	https://www.ncbi.nlm.nih.gov/pubmed/31082797						
																				High Apnea/Hypopnea Index (sleep apnea)*		HP:0010535*											
																				Decreased pulmonary function 		HP:0005952 											
																				Hepatomegaly		 HP:0002240											
																				Limitation of the Joint range of motion		HP:0001376											
																				Six Minute Walk Test 		NA											
									Nanotechnology-based gene therapy (Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene)	NA	ECO:0001565					Direct interaction 	A	direct complementation of a genetically defective protein by gene therapy		Low IDUA activity (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/29122734										
																																	
								GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576	GNeo-IDUA	NA	ECO:0000179					Direct interaction 	A	direct complementation of a genetically defective protein		Neurodegenerative astrogliosis (Neurodegeneration)*	in the olfactory bulb and primary somatosensory cortex	HP:0002180*	https://www.ncbi.nlm.nih.gov/pubmed/28958576										
																				Glycosaminoglycan accumulation (Abnormality of glycosaminoglycan metabolism)*		HP:0004371											
203	 607014	Hurler syndrome 		IDUA	iduronidase, alpha-L				Laronidase (IRT)	DB00090	ECO:0000352					Direct interaction 	A	direct complementation of a genetically defective protein		Hepatosplenomegaly 		HP:0001433	https://www.ncbi.nlm.nih.gov/pubmed/11172140	https://www.ncbi.nlm.nih.gov/pubmed/31630958	https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/31434105	https://www.ncbi.nlm.nih.gov/pubmed/31211405	https://www.ncbi.nlm.nih.gov/pubmed/31196723	https://www.ncbi.nlm.nih.gov/pubmed/31082797	https://www.ncbi.nlm.nih.gov/pubmed/30755342			
																				Abnormality of joint mobility		HP:0011729											
																				Sleep apnea		HP:0010535											
																				Nocturnal hypopnea		HP:0002877											
																				Abnormal apnea–hypopnea index		NA											
																				Urinary glycosaminoglycan excretion 		HP:0003541											
																				Photophobia		HP:0000613											
																				Conjunctival irritation		HP:0030953											
																				Impaired Visual acuity		HP:0007663											
																				Low exercise endurance		NA											
																				Tricuspid regurgitation		HP:0005180											
																				Pulmonary regurgitation		HP:0010444											
																				Dyspnea at rest 		HP:0012763											
																				Pitting edema		HP:0000969											
																				Low quality of sleep		HP:0002360											
																				Daytime somnolence		HP:0002189											
																				White matter abnormalities		HP:0002500	https://www.ncbi.nlm.nih.gov/pubmed/19748810										
																				Brain ventricular dilatation		HP:0002119											
																				Brain MRI abnormalities		HP:0002500											
								Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase	Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase	NA	ECO:0001565					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	In Vitro Experiment 	Lysosomal storage abnormalities (Abnormality of lysosomal metabolism)*		HP:0004356	https://www.ncbi.nlm.nih.gov/pubmed/8700879										
									Neonatal retroviral vector (RV)-mediated gene therapy+immunmodulator(CTLA4-Ig or (CTLA4-Ig + anti-CD40 ligand antibody or anti-CD4 antibody)	NA+NA	ECO:0000179					Direct interaction	A	combination therapeutic procedure+direct complementation of a genetically defective protein by gene therapy+symptomatic therapeutic procedure		Abnormal serum IDUA activity (Abnormal enzyme/coenzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/17311010										
																				Increased bone mineral density 		 HP:0011001											
																				Hearing impairment		HP:0000365											
									CRISPR-Cas9-mediated gene editing	NA	ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein by genome editing		Low IDUA level (Abnormality of circulating enzyme level)*		HP:0011021	https://www.ncbi.nlm.nih.gov/pubmed/30081189	https://www.ncbi.nlm.nih.gov/pubmed/29122734									
																																	
									Cationic liposomes carrying the CRISPR/Cas9 plasmid  MPS I gene	NA	ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein by genome editing	in vivo (mice)	Ventricular hypertrophy		HP:0001714	https://www.ncbi.nlm.nih.gov/pubmed/30170069										
																				Cardiac dilation/ Heart enlargment/cardiomegaly		HP:0001640											
																				Left ventricularc contractility abnormalities		HP:0006670*											
																				Left ventricle dysfunction 		HP:0030872											
204	603174	Homocystinuria due to MTHFR deficiency		MTHFR	methylenetetrahydrofolate reductase	1.5.1.20			Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine	DB04789 + DB00200 +DB00165+ DB06756	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Abnormal Folate level		HP:0040087	https://www.ncbi.nlm.nih.gov/pubmed/11916316										
																				Abnormal serum Methylfolate Level		NA											
								"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract
"	Betaine+Folinic acid	DB06756+DB00650 	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Abnormality of homocysteine metabolism		HP:0010919	https://www.ncbi.nlm.nih.gov/pubmed/25024447										
																				Low muscle tone		HP:0001290											
									Topiramate	DB00273	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Symptomatic © + Mechanistic (B)	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/25024447										
									Betaine+Folic acid+Vitamin B6+Vitamin B12	DB06756+DB00158+DB00165+DB00115	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High plasma homocysteine level (Abnormal homocysteine level)*		HP:0010919	https://www.ncbi.nlm.nih.gov/pubmed/29246599										
								Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773	Vitamin B+Betaine	DB00165+DB6756	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Developmental abnormality		HP:0012759	https://www.ncbi.nlm.nih.gov/pubmed/20356773										
205	236200	Homocystinuria due to CBS deficiency	  Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.	CBS	cystathionine beta-synthase	4.2.1.22		 pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015). 	Pyridoxine	DB00165	ECO:0000352/ECO:0000179	P49L, A114V, I278T, R266K, or R336H		R125Q, E176K, T191M, T262M, or G307S		Direct interaction	A	activity modification of a genetically defective protein	Mehanistic(B)	Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*		HP:0012379*	https://www.ncbi.nlm.nih.gov/pubmed/29119254	https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/14739681							
									δ-aminolevulinate	DB00855	ECO:0001565	R125Q	One of the mutations (R125Q) exhibited an outstanding heme sensitivity, and addition of heme arginate to a fibroblast culture obtained from a patient homozygous for this mutation rescued also the activity in these human cells and increased production of cystathionine			Direct interaction	A	activity modification of a genetically defective protein		Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*		HP:0012379*	https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract										
												R266K								Homocystinuria		HP:0002156											
														H65R																			
								The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.	S-Adenosylmethionine	 DB00118 	ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein					https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract										
								These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU	Bortezomib	DB00188	ECO:0000179	I278T				Direct interaction	A	activity modification of a genetically defective protein	Tried on Mice not human	Misfolding of cystathionine β-synthase (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract										
									ONX-0912	DB11991	ECO:0000179	S466L /I278T 	However, response rates varied, with 100% (8/8) of the p.S466L animals showing correction, but only 38% (10/26) of the p.I278T animals.https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract			Direct interaction	A	activity modification of a genetically defective protein	Tried on Mice not human	Abnormal Hcy level		HP:0010919*	https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract										
																				Homocystinuria		HP:0002156											
								  Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.	Pyridoxine/Betaine	DB00165/DB06756	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		High total homocysteine levels		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/14739681										
																				High total cysteine levels		HP:0010918											
																				Low plasma serine levels		HP:0012279											
																				High blood S -adenosylhomocysteine level 		NA											
								There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.	Serine	DB00133	ECO:0007764					Symptomatic	C	symptomatic therapeutic procedure	No trials / speculation	Low plasma serine	The phenotype represents an expected correction based on a common finding in perople with homocystinuria.	HP:0012279	https://www.ncbi.nlm.nih.gov/pubmed/14739681										
206	602360	L-arginine:glycine amidinotransferase (AGAT) deficiency		GATM	arginine:glycine amidinotransferase	2.1.4.1			Creatine/Creatine phosphate	DB00148/DB13191	ECO:0000352					Functional interaction	B	metabolite replacement		Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/22386973	https://www.ncbi.nlm.nih.gov/pubmed/20625172									
																				Low cerebral creatine content		HP:0012113*											
																				Low developmental score		HP:0012759*											
																				Neurodevelopmental delay		HP:0012758											
																				Cognitive dysfunction		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/20682460										
																				Low IQ score		HP:0001249											
																				Language impairment		HP:0002463	https://www.ncbi.nlm.nih.gov/pubmed/23770102										
																				Behavioral abnormalities 		HP:0000708											
																				Communicative skills abnormalities 		HP:0002474*											
																				Psychomotor retardation 		HP:0001263											
																				Metabolic encephalomyopathy 		NA	https://www.ncbi.nlm.nih.gov/pubmed/20625172										
207	# 612933	Lactate dehydrogenase A deficiency		LDHA	lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme	1.1.1.27			No treatment is available in DDIEM																								
208	# 614128	Lactate dehydrogenase B deficiency		LDHB	lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme	1.1.1.27			No treatment is available in DDIEM																								
209	607330	Lathosterolosis		SC5D	3-beta-hydroxysteroid-delta-5-desaturase				Cholesterol+Simvastatin	DB04540+DB00641	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+metabolite replacement+functional complementation of a genetically defective protein by inhibition		Abnormal blood lathosterol level		HP:0001939*	https://www.ncbi.nlm.nih.gov/pubmed/30097991										
								The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991	Simvastatin	DB00641	ECO:0000352	p.K148E and p.D210E	 A compound heterozygous missense mutation			Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Abnormal neurodevelopmental profile		HP:0012759	https://www.ncbi.nlm.nih.gov/pubmed/24142275										
																				Developmental delay		HP:0001263											
														c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu)						Abnormal blood lathosterol level		HP:0001939*											
210	600890	LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency)		HADHA	3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase	1.1.1.211/4.2.1.17			heptanoate	CHEBI:32362	ECO:0000352					Symptomatic	C	dietary supplementation		Elevation of creatine kinase		HP:0003236	https://www.ncbi.nlm.nih.gov/pubmed/24997711/										
																				Exercise-induced muscle cramps		HP:0003710											
								Dietry treatment supplementation	Docosahexaenoic acid (DHA)	DB03756	ECO:0007121					Symptomatic	C	dietary supplementation		Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/16040264/										
																				Retinopathy progression (Progressive)*		HP:0003676											
																				Reduced visual acuity		HP:0007663											
									Triheptanoin	DB11677	ECO:0000352					Symptomatic	C	dietary supplementation		Cardiomyopathy 		HP:0001638	https://www.ncbi.nlm.nih.gov/pubmed/12122118/										
																				Rhabdomyolysis		HP:0003201											
																				Muscle weakness		HP:0001324											
																				Low quality of life (constitutional symptom)*		HP:0025142	https://www.ncbi.nlm.nih.gov/pubmed/16763896/										
									Bezafibrate	DB01393	ECO:0001565	c.1528G > C		c.1528G > C		Direct interaction 	A	activity modification of a genetically defective protein		Abnormal Fatty acid oxidation		HP:0004359*	https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency)										
												C2129-2A > C								Low long chain 3-Hydroxyacyl-CoA dehydrogenase activity(abnormal enzyme/coenzyme activity)*		HP:0012379											
												c. 1393_1479del-Del exon																					
												c.180 + 3A > G																					
												c.914 T > A																					
												c.982G > A and c.1072C > A																					
211	535000	Leber hereditary optic neuropathy		MT-ND1/MT-ND4L/MT-ND6	mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6				No treatment is available in DDIEM																								
	535000	Leber hereditary optic neuropathy		MT-ND4	mitochondrially encoded NADH dehydrogenase 4				AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)	NA	ECO:0001565	G11778A				Functional interaction	B	functional complementation of a genetically defective protein		Optic nerve damage		HP:0001138	https://www.ncbi.nlm.nih.gov/pubmed/17296905			https://www.ncbi.nlm.nih.gov/pubmed/30107658							
																				Mitochondrial oxidative stress		HP:0012103											
									rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))	NA	ECO:0007121	G11778A				Direct interaction 	A	direct complementation of a genetically defective protein		Abnormal visual acuity		HP:0030532	https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3	https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1									
									MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)	NA	ECO:0007121	G11778A				Direct interaction 	A	direct complementation of a genetically defective protein by gene therapy		Low ATP synthesis		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/30208599										
																				Optic atrophy		HP:0000648											
																				Abnormal visual acuity		HP:0030534											
																																	
								Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/	Idebenone	DB09081	ECO:0000352/ECO:0007121/ECO:0000179	m.3460G>A, m.11778G>A, and m.14484T>C				Functional interaction	B	functional complementation of a genetically defective protein		Abnormal visual acuity		HP:0030532	https://www.ncbi.nlm.nih.gov/pubmed/11723211	https://www.ncbi.nlm.nih.gov/pubmed/11001192	https://www.ncbi.nlm.nih.gov/pubmed/17573650	https://www.ncbi.nlm.nih.gov/pubmed/21788663	https://www.ncbi.nlm.nih.gov/pubmed/21810891/	https://www.ncbi.nlm.nih.gov/pubmed/21483849/	https://www.ncbi.nlm.nih.gov/pubmed/29054473	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/	https://www.ncbi.nlm.nih.gov/pubmed/27071925	https://www.ncbi.nlm.nih.gov/pubmed/28093355	https://www.ncbi.nlm.nih.gov/pubmed/23028832/
																				Abnormal retinal ganglion cell function 		HP:0001112	https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8	https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16	https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13	https://www.ncbi.nlm.nih.gov/pubmed/21788663/							
																				Retinal thickness		HP:0000630											
																				Gliosis		HP:0002171											
																				Functional loss of vision		HP:0000572											
																																	
									Idebenone+Vitamin C+Vitamin B12	DB09081+DB00126+DB00115	ECO:0000352					Functional interaction+Symptomatic+Symptomatic	B+C+C	combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Slow recovery		HP:0012823*	https://www.ncbi.nlm.nih.gov/pubmed/11001192/										
									EPI-743(Vatiquinone)	DB11917	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Disease progression (Rapidly progressive)*		HP:0003678*	https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4	https://www.ncbi.nlm.nih.gov/pubmed/22410442	https://www.ncbi.nlm.nih.gov/pubmed/26448041	https://www.ncbi.nlm.nih.gov/pubmed/21600768/	https://www.ncbi.nlm.nih.gov/pubmed/24093206/						
																				Abnormal visual acuity		HP:0030534											
																				Visual loss		HP:0000572											
																				Retinal ganglion loss		HP:0000479											
									Estrogens	DB00783	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Mitochondrial dysfunction		HP:0003287	https://www.ncbi.nlm.nih.gov/pubmed/20943885										
									Elamipretide (MTP-131)	DB11981	ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein		Increased reactive oxygen species production		HP:0025464	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/	https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3	https://clinicaltrials.gov/ct2/show/NCT02805790								
																				Low ATP synthesis		HP:0025464											
									Curcumin	DB11672	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://clinicaltrials.gov/ct2/show/NCT00528151										
								The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.	Cyclosporine	DB00091	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Disease progression		HP:0003678*	https://www.ncbi.nlm.nih.gov/pubmed/24161764	https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12									
									Corticosteroid+Antiaggregates	H02+B01A	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Large central visual field defect		HP:0001129	https://www.ncbi.nlm.nih.gov/pubmed/11723211										
212	220111	Leigh syndrome, French Canadian type	"Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/"	LRPPRC	leucine-rich pentatricopeptide repeat-containing protein				Methylene blue	DB09241	ECO:0001565	A354V				Functional interaction	B	metabolite replacement		Low COX content and activity 		NA	https://www.ncbi.nlm.nih.gov/pubmed/22202226										
												A354V and C12775STOP								Acidotic crises 		HP:0001941*											
									Propionate 	DB03766	ECO:0001565					Symptomatic	C	symptomatic therapeutic procedure		Palmitate plus lactate-induced cell death(abnormal cell death)*		MP:0000313	https://www.ncbi.nlm.nih.gov/pubmed/25835550										
									L-carnitine	DB00583	ECO:0001565					Symptomatic	C	symptomatic therapeutic procedure		PL-induced cytotoxicity		NA	https://www.ncbi.nlm.nih.gov/pubmed/25835550										
									Trolox ornithylamide hydrochloride	NA	ECO:0001565					Symptomatic	C	symptomatic therapeutic procedure		Increased ROS production		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/25620325/										
																				Decreased activity of mitochondrial complex I		HP:0011923											
																				Decreased activity of mitochondrial complex IV		HP:0008347											
																																	
213	300322	Lesch Nyhan syndrom		HPRT1	hypoxanthine phosphoribosyltransferase 1				Ecopipam ((PSYRX 101)	DB12273	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Self-injurious Behavior		HP:0100716	https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1	https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all	https://www.ncbi.nlm.nih.gov/pubmed/26922636/	https://www.ncbi.nlm.nih.gov/pubmed/27179999/							
									Sapropterin	DB00360	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Behaviour abnormalities		HP:0100851	https://clinicaltrials.gov/ct2/show/NCT00935753										
								No result was added to the study.	Aminomidazole carboxamide riboside	NA	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein					https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4										
								Treatment with tetrahydrobiopterin had no effect on the neurological symptoms although his urinary dopamine excretion increased significantly.https://www.nature.com/articles/pr19852350	Hypoxanthine+ tetrahydrobiopterin	DB04076+DB00360	ECO:0000352					Functional interaction+Symptomatic	B+C	combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure					https://www.ncbi.nlm.nih.gov/pubmed/3728152										
									SAM (S-adenosyl methionine )	DB00118	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Self-injurious behaviour		HP:0100716	https://www.ncbi.nlm.nih.gov/pubmed/16906475/	https://www.ncbi.nlm.nih.gov/pubmed/24001191/	https://www.ncbi.nlm.nih.gov/pubmed/24055166/								
																				Aggressive behavior		HP:0000718	https://www.ncbi.nlm.nih.gov/pubmed/24055166/										
																																	
								The therapy had to be interrupted because of renal colics	Hypoxanthine+Allopurinol 	DB04076+DB00437	ECO:0000352					Functional interaction+Symptomatic		combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure		Disturbances of equilibrium		HP:0002141	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=HYPOXANTHINE+AND+TETRAHYDROBIOPTERIN+TREATMENT+OF+A+PATIENT+WITH+FEATURES+OF+THE+LESCH-NYHAN+SYNDROME%3A+118&btnG=										
																				Aggressive behavior		HP:0000718											
								"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/"	Allopurinol	DB00437	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperuricemia		HP:0002149	https://www.ncbi.nlm.nih.gov/pubmed/17065067	https://www.ncbi.nlm.nih.gov/pubmed/22198833	https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/								
																				Gouty arthritis		HP:0001997											
																																	
									Baclofen 	DB00181	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Spasticity		HP:0001257	https://www.ncbi.nlm.nih.gov/pubmed/16549399										
									Diazepam/Alprazolam	DB00829 or DB00404	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Anxiety		HP:0000739	https://www.ncbi.nlm.nih.gov/pubmed/21126241										
																				Abnormal muscle tone		HP:0003808	https://www.ncbi.nlm.nih.gov/pubmed/21126241										
									Risperidone	DB00734	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Self-mutilation		HP:0000742	https://www.ncbi.nlm.nih.gov/pubmed/8870064/										
									Tetrabenazin	DB04844	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Chorea		HP:0002072	https://www.ncbi.nlm.nih.gov/pubmed/2455472/	https://www.ncbi.nlm.nih.gov/pubmed/12593632									
																				Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/2455472/										
									Carbidopa/levodopa	DB00190/DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/2455472/										
																				Chorea		HP:0002072	https://www.ncbi.nlm.nih.gov/pubmed/2455472/										
																																	
214	240800	Leucine-sensitive hypoglycemia of infancy		ABCC8	ATP binding cassette subfamily C member 8				Diazoxide	DB01119	ECO:0000352	E1506K 				Functional interaction	B	functional complementation of a genetically defective protein		Hypoglycemia		HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/15356046										
												R1353H																					
												delSer1387																					
215	613724	Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY)		SCP2	sterol carrier protein 2				No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/16685654										
216	611105	Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL)		DARS2	mitochondrial aspartyl-tRNA synthetase				acetazolamide	DB00819 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Paroxysmal exercise-induced gait ataxia (exercise-induced episodic ataxia )		HP:0002066*	https://www.ncbi.nlm.nih.gov/pubmed/21749991										
																				Seizures 		HP:0001250											
									glucocorticosteroid	DB00288 	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Spastic bladder		HP:0005340	https://www.ncbi.nlm.nih.gov/pubmed/23644316										
217	607155	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I		FKRP	fukutin-related protein (FKRP)			Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.	Prednisolone	DB00860	ECO:0000352/ECO:0007764					Symptomatic	C	symptomatic therapeutic procedure	Drug name: It has been mentioned that it might be beneficial in compound heterozygous mutations as patients have a milder phenotypes. https://www.ncbi.nlm.nih.gov/pubmed/28931339#	Myositis		HP:0100614	https://www.ncbi.nlm.nih.gov/pubmed/28931339	https://www.ncbi.nlm.nih.gov/pubmed/17446099									
																				Muscle weakness		HP:0001324											
																				Difficulty walking		HP:0002355											
																				Rapid progression		HP:0003678											
									rAAV-Fkrp	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Abnormal serum creatine kinase		HP:0040081	https://www.ncbi.nlm.nih.gov/pubmed/25048216	https://www.ncbi.nlm.nih.gov/pubmed/23817215	https://www.ncbi.nlm.nih.gov/pubmed/28334834	https://www.ncbi.nlm.nih.gov/pubmed/28480302							
																				Muscle dystrophy		HP:0006785	https://www.ncbi.nlm.nih.gov/pubmed/28107841										
																				Abnormal muscle function		HP:0011804											
218	609308	LGMD2K		POMT1	protein O-mannosyltransferase 1	2.4.1.109			No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/17339125										
219	611307	Limb-girdle muscular dystrophy type 2I (LGMD2I)		ANO5	anoctamin 5	Q75V66			No treatment is available in DDIEM																								
220	253601	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B		DYSF	dysferlin	O75923			Resolaris (ATYR1940)	NA	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Abnormal muscle function		HP:0011804	https://clinicaltrials.gov/ct2/show/NCT02579239	https://musculardystrophynews.com/resolaris-atyr1940/	https://www.ncbi.nlm.nih.gov/pubmed/17339125								
221	253600	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A		CAPN3	calpain 3	3.4.22.17			AAV2 /1-mSeAP-propmyoD76A	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Muscle atrophy		HP:0003797	https://www.ncbi.nlm.nih.gov/pubmed/17330087	https://www.ncbi.nlm.nih.gov/pubmed/17339125									
																				Abnormal muscle strenght		HP:0001324				https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A							
									(r) AAV2/1-mediated calpain 3	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Low muscle mass		HP:0003199	https://www.ncbi.nlm.nih.gov/pubmed/17330087										
222	608099	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D		SGCA	sarcoglycan alpha	Q16586 			AAV2/1-MCK-Sgca	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy	Drug name: Tried in mice not human	Decreased muscle mass		HP:0003199	https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+α-sarcoglycan+deficiency	https://www.ncbi.nlm.nih.gov/pubmed/17339125	https://www.ncbi.nlm.nih.gov/pubmed/15252120								
223	608896	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C		SGCG	sarcoglycan gamma	Q16586 			AAV1-gamma-sarcoglycan 	NA	ECO:0007121									Reduced muscle fiber gamma sarcoglycan		HP:0030108	https://clinicaltrials.gov/ct2/show/NCT01344798?cond=MUSCULAR+DYSTROPHY%2C+LIMB-GIRDLE%2C+TYPE+2C%3B+LGMD2C&draw=2&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/22240777	https://www.ncbi.nlm.nih.gov/pubmed/16635485								
224	246650	LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY		LMF1	lipase maturation factor 1	Q96S06		Poor compliance to the treatment was noticed	Fenofibrate+ω-3 fatty acids+EPA+DHA	DB01039+DB11133+DB00159 +DB03756	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein	Drug name: Poor compliance to the treatment was noticed 	Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/19820022										
								Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil	gemfibrozil+ω-3 fatty acids	DB01241+DB11133	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein	Drug name: Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil (600 mg twice a day	Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/19820022										
									Insulin aspart+Fibrate(gemfibrozil)+ ω-3 fatty acids	DB01306+DB01241+DB11133	ECO:0000352	W464X				Symptomatic+Functional interaction+Functional interaction	C+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein	Drug name: Improvement in the triglycride level startrd Under insulin therapy with a good blood glucose control (glycosylated hemoglobin 5.6%) and an improved lipid profile with TG plasma levels as low as 195 mg/dl (2.2 mmol/liter)	Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/19820022										
																				Hyperglycemia		HP:0003074											
								A low fat regimen was added to metformin while treating the patient.	Metformin	DB00331	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypertriglyceridemia		HP:0002155	https://www.ncbi.nlm.nih.gov/pubmed/17994020/										
225	614462	Lipoic acid synthetase deficiency		LIAS	lipoic acid synthetase	2.8.1.8			Topiramate+lamotrigine	DB00273+DB00555	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/24777537										
226	247100	Lipoid proteinosis of Urbach and Wiethe		ECM1	extracellular matrix protein 1	Q16610			Acitretin	DB00459	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Skin lesion		HP:0011122	https://www.ncbi.nlm.nih.gov/pubmed/24748909	https://www.ncbi.nlm.nih.gov/pubmed/28720532									
																				Skin papules		HP:0200034											
																				Mucosal lesions (Abnormal oral mucosa morphology)*		HP:0011830											
																				Hoarseness		HP:0001609	https://www.ncbi.nlm.nih.gov/pubmed/23259080/	https://www.ncbi.nlm.nih.gov/pubmed/18808438/									
																				Elbow skin thickening		HP:0001072	https://www.ncbi.nlm.nih.gov/pubmed/28681064										
																				Hyperkeratosis		HP:0000962											
																				Verrucous lesions		HP:0012500											
227	309000	Lowe oculocerebrorenal		OCRL	inositol polyphosphate 5-phosphatase OCRL-1	(3.1.3.36 and 3.1.3.56) or 3.1.3.86		"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency"	Sodium bicarbonate	DB01390	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Proximal tubular dysfunction		HP:0000114	https://www.ncbi.nlm.nih.gov/pubmed/12937245	https://www.ncbi.nlm.nih.gov/pubmed/20301653	https://www.ncbi.nlm.nih.gov/pubmed/27708066								
									Potassium bicarbonate	DB11098	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hypokalemia		HP:0002900	https://www.ncbi.nlm.nih.gov/pubmed/20301653	https://www.ncbi.nlm.nih.gov/pubmed/27708066									
								"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency"	Potassium citrate	DB09125	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Metabolic acidosis (Hyperchloremic metabolic acidosis)		HP:0004918	https://www.ncbi.nlm.nih.gov/pubmed/20301653										
																				Hypokalemia		HP:0002900											
								"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency"	Phosphate+Calcitriol	DB14573+DB00136	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Renal rickets		HP:0002748	https://www.ncbi.nlm.nih.gov/pubmed/20301653										
																Symptomatic	C			Hypophosphatemia		HP:0002148	https://www.ncbi.nlm.nih.gov/pubmed/20301653										
								"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency"	1-OH vitamin D	DB11094	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Hyperparathyrodism		HP:0000867	https://www.ncbi.nlm.nih.gov/pubmed/2017228	https://www.ncbi.nlm.nih.gov/pubmed/27708066	https://www.ncbi.nlm.nih.gov/pubmed/18480301/								
									Pamidronate +Growth hormone	DB00282+DB00052	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Hypophosphatasia		HP:0002148	https://www.ncbi.nlm.nih.gov/pubmed/19773212/										
																				Osteoporosis		HP:0000939											
									Thiazide	DB01325	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High calcium excretion		HP:0002150	https://www.ncbi.nlm.nih.gov/pubmed/26251718										
									L-carnitine	DB00583	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Secondary carnitine deficiency (Carnitine deficiency)*		HP:0003234	https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf	https://www.ncbi.nlm.nih.gov/pubmed/20301653	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=A+First+Reported+Case+of+Oculocerebrorenal+Syndrome+of+Lowe+in+Hong+Kong+and+Review+of+Literature&btnG=								
228	222700	Lysinuric protein intolerance	General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/	SLC7A7	Y+L amino acid transporter 1	Q9UM01		"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650"	Citrulline	DB00155	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	 Drug name: in "Low-dose"	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/27567650	https://www.ncbi.nlm.nih.gov/pubmed/25335805	https://www.ncbi.nlm.nih.gov/pubmed/22402328	https://www.ncbi.nlm.nih.gov/pubmed/6777479	https://www.ncbi.nlm.nih.gov/pubmed/25859380						
								The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805	corticosteroids (Amcinonide)+cyclosporin	DB00288+DB00091	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	 Drug namre: The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805	Hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*	Only one patient improved using this regimen in this study. The other two patients required platelets transfusion.	HP:0010978	https://www.ncbi.nlm.nih.gov/pubmed/28057010										
								THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.	Alendronate	DB00630	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Osteopenia		HP:0000938	https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract										
									ACEI (Benazepril)	DB00542	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Kidney failure 		HP:0000083											
																				Proteinuria		HP:0000093											
																				Hypertension		HP:0000822											
								Drug has no difference in terms of prognosis.	Sodium phenylbutyrate	DB06819	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	Drug has no difference in terms of prognosis.	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/28057010	https://www.ncbi.nlm.nih.gov/pubmed/26865117	https://www.ncbi.nlm.nih.gov/pubmed/27567650	https://www.ncbi.nlm.nih.gov/pubmed/20301535							
								Drug has no difference in terms of prognosis.	Sodium benzoate	DB03793	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	Drug has no difference in terms of prognosis.	Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/28057010	https://www.ncbi.nlm.nih.gov/pubmed/20301535									
									Lysine	DB00123	ECO:0000352					Functional interaction	B	metabolite replacement		Hypolysinemia		HP:0500142											
								"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650"	Lysine/Arginine/carnitine/Citrulline	DB00123/DB00125/DB00583/DB00155	ECO:0000352					Functional interaction	B	metabolite replacement	No obvious benefit from oral supplementation with citrulline, lysine or arginine.	Orotic aciduria	The drug works through preventing the aciduria and the hyperammonemia rather than treating it.  	HP:0003218	https://www.ncbi.nlm.nih.gov/pubmed/25614305										
																Symptomatic	C		No obvious benefit from oral supplementation with citrulline, lysine or arginine.	Hypolysinemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/27567650	https://www.ncbi.nlm.nih.gov/pubmed/20301535									
																				Intracellular defect of arginine		HP:0005961											
																			The dosage of L-citrulline dosage was a subject of controversy because of the possibility that it could increase inflammatory damages through its conversion to arginine and NO. L-Citrulline supplementation is thus usually limited to 100 mg/kg/d	Hyperproteinemia		HP:0002152											
									Growth hormone	DB00052	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	In order to get a favorable outcome in GH-treated children, Treatment with rhGH should be started early.	Growth impairment		HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/16775724/	https://www.ncbi.nlm.nih.gov/pubmed/25614305	https://www.ncbi.nlm.nih.gov/pubmed/23430827/								
																				Short stature		HP:0004322											
									Carnitine	DB00583	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Hyperammonemia		HP:0001987	https://www.ncbi.nlm.nih.gov/pubmed/28057010	https://www.ncbi.nlm.nih.gov/pubmed/28057010									
								The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650	Sodium benzoate+ L-carnitine+ low dose citrulline 	DB03793+DB00583+DB00155	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Episodic behavioral abnormalities (Behavioral abnormality)*		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/27567650										
																				Social interaction defect		HP:0000735											
																				Lack eye-eye contact		HP:0000817											
																				Hepatosplenomegaly		HP:0001433											
									Sargramostim	DB00020	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification	symptomatic therapeutic procedure	Pulmonary Alveolar Proteinosis		HP:0006517	https://www.ncbi.nlm.nih.gov/pubmed/27783330	https://www.ncbi.nlm.nih.gov/pubmed/25335805	https://www.ncbi.nlm.nih.gov/pubmed/29058386	https://www.ncbi.nlm.nih.gov/pubmed/21110863/							
																				Low pulmonary function		HP:0005952											
									Regramostim	DB05386	ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Pulmonary Alveolar Proteinosis		HP:0006517	https://www.ncbi.nlm.nih.gov/pubmed/25335805	https://www.ncbi.nlm.nih.gov/pubmed/29058386	https://www.ncbi.nlm.nih.gov/pubmed/21110863/	https://www.ncbi.nlm.nih.gov/pubmed/28649527		https://www.ncbi.nlm.nih.gov/pubmed/24886114					
																				Low pulmonary function		HP:0005952											
									Prednisolone+mycophenolate mofetil	DB00860+DB00688	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Membranoproliferative glomerulonephritis		HP:0000793	https://www.ncbi.nlm.nih.gov/pubmed/28087478										
229	248360	Malonyl-CoA decarboxylase Deficiency		MLYCD	malonyl-CoA decarboxylase	4.1.1.9		"The diet regime consists of 30% long‐chain triglycerides – LCTs; 70% MCTs in this study https://www.ncbi.nlm.nih.gov/pubmed/28781843 
In another study the diset regime consisited of  (Long chain triglyceride-restricted/medium-chain triglyceride-supplemented diet with the composition of  1.9% energy from LCT, 25% from MCT and the remainder carbohydrate. https://www.ncbi.nlm.nih.gov/pubmed/20549361
While in two other studies the diet regime didn't improve the case. https://www.ncbi.nlm.nih.gov/pubmed/9177981?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/17535268?dopt=Abstract"	Carnitine+Fat-limited diet+High carbohydrate diet+Fish oil	DB00583+NA+NA+DB13961	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+dietary regime modification+dietary regime modification+dietary regime modification		High urinary malonic acid		HP:0012120	https://www.ncbi.nlm.nih.gov/pubmed/28781843	https://www.ncbi.nlm.nih.gov/pubmed/24613099		https://www.ncbi.nlm.nih.gov/pubmed/26858006	https://www.ncbi.nlm.nih.gov/pubmed/8259873?dopt=Abstract						
																				High blood malonylcarnitine level		HP:0031544	https://www.ncbi.nlm.nih.gov/pubmed/26858006										
																				Low endurance		HP:0025142	https://www.ncbi.nlm.nih.gov/pubmed/26858006										
																				Failurre to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/28781843										
																				Cardiomyopathy progrssion (Progressive)*		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/28781843	https://www.ncbi.nlm.nih.gov/pubmed/16078122									
																				Muscular hypotonia		HP:0001252	https://www.ncbi.nlm.nih.gov/pubmed/16078122										
																				Delayed ability to sit		HP:0025336	https://www.ncbi.nlm.nih.gov/pubmed/16078122										
																				Abnormal cardiac ventricular function		HP:0030872	https://www.ncbi.nlm.nih.gov/pubmed/20549361										
230	614202	MAN1B1-CDG		MAN1B1	mannosidase alpha class 1B member 1				No treatment is available in DDIEM														https://www.ncbi.nlm.nih.gov/pubmed/29908352										
231	611722	Krabbe disease atypical due to Saposin A deficiency		PSAP	prosaposin				No treatment is available in DDIEM																								
232	530000	Kearns-Sayre syndrome							Folinic acid	DB00650	ECO:0000352					Functional interaction	B	metabolite replacement	"Drug has a controversial study regarding patients reponce to treatment. https://www.ncbi.nlm.nih.gov/pubmed/28318733
"	Low 5‐MTHF level		NA	https://www.ncbi.nlm.nih.gov/pubmed/16365882	https://www.ncbi.nlm.nih.gov/pubmed/28318733									
																				White matter alteration		HP:0002500											
																				Deambulation		HP:0100022											
									Growth Hormone	DB00052	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Short Stature		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/27718492										
									Coenzyme Q10	DB09270	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Corneal Oedema		HP:0012040	https://www.ncbi.nlm.nih.gov/pubmed/27442316	https://www.ncbi.nlm.nih.gov/pubmed/27709644	https://www.ncbi.nlm.nih.gov/pubmed/26884075								
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/26118651										
									L-carnitine	DB00583	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Mitochondrial respiratory chain defects		HP:0200125	https://www.ncbi.nlm.nih.gov/pubmed/19891905										
																				Myopathy		HP:0003198	https://www.ncbi.nlm.nih.gov/pubmed/26884075										
									Dopamine+Dobutamine+Thiazide+Milrinone	DB00988+DB0084+DB00232+DB00235	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Symptomatic	C+C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Acute congestive heart failure		HP:0001635	https://www.ncbi.nlm.nih.gov/pubmed/26884075										
									Mitochonic acid 5	NA	ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Mitochondrial dysfunction		HP:0003287	https://www.ncbi.nlm.nih.gov/pubmed/26118651										
																				Decreased cellular ATP level		HP:0011925*											
																																	
									Insulin	DB00030	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Diabetes mellitus		HP:0000819	https://www.ncbi.nlm.nih.gov/pubmed/25092642										
								Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001	Cysteamine bitartrate	DB00847	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure					https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4	https://clinicaltrials.gov/ct2/show/NCT02473445									
									Sodium Pyruvate	DB00119	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Elevated serum lactate level		HP:0002151	https://www.ncbi.nlm.nih.gov/pubmed/30738201										
																				High lactate/pyruvate ratio (Mitochondrial respiratory chain defects)*		HP:0200125											
																				Increased lateral ventricular lactate level		NA											
																				High serum GDF15 level		NA											
									Phenobarbital+phenytoin	DB01174 +DB00252	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Generalized tonic-clonic seizures		HP:0002069											
																																	
233	609242	Kanzaki disease/schindler Disease type 2		NAGA	alpha-N-acetylgalactosaminidase			 A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.	Iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)	NA	ECO:0000179/ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein	clinical candidate , tested invitro and in cellular experiments 	Abnormal alpha-N-acetylgalactosaminidase (Abnormal enzyme/coenzyme activity)		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/23045655										
									L-deoxygalactonojirimycin (DGJ)	DB05018	ECO:0000179/ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein															
234	243500	Isovaleric acidemia		IVD	isovaleryl-CoA dehydrogenase				Carglumic acid	DB06775	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Acute hyperammonemia		HP:0008281	https://www.ncbi.nlm.nih.gov/pubmed/21207059	https://www.ncbi.nlm.nih.gov/pubmed/21403788									
								1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338	L-carnitine +L- glycine	DB00583+DB00145	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High toxic acyl-CoA level		NA	https://www.ncbi.nlm.nih.gov/pubmed/21290185	https://www.ncbi.nlm.nih.gov/pubmed/12069539/	https://www.ncbi.nlm.nih.gov/pubmed/20807522	https://www.ncbi.nlm.nih.gov/pubmed/19210957							
																				Abnormal Na+,K+-ATPase activity(Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/15624372										
																				Metabolic acidosis		HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/16602101										
																				High 3-hydroxyisovaleric acid level (C5)		NA	https://www.ncbi.nlm.nih.gov/pubmed/17299485	https://www.ncbi.nlm.nih.gov/pubmed/16602101/									
																				Metabolic stress	The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.	HP:0001942	https://www.ncbi.nlm.nih.gov/pubmed/8804338										
																				Developmental delay		HP:0001263											
235	611283	Isobutyryl-CoA dehydrogenase deficiency	It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379	ACAD8	isobutyryl-CoA dehydrogenase				L-carnitine	DB00583	ECO:0000352					Functional interaction	B	metabolite replacement		Carnitine deficiency		HP:0003234	https://www.ncbi.nlm.nih.gov/pubmed/28053874	https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg	https://www.ncbi.nlm.nih.gov/pubmed/9889013/								
																				Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg										
									L- carnitine+valine-restricted diet+riboflavin 	DB00583+NA+DB00140	ECO:0000352					Functional interaction+Functional interaction+Symptomatic	B+B+C	combination therapeutic procedure+metabolite replacement+dietary exclusion+symptomatic therapeutic procedure		Growth abnormality		HP:0001507	https://www.ncbi.nlm.nih.gov/pubmed/16857760?dopt=Abstract&holding=npg										
236	261000	Intrinsic factor deficiency		GIF	gastric intrinsic factor			"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/"	Vitamin B12	DB00115	ECO:0000352					Functional interaction	B	metabolite replacement		Low levels of serum vitamin B12		HP:0100502	https://www.ncbi.nlm.nih.gov/pubmed/24424200	https://www.ncbi.nlm.nih.gov/pubmed/25308559	https://www.ncbi.nlm.nih.gov/pubmed/6823973	https://www.ncbi.nlm.nih.gov/pubmed/9694707							
																				High RBC's mean corpuscular volume 		HP:0025548											
																				Low Hemoglobin concentration		HP:0020062											
																				Abnormal reticulocyte count		HP:0004312											
									Corticosteroid	DB00860						Symptomatic	C	symptomatic therapeutic procedure		Gastric mucosal atrophy (Abnormality of gastric mucosa)*		HP:0004295	https://www.ncbi.nlm.nih.gov/pubmed/24424200	https://www.ncbi.nlm.nih.gov/pubmed/921733									
237	608747	insulin-like growth factor I deficiency		IGF1	insulin like growth factor 1	P05019		The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.	Recombinant human IGF1(Mecasermin)	DB01277	ECO:0007121/ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein		Low height velocity		HP:0004322	https://www.ncbi.nlm.nih.gov/pubmed/10323388	https://www.ncbi.nlm.nih.gov/pubmed/27884013	https://www.ncbi.nlm.nih.gov/pubmed/24639006	https://www.ncbi.nlm.nih.gov/pubmed/23887143	https://www.ncbi.nlm.nih.gov/pubmed/17192294/	https://www.ncbi.nlm.nih.gov/pubmed/19627167	https://www.ncbi.nlm.nih.gov/pubmed/10549306	https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1	https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10	https://clinicaltrials.gov/ct2/show/NCT00125164?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=7	https://clinicaltrials.gov/ct2/show/NCT00330668?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=6
																				Low lean body mass		HP:0045082											
																				Abnormal linear growth (Decreased linear growth/Abnormal body height)*		HP:0000002											
																				Low insulin senstivity		HP:0008189											
																				Abnormal circulating GH level		HP:0032367											
																				Abnormal circulating IGFBP level		HP:0031034											
																				Abnormal circulating insulin level		HP:0040215											
																				Decreased body mass index		HP:0045082	https://www.ncbi.nlm.nih.gov/pubmed/10770174										
																				Abnormal Body fat composition		HP:0025521											
																				Insulin resistance		HP:0000855											
								The study is terminated (The study was prematurely terminated due to strategic reasons.)	NutropinAq® (Somatropin [rDNA origin]	DB00052	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Short stature		HP:0004322	https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4										
								The study is terminated (The study was prematurely terminated due to strategic reasons.)	Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])	DB01277+DB00052	ECO:0007121					Direct interaction+Functional interaction	A+B	combination therapeutic procedure+direct complementation of a genetically defective protein+functional complementation of a genetically defective protein		Short stature		HP:0004322	https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4										
								Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement	Mecasermin rinfabate	DB14751	ECO:0000352					Direct interaction	A	direct complementation of a genetically defective protein	Drug name: Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement	hypoglycemia	The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect. 	HP:0001943	https://www.ncbi.nlm.nih.gov/pubmed/19627167										
																				Low serum ICFBP level		NA											
238	271245	Infantile-onset spinocerebellar ataxia	Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.	TWNK	twinkle mtDNA helicase	Q96RR1		The drug is occasionally effective especially when started early in status epilepticus.	Benzodiazepines	DB00252	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	Drug nmae:However, phenytoin and phenobarbitates are ineffective in most affected individuals	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/20301746										
								The drug has some effects but hyponatremia is a troublesome side effect.	Oxcarbazepine	DB00776	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Short nocturnal tonic seizures		HP:0031951	https://www.ncbi.nlm.nih.gov/pubmed/19304794	https://www.ncbi.nlm.nih.gov/pubmed/20301746									
								Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.	Valproate	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure	 Drug name: Should be avoided as it results in elevated liver enzymes only when treated with valproate	Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/27551684	https://www.ncbi.nlm.nih.gov/pubmed/19304794/									
									Selective serotonin reuptake inhibitors+Antipsychotics	N06AB +N05A	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Agitation		HP:0000713	https://www.ncbi.nlm.nih.gov/pubmed/19304794										
																				Aggressive behavior		HP:0000718											
									Carbamazepine	DB00564	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Complex partial seizure		HP:0002384											
																				Generalized convulsion		HP:0002197											
									Topiramate + pyridoxine	"DB00273+DB00165
"	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/27551684										
								The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890 	Creatine	DB00583	ECO:0007764					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Abnormal circulating creatinine level		HP:0012100	https://www.ncbi.nlm.nih.gov/pubmed/30373890										
								Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891	Glutathione [N‐acetyl‐cysteine]	DB00143	ECO:0007764					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/30373890										
																				Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/30373890										
								A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892	NAD+ [nicotinamide riboside]	DB14933	ECO:0007764					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Niacinamide depletion		NA	https://www.ncbi.nlm.nih.gov/pubmed/30373890										
239	256600	Infantile neuroaxonal dystrophy		PLA2G6	85/88 kDa calcium-independent phospholipase A2	3.1.1.4		"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/"	RT001 (11,11-di-deutero-linoleic acid ethyl ester)	NA	ECO:0007121/ECO:0000352					Functional interaction	B	metabolite replacement		Chronic constipation		HP:0012450	https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1	http://n.neurology.org/content/90/15_Supplement/P3.327									
																				Bulbar dysfunction		HP:0001283											
																				Functional motoe deficit		HP:0004302											
																				Defective eye motor function		HP:0000496											
																				Poor head control 		HP:0002421											
																																	
								"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971"	Desipramine	DB01151	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Lysosomal stress (Abnormality of lysosomal metabolism)*	In the mouse model syudy	HP:0004356	https://clinicaltrials.gov/ct2/show/NCT03726996	https://www.ncbi.nlm.nih.gov/pubmed/29909971									
																				Neurodegeneration	In the mouse model syudy	HP:0002180											
240	269920	Free sialic acid storage disease		SLC17A5	solute carrier family 17 member 5	Q9NRA2 		Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions. https://www.ncbi.nlm.nih.gov/pubmed/20301643	No treatment is available in DDIEM								C							https://www.ncbi.nlm.nih.gov/pubmed/20301643									
241	604369	Salla Disease		SLC17A5	solute carrier family 17 member 5	Q9NRA2 			Levetiracetam	DB01202	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Generalized tonic-clonic seizure		HP:0002069	https://www.ncbi.nlm.nih.gov/pubmed/28662915										
									Phenobarbital	DB01174	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/12794688										
																																	
																																	
242	605820	Inclusion body myopathy 2		GNE	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	3.2.1.183, 2.7.1.60			ManNac (N-acetylmannosamine)	DB12536	ECO:0007121					Functional interaction	B	metabolite replacement		Decreased sialylation of muscle glycans		HP:0012350	https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/28641925	https://www.ncbi.nlm.nih.gov/pubmed/26546927								
																				Low circulating levels of free sialic acids		HP:0012363											
																				Rimmed vacuoles		HP:0003805	https://www.ncbi.nlm.nih.gov/pubmed/21517694										
																				Amyloid deposition		HP:0003216*	https://www.ncbi.nlm.nih.gov/pubmed/21517694										
									Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine)	CHEBI:17012+DB12536	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+metabolite replacement+metabolite replacement		Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/28641925	https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/26546927	https://www.ncbi.nlm.nih.gov/pubmed/20030229							
																				"Decreased sialylation of muscle glycans
"		HP:0012350											
									GNE gene lipoplex	NA	ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Decline of muscle strength (Muscle weakness)		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/21517694										
									Sialic acid	CHEBI:17012						Functional interaction	B	metabolite replacement		Muscle weakness		HP:0001324											
243	252500	I cell disease		GNPTAB	(α) &(β)GlcNAc-1-phosphotransferas				No treatment is available in DDIEM																								
244	261100	Imerslund-Grasbeck syndrome		CUBN/AMN	cubilin/amnion associated transmembrane protein				Methylcobalamin	DB03614	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein	Drug name :This study has been conducted in puppies but the treatment's results are the same for humans based on this sudy https://www.ncbi.nlm.nih.gov/pubmed/18768530	Megalobalstic anaemia		HP:0001889	https://www.ncbi.nlm.nih.gov/pubmed/14593474	https://www.ncbi.nlm.nih.gov/pubmed/27942180	https://www.ncbi.nlm.nih.gov/pubmed/26958680	https://www.ncbi.nlm.nih.gov/pubmed/26040326	https://www.ncbi.nlm.nih.gov/pubmed/23364648	https://www.ncbi.nlm.nih.gov/pubmed/22219566					
																				Low level of serum B12		HP:0040126											
																				Neurological abnormalities		HP:0000707											
																				Normocytic anemia		HP:0001897	https://www.ncbi.nlm.nih.gov/pubmed/29572946	https://www.ncbi.nlm.nih.gov/pubmed/18768530									
																				Hyperammonemia		HP:0001987											
																				Increased liver enzyme activities		HP:0002910											
																				Abnormal methylmalonic acid level.		HP:0012120											
																				Hyperpigmentation		HP:0000953	https://www.ncbi.nlm.nih.gov/pubmed/24222293										
245	242600	Iminoglycinuria		SLC36A2 /SLC6A20/SLC6A19	solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19				No treatment is available in DDIEM																								
246	605637	Inclusion body myopathy type 3		MYH2	myosin heavy chain 2				No treatment is available in DDIEM																								
247	246450	3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD		HMGCL	HMG-CoA lyase				Carnitine+high-carbohydrate+low-protein+ low-fat diet	DB00583+NA+NA+NA	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+dietary regime modification+dietary regime modification+dietary regime modification		Disease progression		HP:0003678	https://www.ncbi.nlm.nih.gov/pubmed/28220407	https://www.ncbi.nlm.nih.gov/pubmed/29565174	https://www.ncbi.nlm.nih.gov/pubmed/26997609/	https://www.ncbi.nlm.nih.gov/pubmed/2443756	https://www.ncbi.nlm.nih.gov/pubmed/1886403	https://www.ncbi.nlm.nih.gov/pubmed/28220407					
																				Decreased plasma carnitine		HP:0003234											
									Leucine-restricted diet	NA	ECO:0000352					Symptomatic	C	dietary exclusion		White matter changes		HP:0007103	https://www.ncbi.nlm.nih.gov/pubmed/17628222/										
								The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690	Glucose+leucine-restricted diet	DB01914+NA	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+dietary exclusion		Nonketotic hypoglycemia		HP:0001958	https://www.ncbi.nlm.nih.gov/pubmed/17628222/	https://www.ncbi.nlm.nih.gov/pubmed/28220407									
																				Acute metabolic decompensation (Metabolic acidosis)*		HP:0001942											
																																	
1	# 268200	Myoglobinuria, acute recurrent, autosomal recessive		LPIN1	Phosphatidate phosphatase	3.1.3.4			Tauroursodeoxycholic acid	DB08834	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein	Drug name: Study was done on preclinical model of the disease.	ER (endoplasmic reticulum) stress		NA	https://www.ncbi.nlm.nih.gov/pubmed/30420558										
																				High triglyceride levels		HP:0002155											
																				Muscle weakness		HP:0001324											
									Bezafibrate	DB01393	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Increased muscle lipid droplets		HP:0012240	https://www.ncbi.nlm.nih.gov/pubmed/30420558										
																				ER (endoplasmic reticulum) stress		NA											
																				Muscle weakness		HP:0001324											
																				Fiber necrosis		HP:0003713											
																				Myopathy		HP:0003198											
2	# 550500	Myoglobinuria recurrent		MT-CO1/MT-CYB/MT-CO3	Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3	1.9.3.1/P00403/P00414			No treatment is available in DDIEM																								
3	 # 545000	Myoclonic epilepsy with ragged red fibers 	Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.	MT-TK	Mitochondrially encoded tRNA lysine			"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://www.ncbi.nlm.nih.gov/pubmed/21494841"	Levetiracetam/Clonazepam/Zonisamide	DB01202/DB01068/DB00909	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Myoclonic epliepsy		HP:0002123	https://www.ncbi.nlm.nih.gov/pubmed/14981187		https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010	https://www.ncbi.nlm.nih.gov/books/NBK1520/	https://www.ncbi.nlm.nih.gov/pubmed/21494841						
									Coenzyme Q10+L-carnitine+ lipoic acid	DB09270+DB00583+ DB00166	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Ankle weakness progression (Disease progression)*		HP:0003287	https://www.ncbi.nlm.nih.gov/pubmed/17080429										
																				High resting plasma lactate concentration 		HP:0003288	https://www.ncbi.nlm.nih.gov/pubmed/17275787										
									Levetiracetam+ l-carnitine +CoQ10 	DB01202+DB00583+DB09270	ECO:0000352					Symptomatic+Functional interaction+Functional interaction	C+B+B	combination therapeutic procedure+symptomatic therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Myoclonus		HP:0002123											
																				Low quality of life (Constitutional symptoms)*		HP:0025142	https://www.ncbi.nlm.nih.gov/pubmed/28686997	https://www.ncbi.nlm.nih.gov/pubmed/21494841									
									Piracetam	DB09210	ECO:0000352	m.8344A > G	In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/			Symptomatic	C	symptomatic therapeutic procedure		Myoclonic seizures		HP:0002123	https://www.ncbi.nlm.nih.gov/pubmed/28717435										
									Clonazepam	DB01068	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Asterixis-like movement (Abnormality of movement)		HP:0100022	https://www.ncbi.nlm.nih.gov/pubmed/1490314										
4	# 601776	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1		CHST14	Dermatan-4-sulfotransferase-1	2.8.2.35			Magnesium	DB14513	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Constipation		HP:0002019	https://www.ncbi.nlm.nih.gov/pubmed/21744491										
5	# 300559	GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY	Most patients do not require any specific treatment.https://rarediseases.info.nih.gov/diseases/3858/muscular-phosphorylase-kinase-deficiency#	PHKA1	alpha subunit of muscle phosphorylase kinase	2.7.11.19			Cortisone	DB14681	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Muscular hypotonia		HP:0001252	https://www.ncbi.nlm.nih.gov/pubmed/15637709										
								In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410 	Glucose	DB01914	ECO:0000352					Functional interaction	B	metabolite replacement		Exercise intolerance		HP:0009020	https://www.ncbi.nlm.nih.gov/pubmed/18401027										
6	# 602541	Congenital megaconial myopathy	Cardiac involvement occurs relatively frequently in the patients with megaconial congenital muscular dystrophy, Heart transplanation is considered a successful therapeutic option in those patients not responding to medical treatment. https://www.ncbi.nlm.nih.gov/pubmed/26855408	CHKB	Choline/ethanolamine kinase	2.7.1.32/2.7.1.82			L-carnitine	DB00583	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*		HP:0003287*	https://www.ncbi.nlm.nih.gov/pubmed/26006750										
									Riboflavin	DB00140	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*		HP:0003287*											
									Thiamine	DB00152	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Neurological disorder of mitochondrail dysfunction (mitochondrail dysfunction)*		HP:0003287*											
									Corticosteroid	D07A	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Nummular eczema (Eczema)*		HP:0000964*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/										
									B-Blockers+Angiotensin-converting enzyme inhibitors	C07+C09	ECO:0000352					Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Cardiomyopathy		HP:0001638	https://www.ncbi.nlm.nih.gov/pubmed/26067811										
7	# 253280	Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3		POMGNT1	Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1	Q8WZA1			botulinum toxin	DB00083	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Strabismus		HP:0000486	https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract										
																				Esotropia		HP:0000565											
									Ad5-LARGE-eGFP	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Muscle dystrophy 		HP:0003560	https://www.ncbi.nlm.nih.gov/pubmed/15184894										
8	# 236670	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1		POMT1	protein O-mannosyltransferase 1	2.4.1.109			Ad5-LARGE-eGFP	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Muscle dystrophy 		HP:0003560	https://www.ncbi.nlm.nih.gov/pubmed/15184894										
9	# 613150	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2		POMT2	Protein O-mannosyl-transferase 2	2.4.1.109			Diuretics	C03	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Congestive cardiac failure		HP:0001635	https://www.ncbi.nlm.nih.gov/pubmed/28980384										
																				Tachypnea		HP:0002789											
10	# 253800	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4		FKTN	Fukutin	O75072			Antisense oligonucleotide	NA	ECO:0001565/ECO:0000179					Direct interaction 	A	activity modification of a genetically defective protein by transcriptional or translational modification		Abnormal Fukutin function(		NA	https://www.ncbi.nlm.nih.gov/pubmed/21979053										
11	# 613153	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5		FKRP	Fukutin-related protein	Q9H9S5			Adeno-associated Virus 9 Mediated FKRP Gene Therapy	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Abnormal muscle function		HP:0011804	https://www.sciencedirect.com/science/article/pii/S152500161632250X										
									Ad5-LARGE-eGFP	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Muscle dystrophy 		HP:0003560	https://www.ncbi.nlm.nih.gov/pubmed/15184894										
12	# 613154	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6		LARGE	LARGE xylosyl- and glucuronyltransferase 1	O95461			Ad5-LARGE-eGFP	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Muscle dystrophy 		HP:0003560	https://www.ncbi.nlm.nih.gov/pubmed/15184894										
13	# 614643	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7		ISPD	D-ribitol-5-phosphate cytidylyltransferase	2.7.7.40			No treatment is available in DDIEM																								
14	# 614830	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8		POMGNT2	Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2	2.4.1.312			No treatment is available in DDIEM																								
15	# 616538	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9		DAG1	Dystroglycan	Q14118			No treatment is available in DDIEM																								
16	# 615041	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10		RXYLT1	Ribitol-5-phosphate xylosyltransferase 1	Q9Y2B1			No treatment is available in DDIEM																								
17	# 615181	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11		B3GALNT2	UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2	2.4.1.313			Phenobarbital	DB01174	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/29273094										
18	# 615249	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12		POMK	Protein O-mannose kinase	2.7.1.183			No treatment is available in DDIEM																								
19	# 615287	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13		B4GAT1	Beta-1,4-glucuronyltransferase 1	O43505			No treatment is available in DDIEM																								
20	151800	Multiple symmetric lipomatosis	The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/	MT-TK					Salbutamol	DB01001	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure	Drug name: A correlated gene mutation has not been discovered. https://www.ncbi.nlm.nih.gov/pubmed/8190288	Rapid progression in body fat mass (Abnormality of adipose tissue* )		HP:0009124*	https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract										
																				Disease progression (Progressive)*		HP:0003676											
																				Increased intraabdominal fat		HP:0008993											
																																	
21	# 272200	Multiple sulfatase deficiency		SUMF1	Formylglycine-generating enzyme	1.8.3.7			No treatment is available in DDIEM											Low metabolic rate (Abnormality of fatty acid metabolism)*		HP:0004359*											
22	# 162300	Multiple endocrine neoplasia type 2B		RET	Proto-oncogene tyrosine-protein kinase receptor Ret	2.7.10.1			Dexamethasone	DB01234	ECO:0001565					Direct interaction	A	procedure to mitigate dominant effects of a genetically abnormal protein	Drug name: The trial was conducted on a cell line that is held to be an in vitro model for medullary carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157381/ 	Abnormal cellular proliferation		HP:0031377	https://www.ncbi.nlm.nih.gov/pubmed/10947080	https://www.ncbi.nlm.nih.gov/pubmed/3491070/									
								Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract	Vandetanib	DB05294	ECO:0007121	M918T				Direct interaction	A	procedure to mitigate dominant effects of a genetically abnormal protein	Mutation improved: If data from the ARMS assay are taken into account, patients with sporadic MTC received benefit from vandetanib whether their tumors were M918T positive or negative; however, the response rate was greater in those who had an M918T mutation. https://www.ncbi.nlm.nih.gov/pubmed/22025146/	Low quality of life (Constitutional symptom)*		HP:0025142*	https://www.ncbi.nlm.nih.gov/pubmed/23766359										
																				Pain		HP:0012531											
																				Objective response rate (ORR)		NA	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/										
																				Disease progression rate (Rapid disease progression)		HP:0003678	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/										
																				Short Progression-free survival (Rapidly progressive )*		HP:0003678	https://www.ncbi.nlm.nih.gov/pubmed/22025146/	https://www.ncbi.nlm.nih.gov/pubmed/20371662/	https://www.ncbi.nlm.nih.gov/pubmed/27650489	https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract							
																				Elevated calcitonin 		HP:0003528	https://www.ncbi.nlm.nih.gov/pubmed/23766359	https://clinicaltrials.gov/ct2/show/NCT00514046									
																				Increased plasma CEA		HP:0031029	https://www.ncbi.nlm.nih.gov/pubmed/23766359	https://clinicaltrials.gov/ct2/show/NCT00514046									
																				Bone pain 		HP:0002653	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/	https://clinicaltrials.gov/ct2/show/NCT00514046									
																				Low skeletal muscle mass		HP:0003199	https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract										
																				Weight loss		HP:0001824	https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract										
																				Decreased adipose tissue		HP:0040063	https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract										
																																	
									Bortezomib + Vandetanib	DB00188+DB05294	ECO:0007121					Direct interaction+Direct interaction	A+A	combination therapeutic procedure+procedure to mitigate dominant effects of a genetically abnormal protein+procedure to mitigate dominant effects of a genetically abnormal protein	Drug name: 	Neoplastic growth		HP:0002664	https://www.ncbi.nlm.nih.gov/pubmed/18381602/	https://www.ncbi.nlm.nih.gov/pubmed/26170630	https://clinicaltrials.gov/ct2/show/NCT00923247	https://www.ncbi.nlm.nih.gov/pubmed/30297385/							
									Cabozantinib ( XL184)	DB08875	ECO:0007121					Direct interaction	A	procedure to mitigate dominant effects of a genetically abnormal protein		Phosphorylation of RET		NA	https://www.ncbi.nlm.nih.gov/pubmed/21606412/	https://clinicaltrials.gov/ct2/show/NCT00215605									
																				Elevated calcitonin		HP:0003528											
																				Short Progression-free survival (Rapidly progressive )*		HP:0003678	https://www.ncbi.nlm.nih.gov/pubmed/24002501/	https://clinicaltrials.gov/ct2/show/NCT00704730									
																				Low tumor response rate 	The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501	NA											
																				Overall survival (premature death)*	Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/	MP:0002083											
																																	
																																	
																																	
																																	
23	# 614080	Multiple congenital anomalies-hypotonia-seizures syndrome  		PIGN	GPI ethanolamine phosphate transferase 1	O95427		Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam	Levetiracetam	DB01202	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/										
								Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam	Topiramate	DB00273	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
								Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam	Oxcarbazepine	DB00776	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250											
24	# 300868	Multiple congenital anomalies-hypotonia-seizures syndrome type 2	Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216	PIGA	Phosphatidylinositol N-acetylglucosaminyltransferase subunit A	2.4.1.198			No treatment is available in DDIEM																								
25	# 300818	Paroxysmal nocturnal hemoglobinuria	PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949	PIGA	Phosphatidylinositol N-acetylglucosaminyltransferase subunit A	2.4.1.199			Eculizumab	DB01257	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Paroxysmal nocturnal hemoglobinuria		HP:0004818	https://www.ncbi.nlm.nih.gov/pubmed/28516949										
26	# 615398	Multiple congenital anomalies-hypotonia-seizures syndrome type 3		PIGT	GPI transamidase component PIG-T	Q969N2		Drugs has decreased rhe frequency of the tonic seizuress	Phenobarbital	DB01174	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tonic seizures (Focal tonic seizures)		HP:0011167*	https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub										
								Drugs has decreased rhe frequency of the tonic seizuress	Clonzepam	DB01068	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tonic seizures (Focal tonic seizures)		HP:0011167*	https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub										
								Drugs has decreased rhe frequency of the tonic seizuress	Potassium bromide	CHEBI:32030	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Tonic seizures (Focal tonic seizures)		HP:0011167*	https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub										
									Acetazolamide	DB00819	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Epileptic apnea (Apneic episodes precipitated by illness, fatigue, stress)		HP:0002872*											
28	# 248510	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB		MANBA	Beta-mannosidase	3.2.1.25			No treatment is available in DDIEM																								
29	# 248600	Maple syrup urine disease type Ia	In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.	BCKDHA	2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial	1.2.4.4		No phenotypes were mentioned in the study. In vitro Study. 	Natural osmolyte trimethylamine N-oxide (TMAO)	CHEBI:15724	ECO:0001565	F364C- alpha  	Activity of F364C- mutant E1 was increased markedly from 1% of wild type without TMAO to 30% with 0.75 M TMAO. https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract	A209D-alpha	The S289L- beta and A209D- alpha mutants showed 0 and 40% residual activities, respectively, in the absence of TMAO, but these activities re- mained unchanged after incubation with the osmolyte	Direct interaction	A	activity modification of a genetically defective protein		Abnormal MSUD enzyme activity (Abnormal enzyme activity)*		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract										
												Y368C- alpha	Y368C- E1 in that residue activity is 3% in the absence of TMAO and 27% in its presence.																				
												Y393N- alpha	TMAO also activated Y393N- E1 with activity increased from 0 to 9% of the wild type, in the absence and the presence of TMAO, respectively.																				
									Norleucine	NA	ECO:0000352					Functional interaction	B	functional complementatin of a genetically defective protein		Branched-chain amino acid accumulation	Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.	HP:0008344	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/										
																				Encephalopathy 	The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.	HP:0001298	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/										
																				High α-ketoisocaproate level		NA											
30	# 248600	Maple syrup urine disease type Ib		BCKDHB	2-oxoisovalerate dehydrogenase subunit beta, mitochondrial	1.2.4.4		There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.	Sodium phenylbutyrate	DB06819	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Elevated branched chain keto-acids in urine (Ketonuria )*		HP:0002919*	https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070	https://www.ncbi.nlm.nih.gov/pubmed/28919799									
																				High plasma branched chain amino acids		HP:0008344	https://www.ncbi.nlm.nih.gov/pubmed/28919799										
31	# 248600	Maple syrup urine disease type II		DBT	Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial	2.3.1.168			Thiamine	DB00152	ECO:0000352					Functional interaction	B	functional complementatin of a genetically defective protein		High plasma branched chain amino acids		HP:0008344	https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006										
32	# 246900	MAPLE SYRUP URINE DISEASE, TYPE III		DLD	Dihydrolipoyl dehydrogenase, mitochondrial	1.8.1.4			N-acetylcysteine +deferoxamine	DB06151+ DB00746	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Memory impairment		HP:0002354	https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070										
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/15938133	https://www.ncbi.nlm.nih.gov/pubmed/12927581									
																				Behavioural abnormalites		HP:0000708											
																				cognitive imapirment		HP:0100543											
																				Learning impairment		HP:0001328											
									Riboflavin	DB00140	ECO:0000352			 		Direct interaction	A	activity modification of a genetically defective protein		Exercise intolerance		HP:0003546	https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub										
																				Mitochondrial proliferation in the muscle		HP:0003200											
																				Myopathy		HP:0003198											
																				Lactic acidosis		HP:0003128											
33	# 261600	PHENYLKETONURIA	Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub	PAH	PHENYLALANINE HYDROXYLASE	1.14.16.1			Tetrahydrobiopterin (sapropterin)	DB00360	ECO:0000352	"P407S
A373T
R241C"	The serum Phe concentrations of patients have those mutaions never exceeded 20 mg/dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub	"Homozygotes of R252W 
Homozygotes of IVS4-1G→A 
Homozygotes of R413P"	Homozygotes of R252W, IVS4-1G→A, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub	Direct interaction	A	activity modification of a genetically defective protein		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/20971365	https://www.ncbi.nlm.nih.gov/pubmed/19323589	https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1	https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub							
									Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/16319949	https://www.ncbi.nlm.nih.gov/pubmed/18362925									
									Phenylalanine ammonia lyase	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/16165390	https://www.ncbi.nlm.nih.gov/pubmed/29941359	https://www.ncbi.nlm.nih.gov/pubmed/25151978	https://www.ncbi.nlm.nih.gov/pubmed/10051643/	https://www.ncbi.nlm.nih.gov/pubmed/10051643/	https://www.ncbi.nlm.nih.gov/pubmed/7071414/					
																				Increased phenylalanine concentration in brain tissue		HP:0500223											
								Only PEGylated Anabaena variabilis (Av) PAL-treated mice demonstrated sustained low Phe levels with weekly injection and was the only PAL evaluated that maintained full enzymatic activity upon PEGylation.	Pegylated recombinant phenylalanine ammonia lyase	NA	ECO:0000179/ECO:0007121					Direct interaction	A	direct complementation of a genetically defective protein		Hyperphenylalaninemia		HP:0004923	https://www.ncbi.nlm.nih.gov/pubmed/28282402	https://www.ncbi.nlm.nih.gov/pubmed/21803624	https://www.ncbi.nlm.nih.gov/pubmed/19095795/	https://clinicaltrials.gov/ct2/show/NCT00634660	https://clinicaltrials.gov/ct2/show/NCT00924703	https://clinicaltrials.gov/ct2/show/NCT01212744					
																																	
34	# 261600	HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED		PAH	PHENYLALANINE HYDROXYLASE	1.14.16.1			Tetrahydrobiopterin	DB00360	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Hyperphenylalaninemia		HP:0004923											
									Pegvaliase	DB12839	ECO:0007121+ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Abnormal blood Phenylalanine levels		HP:0004923	https://www.sciencedirect.com/science/article/pii/S1096719218300210	https://www.sciencedirect.com/science/article/pii/S1525001605000845	https://www.pnas.org/content/96/5/2339.short	https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4	https://www.sciencedirect.com/science/article/pii/S1096719205001733	https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117	https://www.pnas.org/content/96/5/2339.short				
35	# 520000	Maternally inherited diabetes and deafness		MT-TL1/MT-TE/MT-TK	tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL	NA			Coenzyme Q10	DB09270	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Muscle weakness		HP:0001324	https://www.ncbi.nlm.nih.gov/pubmed/19323589	https://www.ncbi.nlm.nih.gov/pubmed/24746802									
								Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115	Vitamin B12+imipramine	DB00115+DB00458 	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Diabetic polyneuropathy		HP:0001271	https://www.ncbi.nlm.nih.gov/pubmed/28766015										
									Prokinetic agents	NA	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Epigastric pain 		HP:0410019	https://www.ncbi.nlm.nih.gov/pubmed/28766015										
																				Acid regurgitation		HP:0002020											
									Pregabalin	DB00230	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Neuropathic pain (Abnormality of pain sensation)*		HP:0010832*	https://www.ncbi.nlm.nih.gov/pubmed/28766015										
									Insulin	DB00030	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Diabetes	Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802	HP:0000819	https://www.ncbi.nlm.nih.gov/pubmed/28756474										
									Clonazepam	DB01068	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Involuntary movement		HP:0004305	https://www.ncbi.nlm.nih.gov/pubmed/28756475										
								The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.	Immunosuppressent +Carbonic anhydrase inhibitors	L04+S01EC	ECO:0000352					Symptomatic	C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Macular cystoid changes		HP:0008028	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/										
								The drug was administered through intravitreal injection.	Triamcinolone acetonide	DB00620	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Macular cystoid changes		HP:0011505	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/										
																				Abnormal visual acuity		HP:0030532											
																				Intraretinal cystoid spaces (Retinal disease)*		HP:0000479*											
									Non-steroidal anti-inflammatory agents	M02AA	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Intraretinal cystoid spaces (Retinal disease)*		HP:0000479*	https://www.ncbi.nlm.nih.gov/pubmed/23806424/										
									Vitamins	A11	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Malnutrition		HP:0004395											
									Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine	DB09270+A11EB+B02BA+ DB01022+DB00583	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Symptomatic+Symptomatic	C+C+C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Mitochondrial dysfunction		HP:0003287											
36	# 540000	MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS	MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000	MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2					Coenzyme Q10	DB09270	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Myopathy		HP:0003198	https://www.ncbi.nlm.nih.gov/pubmed/26823911	https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/29596118								
																				Reduced electron transport chain activity (Decreased activity of mitochondrial respiratory chain)*		HP:0008972*	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/										
									Arginine hydrochloride	DB00125	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Stroke-like episodes		HP:0002401	https://www.ncbi.nlm.nih.gov/pubmed/26954033	https://www.ncbi.nlm.nih.gov/pubmed/15728297	https://www.ncbi.nlm.nih.gov/pubmed/26095523								
																				Painful neuropathy (neuropathy)*		HP:0009830*											
																				Congestive heart failure		HP:0001635											
																				Pancreatic beta-cell dysfunction		HP:0006279											
									Nicotinamide Riboside	DB03227	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Muscle abnormality related to mitochondrial dysfunction		HP:0003800	https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2	http://ichgcp.net/clinical-trials-registry/NCT03432871									
									Sodium Pyruvate	DB00119	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Elevated serum lactate level		HP:0002151	https://www.ncbi.nlm.nih.gov/pubmed/30738201										
																				High lactate /pyruvate ratio		NA											
																				Increased lateral ventricular lactate level		NA											
																				High serum GDF15 level		NA											
									Duloxetine	DB00476	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Depression		HP:0000716	https://www.ncbi.nlm.nih.gov/pubmed/29596118										
									Taurine 	DB01956	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Oxidative stress		HP:0025464											
																				Mitochondrial dysfunction		HP:0003287											
									Idebenone	DB09081	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Decreased activity of mitochondrial ATP synthase complex		HP:0011925	https://clinicaltrials.gov/ct2/show/NCT00887562	https://www.ncbi.nlm.nih.gov/pubmed/8757046									
									Idebenone+Riboflavin	DB09081+DB00140	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Neurological abnormality		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/11382201										
																				Abnormal EEG (focal epileptiform activity)		HP:0002353											
																				Hyperintensity of cerebral white matter on MRI		HP:0030890											
																				Stroke-like attacks		HP:0002401											
									Idebenone+Coenzyme Q10	DB09081+DB09270	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Abnormal EEG		HP:0002353	https://www.sciencedirect.com/science/article/pii/0022510X89901123										
37	# 610090	PNPO deficiency 		PNPO	Pyridoxamine 5'-phosphate oxidase	1.4.3.5			Pyridoxine	DB00165	ECO:0000352	R229W				Functional interaction	B	functional complementatin of a genetically defective protein		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency										
																				Clonic contractions	There was partial improvement then patients died	MP:0003996											
																				Lip-smacking automatisms (Epilepsy)*		HP:0001250											
																																	
																																	
																																	
																																	
																																	
									Pyridoxal phosphate	DB00114	ECO:0000352					Functional interaction	B	metabolite replacement		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/12747882										
																				Developmental delay		HP:0001263											
																																	
									Phenobarbitone	DB01174	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Seizures		HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
38	# 613839	Megaloblastic anemia due to dihydrofolate reductase deficiency 		DHFR	Dihydrofolate reductase	1.5.1.3			Folinic acid	DB00650	ECO:0000352					Functional interaction	B	metabolite replacement		Low total RBC folate level		HP:0040087	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
																				Bone marrow megaloblastic changes		HP:0001980	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
																				Low 5-MTHF level		HP:0012446	https://www.ncbi.nlm.nih.gov/pubmed/21310277	https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract									
																				Abscent 5-MTHF (Abnormal CSF metabolite level)*		HP:0025454*	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
																				Abnormal CSF folate level		HP:0012446	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
																				Megaloblastic anemia		HP:0001889	https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract										
																																	
																																	
									Hydroxycobalamin+Folic acid	DB00200+DB00158	ECO:0000352					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Abnormal hemoglobin level		HP:0025546	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
																				Abnormal MCV level		HP:0025065											
									Phenobarbitone+levetiracetam	DB01174+DB01202 	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Seizure	Partial improvement in seizures on this regimen	HP:0001250	https://www.ncbi.nlm.nih.gov/pubmed/21310277										
39	# 309400	Menkes disease		ATP7A	Copper-transporting ATPase 1	7.2.2.8		"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011"	Copper Histidine	PubChem CID: 151722	ECO:0000352/ECO:0007121	G666R		2757delAG	We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/	Functional interaction	B	functional complementation of a genetically defective protein		Abnormal brain electrical activity		HP:0002353	https://www.ncbi.nlm.nih.gov/pubmed/20652413/	https://www.ncbi.nlm.nih.gov/pubmed/10401004/	https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1	https://www.ncbi.nlm.nih.gov/pubmed/16786254							
												N1304S		Del ex20–23						Seizures		HP:0001250			https://www.ncbi.nlm.nih.gov/pubmed/18256395								
												IVS9,DS,+6T→G		Q1385X						Neurological abnormalities.		HP:0000707			https://www.ncbi.nlm.nih.gov/pubmed/30384011	https://www.ncbi.nlm.nih.gov/pubmed/9511979							
																				Neurologic burden		HP:0002344	https://clinicaltrials.gov/ct2/show/results/NCT00001262										
																				Rapid disease progression		HP:0003678	https://www.ncbi.nlm.nih.gov/pubmed/30384011										
																				Eplieptic discharge (Interictal EEG abnormality)*		HP:0025373	https://www.ncbi.nlm.nih.gov/pubmed/8223785										
																				Low muscular tone		HP:0001290											
																				Appendicular hyoptonia		HP:0012389	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/										
																				Socio-cognitive abnormality (Neurodevelopmental abnormality)*		HP:0012759*											
																				Poor weight gain		HP:0001508											
																				Woolly hair		HP:0002224											
																				Hypopigmented skin		HP:0001010											
								However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.	Thiuram + (Copper Dimethyldithiocarbamate (Cu-DMDTC ))	DB13245+PubChem CID:472181	ECO:0000179					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Low Brain Copper (Abnormal copper levels)*		HP:0010836*	https://www.ncbi.nlm.nih.gov/pubmed/22815746	https://www.ncbi.nlm.nih.gov/pubmed/30384011									
																				Copper accumulation in kidney (Abnormal copper levels)*		HP:0010836*											
									Copper nitrilotriacetate (Cu-NTA)	PubChem CID: 56840862 	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Low survival rate (Mortality)*		HP:0040006*	https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism										
								Due to its strong copper chelation capability, a copper salt should be added simultaneously	Alpha-lipoic acid	DB00166	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Copper storage abnormalities (Copper storage abnormalities)*		HP:0010836*	https://www.ncbi.nlm.nih.gov/pubmed/30384011	https://www.sciencedirect.com/science/article/abs/pii/088789949190052M									
								Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521	Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Low life span (Mortality)*		HP:0040006*	https://www.ncbi.nlm.nih.gov/pubmed/30127521	https://www.ncbi.nlm.nih.gov/pubmed/31160463									
									Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine	NA	ECO:0000179					Direct interaction+Functional interaction	A+B	combination therapeutic procedure+direct complementation of a genetically defective protein+functional complementation of a genetically defective protein		Low brain copper levels (Abnormal copper levels)*		HP:0010836*	https://www.ncbi.nlm.nih.gov/pubmed/30090842										
																				Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*		HP:0012535*											
																				Abnormal growth		HP:0001507											
																				Brain mitochondrial abnormalities (Mitochondrial dysfunction)		HP:0003287*											
																				Behavioral abnormality		HP:0000708											
																				Neurological abnormalties		HP:0000707											
41	# 250850	Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent	"Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891
The incorrect administration of pyridoxine in MAT I/III deficiency reduces methionine levels in the blood and brain by activating CBS, which in turn reduces SAMe in the brain and worsens neurological symptoms. https://www.ncbi.nlm.nih.gov/pubmed/30389272"	MAT1A	S-adenosylmethionine synthase isoform type-1	2.5.1.6			S-adenosylmethionine	DB00118	ECO:0000352					Functional interaction	B	metabolite replacement		Poor appetite	Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	HP:0004396	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Low IQ		HP:0001249	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025								
																				Behavioural abnormalities		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Abnormal Awake EEG 		HP:0002353	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025								
																				Delayed mylination		HP:0012449	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Hyperreflexia		HP:0001347	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Irritability		HP:0000737	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Foot clouns		HP:0011448	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Poor weight gain		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Delayed motor milestone		HP:0001270	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Neurodevelopmental abnormalities		HP:0012759	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Brain demylination		HP:0007266	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025	https://www.ncbi.nlm.nih.gov/pubmed/19585268	https://www.sciencedirect.com/science/article/pii/014067369192373A								
									Valproic acid	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Myoclonic epilepsy		HP:0002123	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/										
42	# 250850	Persistent Hypermethioninemia		MAT1A	S-adenosylmethionine synthase isoform type-1	2.5.1.6			S-adenosylmethionine	DB00118	ECO:0000352					Functional interaction	B	metabolite replacement		Poor appetite	Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	HP:0004396	https://www.ncbi.nlm.nih.gov/pubmed/27671891	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Low IQ		HP:0001249	https://www.ncbi.nlm.nih.gov/pubmed/27671892	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025								
																				Behavioural abnormalities		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/27671893	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Abnormal Awake EEG 		HP:0002353	https://www.ncbi.nlm.nih.gov/pubmed/27671894	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025								
																				Delayed development		HP:0001263	https://www.ncbi.nlm.nih.gov/pubmed/27671895	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/27671896	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/									
																				Hyperreflexia		HP:0001347	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Irritability		HP:0000737	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Foot clouns		HP:0011448	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Poor muscle tone		HP:0001290	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Poor weight gain		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Delayed motor milestone		HP:0001270	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Neurodevelopmental abnormality		HP:0012759	https://www.ncbi.nlm.nih.gov/pubmed/30389272										
																				Brain demylination		HP:0007266	https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025	https://www.ncbi.nlm.nih.gov/pubmed/19585268	https://www.sciencedirect.com/science/article/pii/014067369192373A								
									Valproic acid	DB00313	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Myoclonic epilepsy		HP:0002123	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/										
43	# 277400	METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE		MMACHC	Methylmalonic aciduria and homocystinuria type C protein	Q9Y4U1		"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels"	Hydroxicobalamin+betaine+Folinic acid	DB00200+DB06756+DB00650	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Haemolysis		HP:0001878	https://www.ncbi.nlm.nih.gov/pubmed/24210589	https://www.ncbi.nlm.nih.gov/pubmed/26369474	https://www.ncbi.nlm.nih.gov/pubmed/3950820/								
																				Elevated total plasma homocysteine		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/24210590	https://www.ncbi.nlm.nih.gov/pubmed/26369474	https://www.ncbi.nlm.nih.gov/pubmed/3950820/	https://www.ncbi.nlm.nih.gov/pubmed/9266389		https://www.ncbi.nlm.nih.gov/pubmed/19821145					
																				High urine methylmalonic acid level 		HP:0012120	https://www.ncbi.nlm.nih.gov/pubmed/19821145										
																				Impaired renal function		HP:0012211	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/										
																				Decreased glomerular filtration rate		HP:0012213	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/										
																				Fatigue		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/3950820/										
																				Anorexia		HP:0002039	https://www.ncbi.nlm.nih.gov/pubmed/3950820/										
																				Delirium 		HP:0031258	https://www.ncbi.nlm.nih.gov/pubmed/3950820/										
																				Spasticity		HP:0001257	https://www.ncbi.nlm.nih.gov/pubmed/3950820/										
																				Lower limb hyperreflexia		HP:0002395	https://www.ncbi.nlm.nih.gov/pubmed/3950820/										
								All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)	Hydroxicobalamin+betaine+Folinic acid+Vitamin B complex	DB00200+DB06756+DB00650+A11EA	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		Psychiatric disturbances		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/30863077										
																				Lower extremity weakness		HP:0007340	https://www.ncbi.nlm.nih.gov/pubmed/30863077										
																				Gait instability		HP:0002317	https://www.ncbi.nlm.nih.gov/pubmed/30863077										
																																	
								Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/	Hydroxicobalamin+betaine+carnitine	DB00200+DB06756+DB00583	ECO:0000352					Functional interaction+Functional interaction+Functional interaction	B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High urine methylmalonic acid level 		HP:0012120	https://www.google.com/search?client=safari&rls=en&q=Clinical+heterogeneity+and+prognosis+in+combined+methylmalonic+aciduria+and+homocystinuria+(cblC&ie=UTF-8&oe=UTF-8	https://www.ncbi.nlm.nih.gov/pubmed/25511120									
																				Elevated total plasma homocysteine		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/9266389	https://www.ncbi.nlm.nih.gov/pubmed/25511120									
																				High urine methylmalonic acid level 		HP:0012120	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Abnormal brain stem auditory evoked potentials		HP:0006958	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Abnormal visual evoked potentials		HP:0000649	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Mental impairment		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Emotional lability		HP:0000712	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Psychiatric disturbances		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Difficulty walking		HP:0002355	https://www.ncbi.nlm.nih.gov/pubmed/2873525/										
																				Dementia		HP:0000726	https://www.ncbi.nlm.nih.gov/pubmed/17431913										
																																	
									Hydroxicobalamin	DB00200	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Megaloblastic anemia		HP:0001889	https://www.ncbi.nlm.nih.gov/pubmed/7357085/	https://www.ncbi.nlm.nih.gov/pubmed/17431913									
																				Methylmalonic aciduria		HP:0012120	https://www.ncbi.nlm.nih.gov/pubmed/7357085/	https://www.ncbi.nlm.nih.gov/pubmed/17431913									
																				Elevated blood homocystine		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/19821145										
																				Dementia		HP:0000726	https://www.ncbi.nlm.nih.gov/pubmed/6749192/	https://www.ncbi.nlm.nih.gov/pubmed/25511120									
																				Myelopathy		HP:0002196	https://www.ncbi.nlm.nih.gov/pubmed/6749192/										
																				Gait instability		HP:0002317	https://www.ncbi.nlm.nih.gov/pubmed/17431913										
									Coumadin	DB00682	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Deep venous thrombosis		HP:0002625	https://www.ncbi.nlm.nih.gov/pubmed/11320193/										
									Fluoxetine	DB00472	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Emotional lability		HP:0000712	https://www.ncbi.nlm.nih.gov/pubmed/25511120										
																				Poor eye contact		HP:0000817	https://www.ncbi.nlm.nih.gov/pubmed/25511120										
									Lorazepam	DB00186	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Abnormal mental status		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/25511120										
								The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120	Zonisamide	DB00909	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Sleep cycle disturbance		HP:0002360	https://www.ncbi.nlm.nih.gov/pubmed/25511120										
								"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120"	Methylprednisolone sodium succinate+Immune Globulin 	DB14644+DB00028	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Autoimmune encephalopathy(Encephalopathy)*/(Autoimmune disorder)*	"Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120"	HP:0001298*/HP:0002960*	https://www.ncbi.nlm.nih.gov/pubmed/25511120										
									Risperidone	DB00734	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Psychiatric disturbance		HP:0000708	https://www.ncbi.nlm.nih.gov/pubmed/17431913										
									Hydroxicobalamin+betaine+Folinic acid+carnitine	DB00200+DB06756+DB00650+DB00583	ECO:0000352					Functional interaction+Functional interaction+Functional interaction+Functional interaction	B+B+B+B	combination therapeutic procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein		High urine methylmalonic acid level 		HP:0012120	https://www.ncbi.nlm.nih.gov/pubmed/18848477										
																				Elevated total plasma homocysteine		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/18848477										
									Vatiquinone (Epi-743)	DB11917	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/	https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1									
																																	
																																	
																																	
																																	
44	# 277410	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;		MMADHC	Methylmalonic aciduria and homocystinuria type D protein, mitochondrial	Q9H3L0																											
45	# 250940	Methylcobalamin deficiency cbl G type 		MTR	Methionine synthase	2.1.1.13			Eculizumab	DB01257	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Microhematuria		HP:0002907	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Microalbuminura		HP:0012594	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Anemia		HP:0001903	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Thrombocytopenia		HP:0001873	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Thrombotic microangiopathy		NA	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
									Hydroxicobalamin	DB00200	ECO:0000352					Direct interaction	A	activity modification of a genetically defective protein		Elevated plasma homocysteine concentration		HP:0002160	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Megaloblastic anemia		HP:0001889	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Thrombocytopenia		HP:0001873	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Granulocytopenia		HP:0001913	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Microhematuria		HP:0002907	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Neurological abnormality		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																				Developmental delay		HP:0001263	https://www.ncbi.nlm.nih.gov/pubmed/28210839										
																																	
																																	
46	# 236270	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE		MTRR	Methionine synthase reductase	1.16.1.8			Hydroxycobalamin+Betaine+Folate	DB00200+DB06756+DB00158	ECO:0000352					Functional interaction	B+C+C	combination therapeutic procedure+functional complementation of a genetically defective protein+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Macrocytic anemia		HP:0001972	https://www.ncbi.nlm.nih.gov/pubmed/25978498	https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract									
																				Neurological impairment		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/25978498										
																				Low heamoglobin level		HP:0001903											
																				Increased mean corpuscular volume 		HP:0005518	https://www.ncbi.nlm.nih.gov/pubmed/25978498										
																				Decreased methionine level		MP:0030642	https://www.ncbi.nlm.nih.gov/pubmed/25978498										
																				Hyperhomocysteinemia	Slight improvement 	NA	https://www.ncbi.nlm.nih.gov/pubmed/18050048?dopt=Abstract										
	# 157640	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1		POLG	DNA polymerase subunit gamma-1	2.7.7.7			Levodopa	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Limb dystonia		HP:0001332	https://www.ncbi.nlm.nih.gov/pubmed/30838265										
																				Axial dystonia		HP:0002530	https://www.ncbi.nlm.nih.gov/pubmed/30838265										
																				Gait abnormality		HP:0001288	https://www.ncbi.nlm.nih.gov/pubmed/30838265										
																				Parkinsonism		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/24943079										
																				Tremor		HP:0001337	https://www.ncbi.nlm.nih.gov/pubmed/30941926										
																				Rigidity		HP:0002063	https://www.ncbi.nlm.nih.gov/pubmed/30941926										
																				Bradykinesia		HP:0002067	https://www.ncbi.nlm.nih.gov/pubmed/30941926										
	# 610131	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4		POLG2	DNA polymerase subunit gamma-2, mitochondrial	2.7.7.7		The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract	Phenytoin+oxcarbazepine+levetiracetam	DB00252+DB00776+ DB01202  	ECO:0000352					Symptomatic+Symptomatic+Symptomatic	C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Mitochondrial epilepsy (Epilepsy)*		HP:0001250*	https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract										
																																	
									Coenzyme Q10	DB09270						Symptomatic	C	symptomatic therapeutic procedure		Mitochondrial myopathy		HP:0003737	https://www.ncbi.nlm.nih.gov/pubmed/27442316										
																				Low energy level		HP:0003473											
									Prednisone	DB00635 						Symptomatic	C	symptomatic therapeutic procedure		Inflammatory myopathy		HP:0009071	https://www.ncbi.nlm.nih.gov/pubmed/25674260										
																				Dysphagia		HP:0002015											
																																	
																				Neck muscle weakness		HP:0000467											
																																	
																				Dysarthria		HP:0001260											
																																	
																																	
																																	
	# 258450	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1		POLG	DNA polymerase subunit gamma-2	2.7.7.7		Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260	Levodopa	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Parkinsonism		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/12872260										
	# 609283	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2		SLC25A4	ADP/ATP translocase 1	P12235																											
	# 616479	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2		RNASEH1	Ribonuclease H1	3.1.26.4			No treatment is available in DDIEM																								
	# 609286	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3		TWNK	Twinkle protein, mitochondrial	3.6.4.12		Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260	Levodopa	DB01235	ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		Parkinsonism		HP:0001300	https://www.ncbi.nlm.nih.gov/pubmed/24076137	https://www.ncbi.nlm.nih.gov/pubmed/12872260									
	# 617069	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3		TK2	Thymidine kinase 2, mitochondrial	2.7.1.21																											
																																	
	# 617070	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4		DGUOK	Deoxyguanosine kinase, mitochondrial	2.7.1.113																											
	# 613077	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5		RRM2B	Ribonucleoside-diphosphate reductase subunit M2 B	1.17.4.1																											
	# 618098	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5		TOP3A	DNA topoisomerase 3-alpha	5.6.2.2																											
	# 615156	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6		DNA2	DNA replication ATP-dependent helicase/nuclease DNA2	3.6.4.12/3.1.-.-			Vitamin E+L-carnitine+Dichloroacetate+Creatine	DB00163+DB00583+DB08809+DB00148  	ECO:0000352					Symptomatic+Symptomatic+Symptomatic+Symptomatic	C+C+C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Difficulty walking		HP:0002355	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/										
	# 229300	Friedreich Ataxia		FXN	Frataxin, mitochondrial	1.16.3.1		"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044
"	Idebenone	DB09081	ECO:0007121/ECO:0000352					Symptomatic	C	symptomatic therapeutic procedure		High left ventricular mass index ( Left ventricular hypertrophy)*		HP:0001712*	https://www.ncbi.nlm.nih.gov/pubmed/11907009	https://www.ncbi.nlm.nih.gov/pubmed/12771264	https://www.ncbi.nlm.nih.gov/pubmed/12069112	https://www.ncbi.nlm.nih.gov/pubmed/12771265	https://www.ncbi.nlm.nih.gov/pubmed/18234531						
																				Cardiomyopathy progression (Progressive)*		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/18234531										
																				Progressive neurologic deterioration		HP:0002344											
																				Interventricular septal thickning (Ventricular septum abnormality)*		HP:0010438*	https://www.ncbi.nlm.nih.gov/pubmed/12771264										
																				Neurological abnormality	Another study has an opposing results https://www.ncbi.nlm.nih.gov/pubmed/20697044	HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/17826341	https://www.ncbi.nlm.nih.gov/pubmed/12368988									
																				Cerebellar dysfunction		NA	https://www.ncbi.nlm.nih.gov/pubmed/12368988										
																				"Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)
"		HP:0000570	https://www.ncbi.nlm.nih.gov/pubmed/12368988										
																				Nystagmus		HP:0000639	https://www.ncbi.nlm.nih.gov/pubmed/12368988										
																				Ataxia		HP:0001251											
																				Disease progression (Rapid progression)* 		HP:0003678	https://www.ncbi.nlm.nih.gov/pubmed/18234531										
									Recombinant human erythropoietin (rhuEPO)	DB00016	ECO:0001565/ECO:0007121					Functional interaction	B	activity modification of a genetically defective protein by transcriptional or translational modification		Low Frataxin expression level		NA	https://www.ncbi.nlm.nih.gov/pubmed/16269021?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/21597884/	https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract							
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract									
																				High urinary 8-hydroxydeoxyguanosine level (Abnormality of DNA repair)*		HP:0003254	https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract										
																				Neurological impairment 		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract										
																				Tiredness		HP:0012378	https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract										
																				High ferritin level		HP:0003281	https://www.ncbi.nlm.nih.gov/pubmed/21597884/										
																				Low NADH/NAD ratio (Mitochondrial dysfunction)		HP:0003287	https://www.ncbi.nlm.nih.gov/pubmed/21597884/										
									Rosuvastatin	DB01098	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Decreased apolipoprotein AI level HP:0031799		HP:0031799	https://clinicaltrials.gov/ct2/show/NCT02705547										
									Simvastatin	DB00641	ECO:0001565					Symptomatic	C	symptomatic therapeutic procedure		Decreased apolipoprotein AI level HP:0031800		HP:0031799	https://www.ncbi.nlm.nih.gov/pubmed/29447225										
									Vatiquinone (EPI-743)	DB11917	ECO:0007121/ECO:0000352/ECO:0000179					Symptomatic	C	symptomatic therapeutic procedure		Balber coordination abnormalities (Bulbar signs )*		HP:0002483	https://clinicaltrials.gov/ct2/show/NCT01728064	https://clinicaltrials.gov/ct2/show/NCT01962363	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=	https://www.ncbi.nlm.nih.gov/pubmed/30051753	https://www.ncbi.nlm.nih.gov/pubmed/31417369	https://www.ncbi.nlm.nih.gov/pubmed/31640150					
																				Upper limb coordination (Poor motor coordination)*		HP:0002275	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=EPI-743+for+Friedreichs+Ataxia+Patients+with+Point+Mutations+%28P5.388%29&btnG=										
																							https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Emerging+therapeutics+for+the+treatment+of+Friedreich%E2%80%99s+ataxia&btnG=										
									α-tocopheryl quinone	DB14094	ECO:0007121					Symptomatic	C	symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://clinicaltrials.gov/ct2/show/NCT01035671	https://www.ncbi.nlm.nih.gov/pubmed/22744651	https://www.ncbi.nlm.nih.gov/pubmed/21600768								
								low dose regimen is as effective as the high dose.	CoQ10+Vitamin E	DB09270+DB00163	ECO:00007121					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Mitochondrial dysfunction		HP:0008972	https://www.ncbi.nlm.nih.gov/pubmed/19049556	https://www.ncbi.nlm.nih.gov/pubmed/11357949?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract								
																				Disease progression (Progressive)*		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/19049556									
																				Low cardiac function (Abnormal cardiac ventricular function)*		HP:0030872	https://www.ncbi.nlm.nih.gov/pubmed/15824263?dopt=Abstract										
								Although some improvemant in pediatric patients in this trial, the study is considered to be an overall negative study. 	Methylprednisolone	DB00959	ECO:0007121					Symptomatic/Functional interaction? (Symptomatic)	C/B (C)	symptomatic therapeutic procedure 		Fatigue		HP:0012378	https://www.clinicaltrials.gov/ct2/show/NCT02424435	https://www.ncbi.nlm.nih.gov/pubmed/31206761	https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract								
																				Gait disturbance	Mild imprvement,eventual progresssion	HP:0001288	https://www.clinicaltrials.gov/ct2/show/NCT02424435	https://www.ncbi.nlm.nih.gov/pubmed/31206761									
																				Poor speech		HP:0002466											
									N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide	PubChem CID:56654642  	ECO:0001565/ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein by epigenetic manipulation		Low frataxin level		NA	https://www.ncbi.nlm.nih.gov/pubmed/20098685	https://www.ncbi.nlm.nih.gov/pubmed/25159818	https://www.ncbi.nlm.nih.gov/pubmed/25798128								
									Prednisone+Medrol	DB00635+DB00959	ECO:0000352					Symptomatic	C/B (C)	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure	One patient	Gait disturbance	Mild imprvement,eventual progresssion	HP:0001288	https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract									
									Prednisone	DB00635	ECO:0000352					Symptomatic	C/B (C)	symptomatic therapeutic procedure	Two patient have used the treatment	Gait disturbance		HP:0001288	https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract									
																				Postural instability 	Eventual progression later on.	HP:0002172	https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract										
									Prednisolone	DB00860	ECO:0000352					Symptomatic	C/B (C)	symptomatic therapeutic procedure	Two patients 	Gait disturbance		HP:0001288	https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract									
																				Fatigue		HP:0012378											
																				Falls		HP:0002527											
									Solumedrol	DB14644	ECO:0000352					Symptomatic	C/B (C)	symptomatic therapeutic procedure		Postural instability 	Eventual progression later on.	HP:0002172	https://www.ncbi.nlm.nih.gov/pubmed/22752494?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/26755195?dopt=Abstract									
									Darbepoetin alfa+ idebenone+riboflavin	DB00012+DB09081+DB00140	ECO:00007121					Direct interaction+Symptomatic+Symptomatic	A+C+C	combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Ataxia		HP:0001251	https://www.ncbi.nlm.nih.gov/pubmed/23625326/										
																				Disease progression (Progressive neurologic deterioration)*		HP:0002344											
								In one randomized controlled study, Erythropiotin didn't show any effect on frataxin. https://www.ncbi.nlm.nih.gov/pubmed/22411849/	Erythropoietin	DB00016	ECO:0001565/ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/23859343	https://www.ncbi.nlm.nih.gov/pubmed/31105516	https://www.ncbi.nlm.nih.gov/pubmed/17702040/	https://www.ncbi.nlm.nih.gov/pubmed/18759345	https://www.ncbi.nlm.nih.gov/pubmed/21506154						
									Omaveloxolone (RTA 408)	DB12513	ECO:0001565/ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein by stimulation		Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/30065630	https://clinicaltrials.gov/ct2/show/NCT02255435									
																				Decreased activity of mitochondrial complex I		HP:0011923	https://www.ncbi.nlm.nih.gov/pubmed/30065630										
																				Impaired neurological function (Low mFARS score)		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/30656180										
																				Poor motor coordination 		HP:0002275											
									Sulforaphane	DB12422	ECO:0001565					Direct interaction	A	functional complementation of a genetically defective protein		Redox imbalance (Abnormality of redox activity)		HP:0025463	https://www.ncbi.nlm.nih.gov/pubmed/29057804	https://www.ncbi.nlm.nih.gov/pubmed/31640150	https://www.ncbi.nlm.nih.gov/pubmed/31417369								
																				Lipid peroxidation 		NA	https://www.ncbi.nlm.nih.gov/pubmed/26141703										
																				Mitochondrial imbalance (mitochondrial imbalance)*		HP:0012103	https://www.ncbi.nlm.nih.gov/pubmed/26141703										
																				Inflammation		HP:0012649	https://www.ncbi.nlm.nih.gov/pubmed/31640150										
									Resveratrol	DB02709	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Neurological deficit		HP:0000707	https://www.ncbi.nlm.nih.gov/pubmed/25845763	https://clinicaltrials.gov/ct2/show/NCT01339884	https://clinicaltrials.gov/ct2/show/NCT03933163								
																				Poor speech		HP:0002465	https://www.ncbi.nlm.nih.gov/pubmed/25845763	https://clinicaltrials.gov/ct2/show/NCT01339884									
																				Oxidative stress	There was also a trend for improvement in the SARA, but little evidence of improvement in components of the Friedreich Ataxia Composite Test	HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/25845763	https://clinicaltrials.gov/ct2/show/NCT01339884									
																				Low frataxin level (Abnormal circulating protein level)*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/23418481										
								In one case, a life threatening adverse effect was documented upon a large dose of nicotinamide admnistration for treating Friedreich ataxia.https://ejcrim.com/index.php/EJCRIM/article/view/234	Nicotinamide	DB02701	ECO:0007121/ECO:0001565/ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Frataxin deficiency (Abnormal circulating protein level)*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/24794818	https://www.ncbi.nlm.nih.gov/pubmed/24794816/	https://www.ncbi.nlm.nih.gov/pubmed/23859350/	https://www.ncbi.nlm.nih.gov/pubmed/23474817/	https://clinicaltrials.gov/ct2/show/NCT01589809						
									Interferon Gamma-1b	DB00033	ECO:0007121/ECO:0000179					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Low whole blood frataxin level(Abnormal circulating protein level)*		HP:0010876	https://clinicaltrials.gov/ct2/show/NCT01965327	https://clinicaltrials.gov/ct2/show/NCT03888664?cond=Friedreich+ataxia&draw=2&rank=9	https://clinicaltrials.gov/ct2/show/NCT02797080?cond=Friedreich+ataxia&draw=2&rank=21	https://clinicaltrials.gov/ct2/show/results/NCT02593773?cond=Friedreich+ataxia&draw=2&rank=22							
																				Disease progression (Progressive neurologic deterioration)*		HP:0002344	https://www.ncbi.nlm.nih.gov/pubmed/26634868	https://www.ncbi.nlm.nih.gov/pubmed/30911578									
																				Poor motor coordination 		HP:0002275	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Interferon+gamma+as+a+potential+therapy+for+Friedreich+ataxia&btnG=										
																				Low neuronal frataxin levels		NA	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Interferon+gamma+as+a+potential+therapy+for+Friedreich+ataxia&btnG=	https://www.ncbi.nlm.nih.gov/pubmed/22447512									
																				Sensorimotor neuropathy 		HP:0007141	https://www.ncbi.nlm.nih.gov/pubmed/22447512										
								Deferiprone ,in low concentration, does not subtract iron fromFe–S clusters and it can stimulate frataxin expression, possibly by an iron-dependent mechanism activated by a shift of iron from mitochondria into the cytosol.However;  when its concentration exceeds about 50 micrM in cultured cells, it starts to induce iron depletion rather than redistribution, with deleterious effects on Fe–S enzyme activitiesand frataxin levels. https://www.ncbi.nlm.nih.gov/pubmed/23859349	Deferiprone 	DB08826	ECO:0007121					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Excess iron in the central nervous system (Abnormal serum iron concentration)*		HP:0040130	https://www.ncbi.nlm.nih.gov/pubmed/23859349	https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10	https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13								
																				Disease progression (Progressive neurologic deterioration)*		HP:0002344		https://clinicaltrials.gov/ct2/show/NCT00897221?cond=Friedreich+ataxia&draw=6&rank=10	https://clinicaltrials.gov/ct2/show/NCT00530127?cond=Friedreich+ataxia&draw=6&rank=13								
																				Ataxic gait		HP:0002066	https://www.ncbi.nlm.nih.gov/pubmed/17379741?dopt=Abstract										
																				Neuropathy		HP:0009830	https://www.ncbi.nlm.nih.gov/pubmed/17379741?dopt=Abstract										
																				Low frataxin level (Abnormal circulating protein level)*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/23418481										
									Deferiprone+Idebenone	DB08826+DB09081	ECO:0007121					Direct interaction+Symptomatic	A+C	combination therapeutic procedure+activity modification of a genetically defective protein by transcriptional or translational modification+symptomatic therapeutic procedure	Trial was conducted on 5 patients	Ataxia		HP:0001251	https://www.ncbi.nlm.nih.gov/pubmed/27029487	https://clinicaltrials.gov/ct2/show/NCT00224640?cond=Friedreich+ataxia&draw=2&rank=42									
																				Cardiomyocyte hypertrophy		HP:0031319											
									RT001(11,11-di-deutero-linoleic acid ethyl ester)	NA	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Oxidative stress		HP:0025464	https://clinicaltrials.gov/ct2/show/NCT02445794?term=NCT02445794&draw=2&rank=1	https://clinicaltrials.gov/ct2/show/NCT04102501?cond=Friedreich+ataxia&draw=2&rank=12	https://www.ncbi.nlm.nih.gov/pubmed/29624723	https://clinicaltrials.gov/ct2/show/NCT04102501							
									Acetyl-L-Carnitine 	DB08842	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Incoordination		HP:0002311	https://clinicaltrials.gov/ct2/show/NCT01921868										
									Levocarnitine	DB00583	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein		Impaired oxidative phosphorylation	Mild improvement	NA	https://www.ncbi.nlm.nih.gov/pubmed/15480852										
									Dimethyl fumarate	DB08908	ECO:0001565					Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Low frataxin level (Abnormal circulating protein level)*		HP:0010876	https://www.ncbi.nlm.nih.gov/pubmed/31158268	https://www.ncbi.nlm.nih.gov/pubmed/29057804									
																																	
																																	
																																	
																																	
																																	
	#201910	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY		CYP21A2				Single treatment with an adeno-associated viral vector expressing a functional copy of the mutated gene can only transiently treat adrenocortical hereditary disorders	AAVrh.10-21OH-HA	NA	ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		Low 21-hydroxylase enzyme activity (Abnormal enzyme/coenzyme activity)*	Transient improvement	HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/29316814										
																				Abnormal steroidgenesis profile (Decreased circulating cortisol level)	Transient improvement	HP:0008163											
																				Abnormal steroidgenesis profile (Decreased circulating cortisol level)		HP:0008163											
								Extra-adrenal induction of Cyp21a1	adeno-associated viral vector containing Cyp21a1	NA	ECO:0001565/ECO:0000179					Direct interaction	A	direct complementation of a genetically defective protein by gene therapy		High progesteron/deoxycorticosterone ratio		NA	https://www.ncbi.nlm.nih.gov/pubmed/27432820										
									Abiraterone acetate+Prednisolone        	DB05812+DB00860	ECO:0007121					Functional interaction+Functional interaction	B+B	combination therapeutic procedure+functional complementation of a genetically defective protein by inhibition+functional complementation of a genetically defective protein		Increased circulating androgen level		HP:0030348	https://www.ncbi.nlm.nih.gov/pubmed/24780050	https://clinicaltrials.gov/ct2/show/NCT02574910	https://clinicaltrials.gov/ct2/show/NCT03548246								
																																	
																																	
																																	
																																	
									Carbenoxolone	DB02329	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		Elevated plasma 17-hydroxyprogesterone		HP:0031213	https://www.ncbi.nlm.nih.gov/pubmed/10469007										
																				Increased renin activity		HP:0000841											
																				High TRH-stimulated TSH levels		HP:0002925											
	# 264300	17-beta hydroxysteroid dehydrogenase 3 deficiency		HSD17B3					No treatment is available in DDIEM																								
	#203400	18 Hydroxylase deficiency		CYP11B2					Fludrocortisone	DB00687	ECO:0000352					Functional interaction	B	metabolite replacement		Hyponatremia		HP:0002902	https://www.ncbi.nlm.nih.gov/pubmed/29201470	https://www.ncbi.nlm.nih.gov/pubmed/11174838/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/	https://www.ncbi.nlm.nih.gov/pubmed/22931312	https://www.ncbi.nlm.nih.gov/pubmed/31302112	https://www.ncbi.nlm.nih.gov/pubmed/26936515	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Aldosterone+synthase+deficiency+due+to+a+novel+mutation+in+CYP11B2&btnG=	https://www.ncbi.nlm.nih.gov/pubmed/30864636	https://www.ncbi.nlm.nih.gov/pubmed/11701710	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=	
																				Hyperkalemia		HP:0002153	https://www.ncbi.nlm.nih.gov/pubmed/29201471	https://www.ncbi.nlm.nih.gov/pubmed/26936515	https://www.ncbi.nlm.nih.gov/pubmed/30864636	https://www.ncbi.nlm.nih.gov/pubmed/11701710	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=						
																				Failure to thrive		HP:0001508	https://www.ncbi.nlm.nih.gov/pubmed/29201470	https://www.ncbi.nlm.nih.gov/pubmed/24694176	https://www.ncbi.nlm.nih.gov/pubmed/31302112	https://www.ncbi.nlm.nih.gov/pubmed/26936515	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=						
									NaCl	DB09153	ECO:0000352					Functional interaction	B	metabolite replacement		Hyponatremia		HP:0002902	https://www.ncbi.nlm.nih.gov/pubmed/29201470	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550606/	https://www.ncbi.nlm.nih.gov/pubmed/30864636	https://www.ncbi.nlm.nih.gov/pubmed/26936516	https://www.ncbi.nlm.nih.gov/pubmed/11701710	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Polydipsia%2C+Hyponatremia+and+a+Biochemical+Profile+of+Aldosterone+Synthase+Deficiency&btnG=					
																																	
																																	
																																	
	# 607906	ALG2-CDG (CDG-Ii)		ALG2					No treatment is available in DDIEM																								
	# 601110	ALG3-CDG (CDG-Id)		ALG3					No treatment is available in DDIEM																								
	# 603147	ALG6-CDG (CDG-Ic)		ALG6					No treatment is available in DDIEM																								
	# 608104	ALG8-CDG (CDG-Ih)		ALG8					No treatment is available in DDIEM																								
	# 608776	ALG9-CDG (CDG-IL)		ALG9					No treatment is available in DDIEM																								
	# 613489	COG4-CDG (CDG-IIj)		COG4					No treatment is available in DDIEM																								
	# 613612	COG5-CDG (CDG-IIi)		COG5					No treatment is available in DDIEM																								
	# 608779	COG7-CDG (CDG-IIe)		COG7					No treatment is available in DDIEM																								
	# 611182	COG8-CDG (CDG-IIh)		COG8					No treatment is available in DDIEM																								
	# 264800	PSEUDOXANTHOMA ELASTICUM; PXE		ABCC6					Magnesium phosphate	DB13862	ECO:0000179/ECO:0001565					Functional interaction	B	functional complementation of a genetically defective protein		Ectopic mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*		HP:0003549	https://www.ncbi.nlm.nih.gov/pubmed/19122649/	https://www.ncbi.nlm.nih.gov/pubmed/21671388	https://www.ncbi.nlm.nih.gov/pubmed/22897576/	https://www.ncbi.nlm.nih.gov/pubmed/24330694/	https://www.ncbi.nlm.nih.gov/pubmed/25383264/						
									Magnesium Oxide	DB01377	ECO:0007121/ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Calcium mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*		HP:0003549	https://clinicaltrials.gov/ct2/show/NCT01525875	https://www.ncbi.nlm.nih.gov/pubmed/30826287									
																				Vascular calcification		HP:0004934	https://www.ncbi.nlm.nih.gov/pubmed/20177653/										
									Magnesium carbonate	DB09481	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Ectopic mineralization of connective tissues (Abnormality of connective tissue HP:0003549)*		HP:0003549	https://www.ncbi.nlm.nih.gov/pubmed/20443931/	https://www.ncbi.nlm.nih.gov/pubmed/22897576/	https://www.ncbi.nlm.nih.gov/pubmed/24330694/	https://www.ncbi.nlm.nih.gov/pubmed/25383264/							
									Aluminium hydroxide	DB06723	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Skin abnormalities (Abnormal cutaneous elastic fiber morphology)*		HP:0025082	https://www.ncbi.nlm.nih.gov/pubmed/16198780/										
																				Redundant skin folds		HP:0001582											
																				Vascular claudication (Intermittent claudication)*		HP:0004417											
								Study shows limitations.	Sevelamer hydrochloride	DB00658	ECO:0007121					Functional interaction	B	functional complementation of a genetically defective protein					https://www.ncbi.nlm.nih.gov/pubmed/21496949/										
									pLive-LacZ or pLive-Fetuin-A vector	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Connective tissue mineralisation (Abnormality of connective tissue HP:0003549)*		HP:0003549	https://www.ncbi.nlm.nih.gov/pubmed/20090764/										
									Sodium 4-phenylbutyrate	DB06819	ECO:0001565/ECO:0000179/ECO:0007764	R1114P, S1121W, Q1347H, and R1314W				Direct interaction	A	activity modification of a genetically defective protein		Abnormal substantial transport activity		NA	https://www.ncbi.nlm.nih.gov/pubmed/24352041/	https://www.ncbi.nlm.nih.gov/pubmed/21671388	https://www.ncbi.nlm.nih.gov/pubmed/17890229/								
									PTC124	DB05016	ECO:0001565	p.R1141X,	The drug has the ability to facilitate read-through of nonsense mutations.			Direct interaction	A	activity modification of a genetically defective protein by transcriptional or translational modification		Premature Termination Codon Read-Through of ABCC6		NA	https://www.ncbi.nlm.nih.gov/pubmed/23702584/										
									Bevacizumab	DB00112	ECO:0000352					Functional interaction	B	functional complementation of a genetically defective protein		Reduced visual acuity		HP:0007663	https://www.ncbi.nlm.nih.gov/pubmed/21386758	https://www.ncbi.nlm.nih.gov/pubmed/29279654	https://clinicaltrials.gov/ct2/show/NCT00510965	https://www.ncbi.nlm.nih.gov/pubmed/20703035/							
																				Subfoveal choroidal neovascularization 		HP:0031241	https://www.ncbi.nlm.nih.gov/pubmed/19205505	https://www.ncbi.nlm.nih.gov/pubmed/19996818/	https://www.ncbi.nlm.nih.gov/pubmed/20703035/								
																				Subretinal fluid		HP:0031526	https://www.ncbi.nlm.nih.gov/pubmed/24325973										
																				Hyper-reflective retinal structure (Abnormal retinal vascular morphology)*		HP:0008046	https://www.ncbi.nlm.nih.gov/pubmed/24325973										
									Bisphosphonates (Etidronic acid)	DB01077	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Ectopic mineralisation of skin and aorta		NA	https://www.ncbi.nlm.nih.gov/pubmed/30414410	https://www.ncbi.nlm.nih.gov/pubmed/28701330									
																				Arterial calcification		HP:0003207	https://www.ncbi.nlm.nih.gov/pubmed/29519353										
																				Subretinal neovascularization (Retinal neovascularization)*		HP:0030666	https://www.ncbi.nlm.nih.gov/pubmed/29519353										
								The role of antioxidant therapy for PXE is unclear, and there is a need for controlled clinical trials. Regression was followed by progression during the additional 6-month period of treatment. Plus, It had no effect on ectopic mineralization process on a trial on mice.	Tocopherol acetate+ascorbic acid	DB14003+DB00126	ECO:0000352					Symptomatic+Symptomatic	C+C	combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Fragmented elastic fibers in the dermis		HP:0025167	https://www.ncbi.nlm.nih.gov/pubmed/23675997/										
																				Clumping of elastic fibers in the dermis		HP:0025165	https://www.ncbi.nlm.nih.gov/pubmed/23675997/										
																				Dermis calcification (Subcutaneous calcification)*		HP:0007618	https://www.ncbi.nlm.nih.gov/pubmed/23675997/										
																				Oxidative stress		HP:0025464	https://www.ncbi.nlm.nih.gov/pubmed/23675997/	https://www.ncbi.nlm.nih.gov/pubmed/18049453/									
									5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425)	NA	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein by inhibition		skin mineralization (Ectopic calcification )*		HP:0010766	https://www.ncbi.nlm.nih.gov/pubmed/30130617	https://www.ncbi.nlm.nih.gov/pubmed/28592560	https://www.ncbi.nlm.nih.gov/pubmed/29299451								
								Oral administration may represent a simple route to achieve therapeutic levels of the physiological, non‐toxic metabolite PPi in the blood circulation. 	Pyrophosphate	DB04160	ECO:0000179					Functional interaction	B	functional complementation of a genetically defective protein		Connective tissue calcification (Abnormality in connective tissue)*		HP:0003549	https://www.ncbi.nlm.nih.gov/pubmed/28701330										
																				Ectopic calcification 		HP:0010766	https://www.ncbi.nlm.nih.gov/pubmed/28701330										
	# 259900	Primary hyperoxaluria type 1		AGXT	Serine--pyruvate aminotransferase	2.6.1.51		The regime was accompanied by high fluid intake	Calcium oxalate crystallization inhibitors+ Pyridoxine	NA+DB00165	ECO:0000352	I244T/null						combination therapeutic procedure+symptomatic therapeutic procedure+activity modification of a genetically defective protein 		Nephrocalcinosis		HP:0000121	https://www.ncbi.nlm.nih.gov/pubmed/31905342										
																				Urolithiasis		MP:0005360	https://www.ncbi.nlm.nih.gov/pubmed/31905342										
																				Disease progression		HP:0003676	https://www.ncbi.nlm.nih.gov/pubmed/31905342										
									Pyridoxine	DB00165	ECO:0000352	 c.508 G>A = G630A (Gly170Arg), c.32 C>T = C154T (Pro11Leu), and c.454 T>A = T576A (Phe152Ile) 		33insC and Gly82Arg				activity modification of a genetically defective protein 		High urine oxalate level		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/15253729	https://www.ncbi.nlm.nih.gov/pubmed/15840016	https://www.ncbi.nlm.nih.gov/pubmed/22688746	https://scholar.google.com/scholar_lookup?title=Implications%20of%20genotype%20and%20enzyme%20phenotype%20in%20pyridoxine%20response%20of%20patients%20with%20type%20I%20primary%20hyperoxaluria&journal=Am.%20J.%20Nephrol.&volume=25&pages=183-188&publication_year=2005&author=Monico%2CCG&author=Olson%2CJB&author=Milliner%2CDS	https://www.ncbi.nlm.nih.gov/pubmed/23597595	https://www.ncbi.nlm.nih.gov/pubmed/4064559	https://www.ncbi.nlm.nih.gov/pubmed/24385516	https://www.ncbi.nlm.nih.gov/pubmed/15849466	https://www.ncbi.nlm.nih.gov/pubmed/10069180		
												 Phe152Ile and Ile244Thr	Partial effects of pyridoxine were also observed for two other common AGT mutants on the minor allele (i.e. Phe152Ile and Ile244Thr) 	Gly41Arg 	The minor allele mutant AGT containing a Gly41Arg replacement.					Abnormal kidney function		HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/9604811										
									Pyridoxine + Magnesium citrate	DB00165+DB11110	ECO:0000352							combination therapeutic procedure+activity modification of a genetically defective protein+symptomatic therapeutic procedure		High urine oxalate level		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/15961947										
									Magnesium hydroxide	DB09104	ECO:0000352							symptomatic therapeutic procedure		High urine oxalate level		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/5491877	https://www.ncbi.nlm.nih.gov/pubmed/24798559									
									Potassium citrate	DB09125	ECO:0000352							symptomatic therapeutic procedure		Abnormal renal function		HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/8476722										
																				Nephrolithiasis		HP:0000787											
									Sodium citrate	DB09154	ECO:0000352							symptomatic therapeutic procedure		Abnormal renal function		HP:0012211	https://www.ncbi.nlm.nih.gov/pubmed/15133325	https://www.ncbi.nlm.nih.gov/pubmed/8476722									
																				Renal stones 		HP:0000787											
									Orthophosphate+Pyridoxine	DB14523+DB00165  	ECO:0000352							combination therapeutic procedure+symptomatic therapeutic procedure+activity modification of a genetically defective protein 		Calcium oxalate crystalluria 		HP:0020145	https://www.ncbi.nlm.nih.gov/pubmed/7969325										
																				Progressive renal insufficiency		HP:0012622	https://www.ncbi.nlm.nih.gov/pubmed/7969325										
									Oxazyme OxDc-CLEC(Oxalate-decarboxylase)	NA 	ECO:0000179/ECO:0000269							functional complementation of a genetically defective protein by stimulation		Hyperoxaluria		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/18698135	https://clinicaltrials.gov/ct2/show/NCT01127087									
																				Nephrocalcinosis		HP:0000121											
								When the study was conducted as a clincal trial, it didn't show the promising effect it had on an animal model. Treatment with OC5 did not significantly reduce Uox or Pox. However another clinical study by Hoppe et al. 2006 showed promosing effects on reducing both Uox and Pox.	Oxalobacter formigenes	NA 	ECO:0000179/ECO:0007121							functional complementation of a genetically defective protein by stimulation		Hyperoxaluria		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/21163900	https://www.ncbi.nlm.nih.gov/pubmed/21460356	https://www.ncbi.nlm.nih.gov/pubmed/28718073	https://www.ncbi.nlm.nih.gov/pubmed/27924398	https://www.ncbi.nlm.nih.gov/pubmed/16850020				https://www.ncbi.nlm.nih.gov/pubmed/22688746		
																				hyperoxalemia 		NA	https://www.ncbi.nlm.nih.gov/pubmed/21163900	https://www.ncbi.nlm.nih.gov/pubmed/21460356	https://www.ncbi.nlm.nih.gov/pubmed/16850020								
									Probiotics 	NA 	ECO:0007121							functional complementation of a genetically defective protein by stimulation		Hyperoxaluria 	On treatment, the reduction in urinary oxalate excretion was only modest.	HP:0003159	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1578550/										
								No complete biochemical remission was observedon vitamin B6 therapy, even in the homozygous Gly170Arg study participants	Pyridoxal phosphate	DB00114	ECO:0007121	Gly170Arg						activity modification of a genetically defective protein 		Hyperoxaluria 	The mean relative Uox reduction was 25.5%.	HP:0003159		https://www.ncbi.nlm.nih.gov/pubmed/24385516	https://www.ncbi.nlm.nih.gov/pubmed/12777626								
									Betaine	DB06756	ECO:0007121	G170R/I244T						activity modification of a genetically defective protein 		Hyperoxaluria 		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/24385516	https://clinicaltrials.gov/ct2/show/NCT00283387									
									AAV8-AGXT and AAV5-AGXT	NA 	ECO:0000179							direct complementation of a genetically defective protein by gene therapy		Hyperoxaluria 		HP:0003159	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098628/										
									helper-dependent adenoviral (HDAd) vectors for liver-directed gene therapy	NA 	ECO:0000179							direct complementation of a genetically defective protein by gene therapy		Hyperoxaluria 		HP:0003159	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746739/										
									deno-associated virus (ssAAV) carrying one copy of AGXT cDNA	NA 								direct complementation of a genetically defective protein by gene therapy					https://link.springer.com/article/10.1007/s10545-017-0045-3?shared-article-renderer										
									Hsp60 and Hsp90									functional complementation of a genetically defective protein						https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730394/									
									Polymer-conjugated AGT 	NA	ECO:0001565							direct complementation of a genetically defective protein		Abnormal enzyme/coenzyme activity 		HP:0012379	https://www.ncbi.nlm.nih.gov/pubmed/27993722?dopt=Abstract										
									4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole 	PubChem CID: 2764031 	ECO:0000179							functional complementation of a genetically defective protein by inhibition		Hyperoxaluria 		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/26689264	https://www.ncbi.nlm.nih.gov/pubmed/20054120									
								The clinical trials are either still recruting or active and not recuriting. No results have been postedd based on the trial as of March 15 2020 	Dicer-substrate small interfering RNAs (DsiRNAs) targeting hydroxyacid oxidase 1 (HAO1)  {HAO1 DsiRNA}	NA	ECO:0000179/ECO:0007121							functional complementation of a genetically defective protein by inhibition		Calcium Oxalate Deposition 		HP:0032587	https://www.ncbi.nlm.nih.gov/pubmed/26758691?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/27081720	https://clinicaltrials.gov/ct2/show/NCT04125472?cond=Primary+Hyperoxaluria&draw=3&rank=1	https://clinicaltrials.gov/ct2/show/NCT04152200?cond=Primary+Hyperoxaluria&draw=3&rank=10	https://clinicaltrials.gov/ct2/show/NCT03905694?cond=Primary+Hyperoxaluria&draw=3&rank=13	https://clinicaltrials.gov/ct2/show/NCT03681184?cond=Primary+Hyperoxaluria&draw=3&rank=14	https://clinicaltrials.gov/ct2/show/NCT03350451?cond=Primary+Hyperoxaluria&draw=3&rank=22				
																				Hyperoxaluria 		HP:0003159											
								Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion	(L)-2-oxothiazolidine-4-carboxylate	PubChem CID: 72390 	ECO:0000352/ECO:0007121							functional complementation of a genetically defective protein by inhibition		Elevated Plasma Oxalate 		NA	https://www.ncbi.nlm.nih.gov/pubmed/11851603	https://www.ncbi.nlm.nih.gov/pubmed/9604807									
								OTZ was noted for being more effective than (L)-cysteine	(L)-cysteine /(L)-2-oxothiazolidine-4-carboxylic acid (OTZ)	PubChem CID: 5862/PubChem CID: 72390 	ECO:0000179							functional complementation of a genetically defective protein by inhibition		Hyperoxaluria 		HP:0003159	https://www.ncbi.nlm.nih.gov/pubmed/9598565										
	# 212140	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	Pivoxil-containing cephalosporins can result in symptomatic hypocarnitinemia, therefore it should be avoided. https://www.ncbi.nlm.nih.gov/pubmed/31243204	SLC22A5	Solute carrier family 22 member 5	O76082		Many studies have shown that the use of L-Carnitine resulted in normal development and favourable prognosis.https://www.ncbi.nlm.nih.gov/pubmed/31813139	L-Carnitine	DB00583	ECO:0000352							metabolite replacement		Impaired fat oxidation during exercise		NA	https://www.ncbi.nlm.nih.gov/pubmed/30219858										
																				Repeated episodes of cardiac arrest		HP:0001695	https://www.ncbi.nlm.nih.gov/pubmed/23430858/										
																				Long QT		HP:0001657											
																				Cardiac arrhythmia	The treatment is proven to prevent the phenotype rather than treat it in this published paper	HP:0011675	https://www.ncbi.nlm.nih.gov/pubmed/31558765										
																				Abnormal cardiac ventricular function		HP:0030872	https://www.ncbi.nlm.nih.gov/pubmed/30302293										
																				Left ventricular systolic dysfunction		HP:0025169											
																				Cardiomyopathy		HP:0001638	https://www.ncbi.nlm.nih.gov/pubmed/10650322/										
	#245000	PAPILLON-LEFEVRE SYNDROME		CTSC	Dipeptidyl peptidase 1	3.4.14.1		 The mean daily dose (+/- SD) was 27 +/- 11 mg in adults and 0.7 +/- 0.2 mg/kg in children or adolescents.	Acitretin 	DB00459	ECO:0000352							functional complementation of a genetically defective protein		Corneocytes lipid vacoulation		NA	https://www.ncbi.nlm.nih.gov/pubmed/2965550										
																				Granulocyte lipid vacoulation		NA	https://www.ncbi.nlm.nih.gov/pubmed/2965550										
																				Palmoplantar keratoderma		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/2965550	https://www.ncbi.nlm.nih.gov/pubmed/25313946	https://www.ncbi.nlm.nih.gov/pubmed/1831211?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12492996?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/12637913	https://www.ncbi.nlm.nih.gov/pubmed/8628839?dopt=Abstract					
																				Dystrophic periodontal problem		HP:0000682	https://www.ncbi.nlm.nih.gov/pubmed/8628839?dopt=Abstract										
																				Limb keratoses		NA	https://www.ncbi.nlm.nih.gov/pubmed/2965550										
																				Trunk keratoses		NA	https://www.ncbi.nlm.nih.gov/pubmed/2965550										
																				Periodontitis			https://www.ncbi.nlm.nih.gov/pubmed/25313946	https://www.ncbi.nlm.nih.gov/pubmed/2965550?dopt=Abstract									
																				Shrinking of alveolar gum ridges		HP:0006308	https://www.ncbi.nlm.nih.gov/pubmed/25313946										
																				Decreased periodontal attachment			https://www.ncbi.nlm.nih.gov/pubmed/25313946										
																				Progressive alveolar bone loss		HP:0003676											
																				Hyperkeratosis		HP:0000962	https://www.ncbi.nlm.nih.gov/pubmed/18187837?dopt=Abstract										
								The application of 5% salicylic acid and 10% urea in an ointment base twice daily.	Acitretin+trimethoprim-sulfamethoxazole+Salicylic acid +Urea 	DB00459+PubChem CID: 358641+DB00936+DB03904	ECO:0000352							combination therapeutic procedure +functional complementation of a genetically defective protein+symptomatic treatment procedure		Periodontopathy		HP:0000704	https://www.ncbi.nlm.nih.gov/pubmed/16008657?dopt=Abstract										
																				Palmoplantar keratoderma		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/16008657?dopt=Abstract										
								The formultaion was mixture of 5% salicylic acid and 10% urea in an ointment base twice daily.	Salicylic acid+Urea	DB00936+DB03904	ECO:0000352							combination therapeutic procedure+ symptomatic treatment procedure+symptomatic treatment procedure		Palmoplantar keratoderma		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/12492996?dopt=Abstract										
								"However, one study showed that immunological effects of retinoids may precipitate severe infections in patients with Papillon-Lefèvre syndrome, who probably have a basic, even though not always evident, defect of PMN chemotaxis. https://www.ncbi.nlm.nih.gov/pubmed/2967778?dopt=Abstract
"	Etretinate	DB00926	ECO:0000352							functional complementation of a genetically defective protein		Palmoplantar keratoderma		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/2529483?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/2974305?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/2531126?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10738634?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/6220930?dopt=Abstract	https://scholar.google.com/scholar?q=Siragusa+M%2C+Romano+C%2C+Batticane+N%2C+Batolo+D%2C+Schepis+C.+A+new+family+with+Papillon-Lefèvre+Syndrome%3A+effectiveness+of+etretinate+treatment.%0ACurtis.2000%3B65%0A%3A151–%0A155					
																				Periodontal lesions		HP:0000704	https://www.ncbi.nlm.nih.gov/pubmed/2529483?dopt=Abstract	https://www.ncbi.nlm.nih.gov/pubmed/10738634?dopt=Abstract									
																				Pyoderma		HP:0000999	https://www.ncbi.nlm.nih.gov/pubmed/2974305?dopt=Abstract										
																				Recurrent bacterial infections		HP:0002718	https://www.ncbi.nlm.nih.gov/pubmed/2974305										
																				Gingival swelling and erthyema		HP:0000230											
									Isotretinoin	DB00982	ECO:0000352							functional complementation of a genetically defective protein		Keratoderma		HP:0000982	https://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1986&pages=638-641&journal=J+Am+Acad+Dermatol&author=TQ+Nguyen&author=KE+Greer&author=GB+Fisher&author=PH+Cooper&title=+Papillon–Lefevre+syndrome.+Report+of+two+patients+treated+successfully+with+isotretinoin										
									Urea/lactic acid	DB03904/DB04398	ECO:0000352							symptomatic therapeutic procedure/symptomatic therapeutic procedure		Mild palmoplanter keratosis		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/12637913										
									Lactic acid+Salicylic acid 	DB04398+DB00936	ECO:0000352							combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Mild palmoplanter keratosis		HP:0000982	https://www.ncbi.nlm.nih.gov/pubmed/12637913										
								The drug was used after complete drainage of the abscess intravenously for 4 weeks, followed by oral therapy for another 2 weeks.	Cloxacillin	DB01147	ECO:0000352							symptomatic therapeutic procedure	Pyogenic liver abscess is an increasingly recognized complication for PLS	Pyogenic liver abscess		HP:0100523	https://www.ncbi.nlm.nih.gov/pubmed/12509601										
	# 260800	PENTOSURIA		DCXR	L-xylulose reductase	1.1.1.10			No treatment is available in DDIEM																								
	# 233400	PERRAULT SYNDROME 1		HSD17B4	Peroxisomal multifunctional enzyme type 2	P51659			No treatment is available in DDIEM																								
	# 614926	PERRAULT SYNDROME 2		HARS2	Histidine--tRNA ligase, mitochondrial	6.1.1.21			Conjugated equine estrogen	DB00286	ECO:0000352							metabolite replacement		Delayed pubertal development		HP:0000823	https://www.ncbi.nlm.nih.gov/pubmed/23332201										
	# 614129	PERRAULT SYNDROME 3		CLPP	ATP-dependent Clp protease proteolytic subunit, mitochondrial	3.4.21.92			Estrogen	DB00286	ECO:0000352							metabolite replacement		Puberty and gonadal disorders		HP:0008373	https://www.ncbi.nlm.nih.gov/pubmed/27087618										
	# 615300	PERRAULT SYNDROME 4		LARS2	Probable leucine--tRNA ligase, mitochondrial	6.1.1.4			Risperidone + methylphenidate	DB00734 + DB00422	ECO:0000352							combination therapeutic procedure+symptomatic therapeutic procedure+symptomatic therapeutic procedure		Cognitive impairment		HP:0100543	https://www.ncbi.nlm.nih.gov/pubmed/29205794										
									Estrogen replacement therapy+cyclic progestin	DB00783+DB00396	ECO:0000352							combination therapeutic procedure +metabolite replacement+metabolite replacement		Primary amenorrhea		HP:0000786	https://www.ncbi.nlm.nih.gov/pubmed/29205794										
	# 616138	PERRAULT SYNDROME 5		TWNK	Twinkle protein, mitochondrial	3.6.4.12			Phenobarbital	DB01174	ECO:0000352							symptomatic therapeutic procedure		Tonic-clonic seizure		HP:0002069	https://www.ncbi.nlm.nih.gov/pubmed/25355836										
									Hormone replacement therapy	G03	ECO:0000352							metabolite replacement		Primary amenorrhea		HP:0000786	https://www.ncbi.nlm.nih.gov/pubmed/28178980										
																				Delayed pubertal development		HP:0000823											
	# 617565	PERRAULT SYNDROME 6		ERAL1	GTPase Era, mitochondrial	O75616			No treatment is available in DDIEM																								
	# 261540	PETERS-PLUS SYNDROME		B3GLCT	Beta-1,3-glucosyltransferase	2.4.1.-			Recombinant human growth hormone	DB00052	ECO:0000352							metabolite replacement		Growth retardation		 HP:0001510	https://www.ncbi.nlm.nih.gov/pubmed/14735587										
																				Short stature		HP:0004322											
									 Topical IOP lowering medications	S01E	ECO:0000352							symptomatic therapeutic procedure		Increased intraocular pressure		HP:0007906	https://www.ncbi.nlm.nih.gov/pubmed/31795264										
								The preparation is a topical dorzolamide 2% and hypertonic sodium chloride ophthalmic solution 5% 	Dorzolamide+ Hypertonic sodium chloride	DB00869+DB09153	ECO:0000352							symptomatic therapeutic procedure		Congenital glaucoma 		HP:0008007	https://www.ncbi.nlm.nih.gov/pubmed/32204707										
	# 614921	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It		PGM1	Phosphoglucomutase-1	5.4.2.2			Galactose	DB11735	ECO:00007121/ECO:0001565							Metabolite replacement		Abnormal transferrin glycosylation(Abnormal glycosylation)*		HP:0012345	https://www.ncbi.nlm.nih.gov/pubmed/24499211										
																				Hypogonadotropic hypogonadism			https://www.ncbi.nlm.nih.gov/pubmed/24499211										
																				Abnormal glycosylation of the total serum N-glycome (Abnormal protein N-linked glycosylation)*		 HP:0012347	https://www.ncbi.nlm.nih.gov/pubmed/24499211										
																				Recurrent episodes of rhabdomyolysis (Recurrent)*		HP:0031796	https://www.ncbi.nlm.nih.gov/pubmed/24499211										
																				Progressive cardiomyopathy (Progressive)*			https://www.ncbi.nlm.nih.gov/pubmed/24499211										
																				Elevated hepatic transaminase		HP:0002910	https://www.ncbi.nlm.nih.gov/pubmed/28617415	https://clinicaltrials.gov/ct2/show/NCT03404856?cond=PGM1-CDG&draw=2&rank=1									
																				Reduced antithrombin III activity		HP:0001976	https://www.ncbi.nlm.nih.gov/pubmed/28617415	https://clinicaltrials.gov/ct2/show/NCT03404856?cond=PGM1-CDG&draw=2&rank=1									
																				Abnormal partial thromboplastin time		HP:0003645	https://www.ncbi.nlm.nih.gov/pubmed/28617415	https://clinicaltrials.gov/ct2/show/NCT03404856?cond=PGM1-CDG&draw=2&rank=1									
									Lactose/Galactose	DB04465/DB11735	ECO:0000352							Metabolite replacement		Hypoglycemia													
									Hydrocortisone	DB00741	ECO:0000352							functional complementation of a genetically defective protein	The drrug resulted in  reduction but not disappearance of the hypoglycemic events.	Hypoglycemia			https://www.ncbi.nlm.nih.gov/pubmed/26768186										
									Captopril+metildigoxin	DB01197+DB13401	ECO:0000352							combination therapy procedure+symptomatic treatment procedure+symptomatic treatment procedure	After the noticed improvement the condition worsened at school age. 	Reduced systolic function		HP:0006673	https://www.ncbi.nlm.nih.gov/pubmed/26303607										
									Enalapril+ metoprolol+ hydrocortisone	DB00584+DB00264+DB00741	ECO:0000352							combination therapy procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure		Reduced systolic function		HP:0006673	https://www.ncbi.nlm.nih.gov/pubmed/26303607										
	# 300653	PHOSPHOGLYCERATE KINASE 1 DEFICIENCY		PGK1	Phosphoglycerate kinase 1	2.7.2.3		The patient was put on a classic 3:1 (fat:nonfat) ketogenic diet (KD), however patient developed a hemolytic episode and no responce was recorded in this patient. Authors stated that "A KD is theoretically effective for the neurological/muscular symptoms related to PGK deficiency; therefore, it is not necessary to say that all patients with PGK deficiency with hemolytic anemia should avoid a KD, though caution should be taken when administering a KD to such patients."	Ketogenic diet	NA 	ECO:0000352							dietray regimen modification 					https://www.ncbi.nlm.nih.gov/pubmed/28801086										
									Loop diuretics	C03C	ECO:0000352							symptomatic treatment procedure		Myoglobinuria			https://www.ncbi.nlm.nih.gov/pubmed/26883264										
									Lorazepam+Phenytoin+Midazolam	DB00186+DB00252 +DB00683	ECO:0000352							combination therapy procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure		Status epilepticus 			https://www.ncbi.nlm.nih.gov/pubmed/26883264										
									Levetiracetam	DB01202	ECO:0000352									Recurrent seizures			https://www.ncbi.nlm.nih.gov/pubmed/26883264										
